

JULY 2013

**CURRICULUM VITAE**  
**SERGE G. GAUTHIER**

**GENERAL INFORMATION**

**Place of Birth:**

Montreal, Quebec

**Nationality:**

Canadian

**Present Positions:**

Professor, Department of Departments of Psychiatry, Neurology & Neurosurgery, Medicine  
McGill University

Director, Alzheimer Disease and Related Disorders Unit, McGill Centre for Studies in Aging,  
Douglas Mental Health University Institute

Associate Member, School of Physical and Occupational Therapy, Department of Pharmacology and  
Therapeutics, Center for Medicine Law & Ethics, McGill University

Member, Douglas Mental Health University Institute's Research Center

Membre Associé, Institut Universitaire de Gériatrie  
Université de Montréal

**Address:**

Work: McGill Centre for Studies in Aging  
6825 LaSalle Boulevard,  
Montréal, Québec, Canada H4H 1R3  
Tel: (514) 766-2010 FAX: (514) 888-4050  
E-mail: serge.gauthier@mcgill.ca

## STUDIES

### 1. PREMEDICAL

1961-1969 Cours classique, Collège Ste-Marie, Montréal

### 2. MEDICAL

1969-1973 Médecine, Université de Montréal, Montréal

1970 Medical Research Council Summer Studentship,  
Institut de Recherches Clinique de Montréal,  
Montréal  
Research Director: Dr. Jacques Genest

### 3. POSTGRADUATE

1973-1974 Straight medical internship, Royal Victoria Hospital, Montreal

1974-1976 Neurology residency, McGill University, Montreal

1976-1978 Medical Research Council Fellowship,  
Department of Psychiatry, McGill University, Montreal  
Research Director: Dr. T.L. Sourkes

## DIPLOMAS

1969 B.A. (Biochemistry) Université de Montréal, Montréal

1973 M.D. Université de Montréal, Montréal

1974 Medical License Province of Québec  
(174-0984)

1974 L.M.C.C. Canada

1977 Certification in Province of Québec  
Neurology

1977 Certification in Royal College of Physicians  
Neurology and Surgeons of Canada

1983 Certification in American Board of Neurology and Psychiatry

## AWARDS

1970	MRC Summer Studentship, Clinical Research Institute of Montreal
1976-1978	MRC Fellowship, Department of Psychiatry McGill University, Montreal Research Director: Dr. T.L. Sourkes
1978-1986	Killam Scholarship, Department of Neurology and Neurosurgery, McGill University, Montreal
1989- 1999-2002	Carex Chair for Studies in Aging MRC/PMAC Senior Scientist
2002-2007	CIHR/Rx&D Research Chair

## PRIZES

Medical studies	1st year: Biochemistry Prize 2nd year: Ciba's Prize 3rd year: Frosst's Prize 4th year: Internal Medicine Prize
Postgraduate studies	1976: Pines Scholarship, Jewish General Hospital, Montreal 1978: Francis McNaughton Prize, XIII Canadian Congress of Neurological Sciences, Vancouver
Career	1997 Prix Galien, PMAC, with Drs. J. Poirier and R. Quirion 1998 CCNP Innovations in Neuropsychopharmacology Award, with Drs. J. Poirier and R. Quirion 2000 Médaille 'Médecin de Mérite' de l'Actualité Médicale 2005 Prix de l'oeuvre scientifique, Association des médecins de langue française du Canada 2006 Prix 'Ambassadeur' du Palais des Congrès de Montréal 2007 Elected member of « Best Doctors », North America 2009 Prix d'excellence du Collège Royal des Médecins et Chirurgiens du Canada 2009 Irma Parhad Award, Consortium of Canadian Centers for Clinical Cognitive Research 2012 Prix Hubert Reeves de l'Association des communicateurs scientifiques du Québec pour la valorisation d'ouvrages scientifiques grand public, avec Dr J. Poirier 2013 Médaille du jubilé de diamant de la reine Elizabeth II

## CURRENT MEMBERSHIP IN SOCIETIES

Alzheimer Disease International  
Alzheimer Society of Canada  
American Academy of Neurology  
Association des Neurologues du Québec  
Canadian Neurological Society  
Corporation Professionnelle des Médecins du Québec  
International Psychogeriatric Association  
Royal College of Physicians and Surgeons of Canada

## CLINICAL ACTIVITIES

1976-1980	Consultant in Neurology, Jewish Hospital of Hope, Montreal
1977-1979	Consultant in Neurology, Mount Sinai Hospital, Saint-Agathe-des Monts
1978-1986	Geographic Full Time (GFTU), Montreal Neurological Hospital
1978-	Consultant in Neurology, Royal Victoria Hospital, Montreal
1982-	Consultant in Neurology, Douglas Hospital, Montreal
1983-1986	Consultant in Neurology, Centre Hospitalier Sainte-Thérèse, Shawinigan
1984-1986	Consultant in Neurology, Sainte-Anne-de-Bellevue Veteran's Hospital
1985-1986	Chief of Neurology "A" Service, Montreal Neurological Hospital
1986-1987	Consultant in Neurology, Clinical Research Institute of Montreal
1987-	Consulting Specialist, Department of Medicine, Division of Geriatric Medicine and Division of Neurology Montreal General Hospital, Montreal
1987-1988	Acting Chief, Division of Geriatric Medicine, Montreal General Hospital
1987-	Consultant in Neurology, Montreal Neurological Hospital
1987-	Consultant in Neurology, Sir Mortimer B. Davis Jewish General Hospital
1992-2007	Associate Physician, Department of Medicine, Division of Neurology and Division of Psychiatry, St-Mary's Hospital Centre, Montreal

## UNIVERSITY POSITIONS

1978-1984	Assistant Professor, Department of Neurology and Neurosurgery, McGill University
1980-1984	Assistant Professor, Department of Psychiatry, McGill University
1983-	Associate Member, School of PT and OT, McGill University
1984-1990	Associate Professor, Department of Neurology and Neurosurgery McGill University, with tenure
1984-1988	Associate Professor, Department of Psychiatry, McGill University, with tenure
1986-1988	Associate Professor, Department of Medicine, McGill University, with tenure
1986-	Membre Associé, Institut Universitaire de Gériatrie, Université de Montréal
1987-1997	Director, McGill Centre for Studies in Aging
1988-	Associate member, Department of Pharmacology and Therapeutics, McGill University
1988-	Professor, Department of Medicine, McGill University
1988-	Professor, Department of Psychiatry, McGill University
1991-	Professor, Department of Neurology & Neurosurgery, McGill University
1994-	Associate Member, Centre for Medicine, Ethics & Law, McGill University
1996-	Member, Douglas Mental Health Research Institute

## PARTICIPATION IN COMMITTEES AND BOARDS

1978-1983	Continuous Medical Education Committee Syndicat Professionnel des Neurologues du Québec
1978-1987	Research Evaluation and Ethics (Chairman, 1986-1987);
1979-1986	Infectious Disease Committee, MNH
1979-1994	Scientific Advisory Committee, Huntington Society of Canada
1980-1985	Admissions and Stay Committee (Chairman), MNH
1980-1983	Pharmacy Committee, MNH
1982-1984	Montreal Neurological Hospital Neurology Associates Management Committee
1982-1990	Scientific Advisory Committee, Douglas Hospital
1982	Curriculum Review Committee Department of Psychiatry, McGill University
1982-1985	Admissions and Stay Committee, RVH
1983-1986	Post Graduate Board, RVH Representative of the Department of Neurology and Neurosurgery
1983-1985	Scientific Program Committee (Chairman), XXth Canadian Congress of Neurological Sciences, Montreal, June 1985
1984-1986	Neurology Examination Board (Chairman) Corporation Professionnelle des Médecins du Québec
1984-1985	Search Committee of Neurologist-in-Chief, MNH
1985-1986	Medical Acts Committee (Chairman), MNH
1985-1986	Medical Records Committee, MNH
1986-1993	The Royal College of Physicians and Surgeons of Canada, Corresponding Member, Neurology Examination Board
1987-1997	McGill University's representative on the Douglas Hospital Research Board
1987-1993	McGill University's representative on the Continuous Medical Education section of "l'Actualité Médicale"
1987-1992	Clinical Trials Committee (Chairman), MGH Organizing Committee, Canadian College of Neuropsychopharmacology,
1987-1988	10th Annual Meeting, May 1988
1992-1993	15th Annual Meeting, June 1993
1987-1997	McGill Centre for Studies in Aging standing committees - Executive Committee (Chairman) - Geronto-McGill Editorial Board - Research Steering Committee (co-chairman)
1988	Cyclical Review of the Dept. of Orthopedic Surgery, McGill University
1988-1997	Seniors Independence Research Program - Advisory Committee Member Health and Welfare Canada
1989-1994	Research Committee, Dept. of Psychiatry, McGill University
1989-1992	Biomedical Review Panel (Chairman), Alzheimer Society of Canada
1989-1994	W.H.O. Program for Research on Aging, Canadian representative
1989-1990	Planning Committee, Canadian Consensus Conference on the Assessment of Dementia
1990-1993	Board of Directors, Julius Richardson Rehabilitation Centre
1990-1997	Editor, International Abstracts/Neurology, Doer Press, Montreal
1990-1997	Dept. of Neurology & Neurosurgery, Departmental Advisory Committee
1990	Elected representative on the Dean of Medicine selection committee, McGill University
1992-6, 2011-13	Alzheimer Society of Canada, Research Policy Committee Member
1992-1995	Editorial board, Canadian Journal of Neurological Sciences
1993-1996	Chair, C5R Executive Committee
1993-	Alzheimer Disease International Research Policy Committee, Canadian Representative
1993-1996	Research Ethics Committee, Douglas Hospital
1993-2007	Member of Oversight Committee for the AD Cooperative Study Unit, National Institute of Aging
1994-1998	Editorial Board, Health over 50
1994-1998	Editorial Board, Aging and Cognition
1994-	Editorial Board, Alzheimer's disease and Related Disorders Journal
1994-1998	Research Ethics Committee, St-Mary's Hospital (Chair)
1994-	Steering Committee, International Working Group on Harmonization of Dementia Drug Guidelines (President since 2007)
1995-2000	Task force on revenue generation, Dept. of Psychiatry, McGill University

1996-1998	Comité organisateur du Congrès International francophone de Gériologie, Genève, avril 1998
1997-1999	Canadian Consensus Conference on Dementia (co-chair)
1998-2007	Editor, International Abstracts/Alzheimer's disease, Doer Press
1998-	Editorial Board Member, International Journal of Geriatric Psychiatry
1998-	Editorial Board Member, Revue Canadienne de la maladie d'Alzheimer
1998-	Working Group on the prevention of Alzheimer's Disease, Ronald and Nancy Reagan Research Institute
1998-	Royal College Program in Neuropsychopharmacology (program committee member)
1998-2000	Science in Society Journalism Award (jury member)
1998-2000	Canadians for Health Research; Youth Health Awareness Award, jury member.
1998-2001	Board member, Fédération des Sociétés Alzheimer du Québec
1998-2004	Chair, organizing committee, 8 <sup>th</sup> International Montreal-Springfield Symposium on Advances in Alzheimer Therapy, Montreal 2004
1999	Co-chair, 71 <sup>st</sup> Congress of the Association des médecins de langue française du Canada, Montréal, October 14-15
1999-2003	Chair, site selection committee, C5R
1999-2003	Comité d'éthique central, FRSQ (member)
1999-2009	Chair, Research Ethics Committee, Douglas Hospital
1999-	Member, Executive Committee, World Federation of Neurology Workgroup on Dementia
2001-2007	Chair, Comité d'orientation et de suivi, Consortium Cognition et Vieillesse
2002-	Chair, disease stabilization subcommittee, International Working Group on Harmonization of Dementia Drug Guidelines
2002-	Ethics Institutional Review Board, Faculty of Medicine, McGill University (co-Chair, 2002-03/2004; Chair, 04/2004-2013)
2000-	Associate Editor, International Psychogeriatrics
2003-2009	Chair, IPA Subcommittee on Therapeutics, IPA
2003-2011	Board Member, IPA
2003-2011	Editorial Board (Section Editor), The Journal of Nutrition, Health & Aging
2005-2006	Comité d'experts, aptitude à conduire, Collège des médecins du Québec
2005	Comité de suivi de l'évaluation, Plan d'action ministériel en éthique de la recherche et en intégrité scientifique
2005-	Chair, Comité d'éthique provincial du Québec
2005-2009	Chair, IPA Congress 2009, Montreal.
2006-2007	Vice-president, Scientific Steering Committee and Member, Executive Committee, IPA Osaka 2007
2006	Member, CIHR Standing Committee for Oversight of Grants and Awards Competitions
2006-2009	Member, Expert Committee for Human Research Participant Protection in Canada
2006-2010	Member, Lewy Body Dementia Association Scientific Advisory Committee
2006-2008	Member, Movement Disorders Society Task Force on Parkinson Disease Dementia
2007-2010	Member, Steering Committee of Multi-Domain Intervention Workgroup, Alzheimer's Association & Keep Memory Alive Foundation
2008-	Associate Editor (Neurology), Canadian Journal of Neurological Sciences
2008-	Editorial Board Member, European Neurology
2008-2009	Groupe de travail sur la neuropharmacologie, Commission de l'éthique, de la science et de la technologie, Gouvernement du Québec.
2009-	Editorial Board Member, The World Journal of Biological Psychiatry
2010-	Editorial Board Member, Dementia and Geriatric Cognitive Disorders
2010-	Editorial Board Member, Current Medical Research & Opinion
2010-	Editorial Board Member, The Eurasian Journal of Medicine
2010-	Member, Alzheimer Disease Cooperative Study/National Institute of Aging DSMB
2010-2012	Chair, Alzheimer Society of Canada Scientific Advisory Committee
2010-2011	Special advisor – clinical affairs, CIHR International Collaborative Research Strategy for Alzheimer's Disease (ICRSAD)
2010-2011	Executive committee member, ADNI – 2 (Canadian representative)
2010-	World Federation of Societies of Biological Psychiatry Task Force on Dementias (member)
2011-	Président fondateur du réseau des cliniques mémoires du Québec
2011-	University tenure committee (member), MacDonald Campus.
2012-	External scientific advisory committee (member), ADNI – 2
2012	Vice-Président du premier congrès québécois sur la maladie d'Alzheimer
2012	Ethics task force on publications, Faculty of Medicine (member)
2013	Sub-committee of the Research Ethics Committees of the Faculty of Medicine on multisites studies

## PARTICIPATION IN GRANT REVIEW BOARDS

Alzheimer Association USA (external reviewer)  
 Alzheimer's Drug Discovery Foundation (internal reviewer)  
 Alzheimer Society of Canada (chairman, biomedical review panel 1989-1992; external reviewer)  
 Belgian Science Policy Office (2006)  
 Canadian Institutes of Health Research (internal reviewer, Fund for Dyskinesia and Torticollis, 1982-1986; external reviewer; site visitor; Clinical Trials Committee, chair, external and internal reviewer; Palliative & End of Life Care Committee, external reviewer, 2010-2011; Catalyst grant: secondary analysis of neuroimaging databases committee (chair, 2012).  
 Canadian Institutes of Health Research/Rx & D Canada (external reviewer; site visitor)  
 Fonds de la recherche en santé du Québec (internal reviewer, "recherche en santé mentale", 1985-1986, 1991; "équipes de recherche prioritaire et en émergence", co-chair, 1990; "programme CQRS-FRSQ en santé mentale", 1991, co-chair 1992; "programme Hydro-Québec-FRSQ, recherche clinique", chair, 1993; "programme des centres et instituts", 1994, 1995, 2005, 2013; 'recherche clinique, évaluative et épidémiologique', 2001, 2002, 2003; « éthique de la recherche », chair site visit, 2008)  
 German Government BMBF Funding Initiative for Health in Old Age (2007)  
 Huntington Society of Canada (internal reviewer 1980-1994)  
 National Institutes of Aging, Oversight Committee of Alzheimer Disease Study Unit (full member, 1990-2007); Prevention of dementia (member, 2013).  
 National Institute for Health Research, UK, research for patient benefit programme (RfPB), 2009.  
 Ontario Mental Health Foundation (external reviewer)  
 Parkinson Foundation of Canada (external reviewer)

## RESEARCH GRANTS FUNDED

1978-1980	FRSQ Establishment Grant 780209 - \$ 18,000
1979	Savoy Foundation, Special Equipment Grant - \$ 2,500
1979	McNaughton Fund, Montreal Neurological Institute, Special Equipment Grant - \$ 8,742
1979-1981	MRC, New Operating Grant MA 7068 - \$ 47,190 <i>on adreno-medullary regulation</i>
1981	McNaughton Fund, Montreal Neurological Institute, Special Equipment Grant - \$ 1,864
1981-1983	MRC Two-Year Continuing Grant MA 7068 - \$ 60,678 <i>on adreno-medullary regulation</i>
1982	Savoy Foundation, Special Equipment Grant - \$ 8,000
1982-1984	MRC, Program Grant PG-22, Alzheimer Study Group, Douglas Hospital Research Centre - \$ 226,000 <i>on afferents to the Nucleus Basalis of Meynert</i>
1983-1985	National Health and Welfare, Canada with Prof. L. Gauthier, School of Physical and Occupational Therapy McGill University - \$ 38,400 <i>on group occupational therapy for Parkinson's disease</i>
1983-1985	Quebec Heart Foundation with Dr. J. Henry, Department of Physiology, McGill University - \$ 14,000 <i>on cardio-vascular regulation</i>
1983-1984	MRC 15 months Grant MA 7068 - \$ 40,070 <i>on adreno-medullary regulation</i>

---

1984-1985	Parkinson Foundation of Canada with Dr. R. Quirion, Department of Psychiatry, McGill University - \$ 23,690 <i>on peptide receptors changes in Parkinson's disease</i>
1984-1985	MRC, Program Grant, Alzheimer Study Group, Douglas Hospital Research Centre - \$ 116,500 <i>on afferents to the Nucleus Basalis of Meynert</i>
1984-1987	MRC Program Grant, Positron Emission Tomography Study Group, Montreal Neurological Institute - \$ 581,288 (Core Budget) - \$ 7,412 (Section Budget) <i>on choline analogs for Alzheimer's disease</i>
1985-1986	Infusaid Inc., Norwood, MA, Multicentre Study - \$ 55,000 (site budget) <i>on bethanechol infusion for Alzheimer's disease</i>
1985-1986	Infusaid Inc., Norwood, MA, \$ 31,000 <i>on somatostatin analogs infusion in primates</i>
1985-1986	Sandoz Canada, \$ 10,000 <i>on somatostatin analogs infusion in primates</i>
1985-1986	Parkinson Foundation of Canada with Dr. Yvon Robitaille, Department of Neurology and Neurosurgery, McGill University - \$ 22,596 <i>on dementia in Parkinson's disease</i>
1985-1986	Merck Frosst Research Grant with Dr. Hughes Barbeau, McGill University - \$ 1,000 <i>on cyproheptadine in spasticity</i> Bohringer Ingelheim Ltée Research Grant with Dr. H. Barbeau, McGill University - \$ 5,000 <i>on clonidine in spasticity</i>
1986-1987	Parkinson Foundation of Canada with Dr. Rémi Quirion, Department of Psychiatry, McGill University - \$ 25,000 <i>on peptide receptor changes in Parkinson's disease</i>
1986-1987	Huntington Society of Canada with Drs. Alan Evans and Chris Redies, Department of Neurology and Neurosurgery, McGill University - \$ 5,000 <i>on cerebral metabolic changes in Huntington's disease</i>
1987-1989	FRSQ, Santé Communautaire with Drs. M. Baumgarten, R. Battista, C. Infante-Rivard, R. Becker and J. J. Henley, DSC Sainte-Justine - \$ 75,363 <i>on caregiver burden in Alzheimer's disease</i>
1987-1991	MRC, Program Grant PET Study Group, Montreal Neurological Hospital Dementia Section (Coordinator) \$ 1,900,000 - Total Budget, \$ 4,000 - Section Budget per Year <i>on cerebral blood flow in early Alzheimer's disease</i>
1987-1989	MRC, New Operating Grant with Drs. G. Lacoste-Royal and D. Gauvreau, INRS - Santé - \$ 62,000 <i>on neurofilament genes in Alzheimer's disease</i>
1987-1992	NIH Program Grant, DATATOP Project with Dr. I. Shoulson et al. - \$ 184,000 <i>on antioxydant therapy for Parkinson's disease</i>



---

1987-1988	Parkinson Foundation of Canada with Dr. Rémi Quirion, Department of Psychiatry, McGill University - \$ 28,000 <i>on peptide receptor changes in Parkinson's disease</i>
1987-1988	Parkinson Foundation of Canada with Drs. Yvon Robitaille and R. Quirion, Department of Neurology and Neurosurgery, McGill University - \$ 23,000 <i>on dementia in Parkinson's disease</i>
1987-1988	Janssen Pharmaceutica Inc. Grant with Elliot Kravitz, Dept. of Medicine, McGill University - \$10,000 <i>on the value of domperidone in bromocriptine-induced dyspepsia</i>
1988-1990	American Health Assistance Foundation with Drs. B. Collier and M. Diksic McGill University - \$180,000 <i>on labelled choline analogs for PET imaging</i>
1988-1989	Parkinson Foundation of Canada with Dr. R. Quirion, Department of Psychiatry McGill University - \$29,000 <i>on peptide receptor changes in Parkinson's disease</i>
1989-1995	Merck Frosst Canada - \$156,479 U.S. <i>on the value of Sinemet CR in de novo patients with Parkinson's disease</i>
1990-1992	FRSQ, Santé Mentale with Dr. J. Montplaisir, Laboratoire du Sommeil Université de Montréal - \$114,000 <i>on cholinergic regulation of sleep-wake cycle</i>
1990-1991	Alzheimer Society of Canada with Prof. L. Gauthier and Dr. S. Suissa, McGill University - \$35,000 <i>on the validation of the spatial orientation skill battery</i>
1990-1992	Health and Welfare Canada with Drs. I. McDowell and G. Hill University of Ottawa - \$6.5 million (total budget) - \$206,250 (site budget) <i>on epidemiology of dementia in Canada</i>
1991-1992	Health and Welfare Canada with Prof. L. Gauthier McGill University - \$36,500 <i>on the validation of the spatial orientation skill battery</i>
1990-1993	Social Sciences and Humanities Research Council of Canada with T. Keyserlingk and Maitre K. Glass McGill University - \$63,765 <i>on the development of guidelines for research involving demented subjects</i>
1990-1991	Alzheimer Society, USA with Dr. B. Sherwin McGill University - \$20,970 US <i>on a pilot study for treatment of Alzheimer's disease using estrogens</i>
1991-1992	Dupont Pharma, Canada, principal investigator - \$49,400 <i>on phase IV study of Sinemet CR in Parkinson's disease</i>
1991-1993	Dupont Pharma, Canada principal investigator - \$175,480 <i>on the safety and efficacy of linopirdine in Alzheimer's disease</i>

1991-1994	FRSQ Pharmacy/Pharmacology Program with Dr. R. Quirion and Dr. N.P.V. Nair McGill University - \$90,000/year <i>Development of new muscarinic agonists and MAOB inhibitors</i>
1991-1994	NIH Program Grant with Dr. A. Heyman et al. - \$14,900/year <i>Consortium to establish a registry for Alzheimer's disease (CERAD)</i>
1992-1994	Alzheimer Society of Canada with Prof L. Gauthier and Dr. S. Wood-Dauphinée. McGill University - \$ 43,852 <i>on the validation of a disability assessment in Alzheimer's disease.</i>
1992-1994	Alzheimer Society of Canada with Dr. J. Nalbantoglu and Dr. Y. Robitaille McGill University - \$ 82,628 <i>on genetic mutations in Alzheimer's disease and amyloidosis.</i>
1992-1995	MRC-Operating Grant with J. Montplaisir, University of Montreal - \$180,300 <i>on pharmaco EEG of Alzheimer's disease</i>
1992-1998	MRC-Program Grants with A. Gjedde, McGill University – Global budget \$6,934,040 <i>on positron imaging of neural systems</i>
1993-1994	Eli Lilly, Canada co-investigator - \$150,000 <i>phase IIB study of xanomeline in Alzheimer's disease</i>
1993	Pfizer US - \$71,000 <i>Pilot study on inflammatory markers in blood from patients with Alzheimer's disease</i>
1993-1995	Hoffmann-LaRoche, Canada co-investigator - \$266,400 <i>Efficacy, safety and tolerance of lazabemide in patients with Alzheimer's disease</i>
1994	UpJohn US and the Parkinson Study Group with I. Shoulson et al. - \$68,000 US <i>phase IIB study of pramipexole in Parkinson's disease</i>
1994-1995	Hoechst-Roussel, Canada Inc. co-investigator - \$189,600 <i>Six-month efficacy and safety of besipirdine hydrochloride (HP749) in patients with Alzheimer's disease</i>
1994-1996	Réseau FRSQ en Santé Mentale with R. Quirion et al. - \$875,000 (global budget)
1995-1997	Sandoz Canada co-investigator with M. Panisset - \$208,000 <i>Efficacy and safety of 1-4 mg/day SDZ ENA 713 and 6-12 mg/day SDZ ENA713 I in patients with mild to moderate probable Alzheimer's disease</i>
1995-1997	Smithkline Beecham Pharmaceuticals principal investigator - \$76,000 <i>Efficacy and tolerability of SB202026 in patients suffering from dementia of the probable Alzheimer's type</i>
1995-1997	Santé et Bien Etre Canada With Dr L. Poulin de Courval - \$213,873 <i>Enquête sur les besoins et les attentes du patient dément et des aidants naturels par rapport au médecin de famille</i>

1995-1997	Réseau FRSQ en gériatrie/gérontologie with R. Hébert et al. - \$100,000 (global budget)
1995-1997	Réseau FRSQ en éthique clinique chez l'humain with Dr. Roy et al. - \$100,000 (global budget)
1995-1997	Health and Welfare Canada with Dr. I. McDowell, University of Ottawa - \$5,000,000 (total budget) on Epidemiology of dementia in Canada
1996-1997	Eisai America Inc. Principal Investigator - \$189,600 <i>Safety and efficacy of E2020 in patients with Alzheimer's disease</i>
1996-1997	Hoechst Marion Roussel Principal Investigator - \$131,400 <i>Milameline in patients with mild to moderate Alzheimer's disease</i>
1996-1998	Réseau FRSQ en pharmaco-économie with S. Suissa et al - \$100,000
1998-2001	(global budgets)
1996-1998	MRC-PMAC, Operating Grant No. MT-13553 Principal Investigator - \$74,402 <i>Propentophylline (HWA 285) in the treatment of vascular dementia</i>
1996-1998	MRC-PMAC, Grant No. MT-13560 with K. Rockwood et al - \$81,432 <i>Vascular dementia: diagnostic criteria and outcomes</i>
1996-1997	MRC-PMAC, Research Grant with C. Wolfson et al - \$615,000 <i>Follow-up to the Canadian Study of Health and Aging: progression of dementia</i>
1997-1998	Pfizer Canada Inc. Principal Investigator - \$144,000 <i>Safety and efficacy of donepezil hydrochloride (E2020) in patients with moderate to moderately severe Alzheimer's Disease</i>
1997-2000	MRC-PMAC, Research Grant with H. Feldman et al - \$ 112,500 <i>A cohort study of cognitive impairment of a consortium registry: Dementia in Canada - ACCORD Study</i>
1998-2000	MRC- Program grant #13972 on PET imaging with A. Evans et al, MNH Total budget: \$2, 162, 210
1998-2000	Boehringer, Research grant Site budget: \$103,500 <i>Talsaclidine in mild to moderate dementia of Alzheimer's type</i>
1998-2002	NIA, Research grant with M. Panisset, Centre on Aging – Site budget: \$59,000US <i>Sinemet versus placebo in early Parkinson's disease</i>
1999-2004	Alzheimer Disease Cooperative Study NIA/Eisai/Pfizer – Site budget: \$145,000US <i>Safety and efficacy of vitamin E and donepezil (HCL) (Aricept®) to delay clinical progression from mild cognitive impairment to Alzheimer's disease</i>
1999-2001	NHRDP, Research grant with Dr L, Poulin de Courval - \$180,216 <i>La sécurité des personnes atteintes de démence et vivant à domicile.</i>

---

1999-2001	FRSQ, Research grant With Dr Isabelle Gélinas - \$60,000 <i>Le repérage des personnes atteintes de la maladie d'Alzheimer qui sont des conducteurs non sécuritaires.</i>
1999-2000	Communications Action Santé Inc. Principal Investigator - \$14,580 <i>Protocol for adapting and retesting the Alzheimer's carer's QoL instrument (ACQLI) and the dementia – Quality of life instrument (DqoL) for use in Canada</i>
2000-2001	Neurotherapeutics Inc. Site budget: \$107,730 <i>AIT-082 over 24 weeks in Alzheimer's disease of mild to moderate severity</i>
2000-2001	Eisai Inc. Site budget: \$64,076 <i>Efficacy and safety of donepezil hydrochloride (E2020) in patients with dementia associated with cerebrovascular disease (E2020-A001-307)</i>
2001-2004	Janssen-Ortho Inc. Site budget: \$167,400 <i>Efficacy and safety of galantamine in subjects with mild cognitive impairment clinically at risk for clinically probable Alzheimer's Disease</i>
2001-2004	FRSQ VRQ Global budget \$1, 600, 000. <i>Consortium Cognition et Vieillessement.</i>
2002-2004	GlaxoSmithKline Inc. Site budget: \$964,698 <i>Genetics of Alzheimer's Disease (GenADA)</i>
2002-2008	Pfizer Inc. <i>Lipitor vs placebo in mild Alzheimer's disease over 15 months</i>
2004-2005	CIHR Pilot project With Marie Vanier, Isabelle Gélinas, Thérèse Audet, Louise Demers : \$49,868 <i>Metric properties of a driving simulator for the assessment of safe driving for people in the early stages of Alzheimer's disease.</i>
2001-	Lundbeck Canada Inc. Principal investigator; <i>Memantine vs placebo in moderate to severe Alzheimer's disease</i>
2004-2007	Sanofi-Synthelabo-Aventis. Investigator <i>SR 57667B vs placebo in Alzheimer's disease over 12 months.</i>
2004-2008	Neurochem Pharma. Principal investigator <i>Alzhemed vs placebo in mild Alzheimer's disease over 72 weeks.</i>
2005-2008	Pfizer Canada. Principal investigator - \$20,000 <i>Pilot study on use of Top Symptoms and structured assessment of vascular risk factors in dementia</i>
2005-2008	CIHR – Heart and Stroke Foundation – AD Soc Canada With Sylvie Belleville - \$342,393 <i>Impact of vascular dementia, vascular MCI and vascular health on cognition</i>
2006-2008	Myriad Pharmaceuticals. Site Principal Investigator <i>Safety and efficacy of R-flurbiprofen in mild Alzheimer's disease over 18 months</i>
2006-2007	Genizon. Principal investigator – <i>Genetic studies in French-Canadian populations</i>
2006-2011	CIHR Co-investigator with S Belleville and Christian Bocti - \$510,550 <i>Understanding cognitive changes in mild cognitive impairment: neuropsychological and neuroimaging studies.</i>

2008-2012	CIHR Co-investigator with K. Rockwood et al. - \$4,000,000 <i>The Canadian Dementia Knowledge Translation Network</i>
2008-2009	Réseau de bio-imagerie du Québec. Co-investigator with S Belleville, C. Bocti, F. Massoud. - \$9,514 <i>Mesure quantitative des changements de la matière blanche et lien avec la cognition chez des personnes âgées avec trouble cognitif léger.</i>
2009-2010	CIHR Co-investigator with S. Belleville, F. Massoud, C. Bocti - \$100,000 <i>Relation between structural brain imaging and cognition in mixed and vascular mild cognitive impairment.</i>
2009-2010	Eli Lilly Canada. Site principal investigator <i>Effect of LY450139, a <math>\gamma</math>-secretase inhibitor, on the progression of Alzheimer's disease as compared to placebo.</i>
2009-2011	Sonexa Therapeutics Inc. Canadian principal investigator <i>Double-blind placebo-controlled study of ST101 in the treatment of Alzheimer's disease.</i> <i>Double-blind placebo-controlled study of ST101 in the treatment of Alzheimer's disease in subjects receiving donepezil.</i>
2010	Pfizer Canada Inc. Site principal investigator <i>Phase 3 study with Dimebon (PF-01913539) in moderate to severe Alzheimer's disease.</i>
2010-2015	CIHR Co-investigator with J. Montplaisir, N. Gosselin, O. Monchi, JP Soucy. \$145,909/ year. <i>Sleep and Mild Cognitive Impairment.</i>
2011-2012	Réseau de bio-imagerie du Québec. Co-investigator with M.A. Bruneau, S. Belleville, C. Bocti, P. Giannakopoulos, O. Lungu. - \$10,000 <i>Effet sur la plasticité cérébrale d'un inhibiteur sélectif de la recapture de la sérotonine (IRSC) chez des patients souffrant d'un trouble cognitif léger.</i>
2011-2015	CIHR Co-investigator with P. Rosa-Neto, JP Soucy. - \$157,925/year <i>In vivo quantification of glutamatergic abnormalities in patients with Alzheimer's disease.</i>
2011-2016	CIHR Co-investigator with S. Belleville, O. Monchi. - \$113,217/year. <i>Understanding memory changes and brain plasticity in MCI.</i>
2012-2015	Pfizer-FRSQ Co-investigator with L. Collins, H. Chertkow, S. Duchesne <i>Entre le laboratoire et le chevet: validation de bio-marqueurs optimisés par résonance magnétique pour le diagnostic clinique précoce et le pronostic dans la maladie d'Alzheimer.</i> - \$599,621 total.
2012-2017	CIHR Co-investigator with N. Gosselin, J. Montplaisir, L De Beaumont, J.Gagnon, JP Soucy. \$122,307/ year. <i>Obstructive sleep apnea and Mild Cognitive Impairment.</i>
2012-2016	CIHR Co-investigator with V. Bohbot, H. Chertkow, J. Lerch, M. Rajah. \$254,484 per year. <i>Virtual reality based spatial memory intervention for patients with Mild Cognitive Impairment.</i>
2012	RQRV Co-investigator with S. Belleville, O. Monchi, N. Bier, JM Villalpendo, P. Nolin. \$8,500. <i>Interventions cognitives: faire appel à la réalité virtuelle pour favoriser le Transfert aux situations de vie complexe.</i>
2012-2016	CIHR Team Grant, China-Canada. PI with Drs J. Jia, D. Doucet, G.Y. Hsiung, A. Labbe, P. Rosa-Neto, A.D. Sadovnick. \$250,000 per year. <i>Diagnostic biomarkers for pre-dementia Alzheimer Disease</i>

2012-2016	CQDM network and research grant. Co-investigator with Drs R. Hodge, P. Belec, S. Beleville, J. Doyon, O. Monchi, Y. Deschaintre, C. Bocti. \$1,498,786 total amount. <i>A new window on mitochondrial dysfunction in Alzheimer's disease.</i>
2013-2018	CIHR co-investigator with N. Rajah, J. Pruessner, J. Breitner, C. Grady. \$619,428 total amount <i>Structural and functional neuro-anatomical correlates of memory for context across the adult lifespan.</i>
2013	Molson Knowledge Exchange Fund. Co-applicant with P. Rosa-Neto (PI), J. Pruessner, A. Leuzy. \$25,000. <i>Molson Master Class Series in Alzheimer's disease</i>
2013-2016	Fond d'innovation Pfizer-FRQS. Co-applicant with S. Belleville (PI), D.Boyer, F. Calon, H. Chertkow, S. Duchesne, P. Gaudreau, C. Hudon, MJ Kerggoat, A. Leblanc, N. Leclerc. \$833,076/year. <i>Consortium pour l'identification précoce de la maladie d'Alzheimer</i>
2012-	Abbott M11-793. Randomized double-blind, placebo-controlled study of ABT-426 in subjects mild to moderate Alzheimer's disease and stable doses of acetylcholinesterase inhibitors. PI for Canada. [Training included GCP].
2013-	Abbott M11-428. Long-term safety and tolerability of ABT-126 in subjects with mild to moderate Alzheimer's disease and stable doses of acetylcholinesterase inhibitors. PI for Canada. [Training included GCP]

## CONTRACTS AWARDED

1988	Health and Welfare Canada (LCDC)	\$10,000
1989	Health and Welfare Canada (LCDC)	\$40,000
1989	Health and Welfare Canada (LCDC)	\$10,000
1990	Health and Welfare Canada (LCDC)	\$65,000
	<i>for pilot and field studies of biological factors in Alzheimer's disease</i>	
1995	Cree Board of Health and Social Services of James Bay	
	<i>for pilot study of the role of methylmercury in parkinsonism</i>	
		\$72,480

## CURRENT TEACHING ACTIVITIES

### 1. LECTURES AT MCGILL UNIVERSITY

Lecture on ethics of research in cognition, Neuroethics (NSCI300).

Lecture on pharmacotherapy of dementia, 2<sup>nd</sup> year medical students.

Lecture on dementias, Neurology Residents.

Update on the diagnosis and management of Alzheimer's disease, Psychiatry residents rotations, Douglas Mental Health Research Institute

**2. LECTURES AT UNIVERSITÉ DE MONTRÉAL**

Cours de médecine buccale I, STO 3080, une heure sur la maladie d'Alzheimer

**3. RESEARCH STUDENTS/FELLOWS DIRECTLY SUPERVISED**

1981	Jean St-Louis, MRC Summer Student (2 months)
1982-1986	Kiran Yashpal, Graduate Student, Ph.D. Program, Department of Neurology and Neurosurgery, McGill University
1982-1983	Andrea Cohen, Undergraduate Student, B.Sc. Honors Program, Department of Physiology, McGill University
1983	José Segura, MRC Summer Student (2 months)
1985	Stéphane Ledoux, Neurogeriatric elective (1 months)
1985-1989	Myreille Gauvin, Graduate Student, M.Sc. Program, Department of Neurology and Neurosurgery, McGill University
1987	Hélène Masson, Clinical Research Fellow, Sandoz Canada (6 months)
1988	William Regonold, Neurogeriatric elective (1 month)
1988	Paule Hottin, Clinical Fellow, Neurogeriatric studies
1988	Anthony Hall, Neurogeriatric elective (1 month)
1988	Louise Carrier, Psychogeriatric Studies (6 months)
1988-1994	Isabelle Aubert, Graduate student, M.Sc., Ph.D. Program, Dept. Neurology & Neurosurgery, McGill University
1988-1998	Amalia Issa, Graduate student, M.Sc., Ph.D. Program, Dept. Neurology & Neurosurgery, McGill University
1988	Claus Wallech, Neurology Fellow, Federal Republic of Germany (4 months)
1989-1990	Annie Baccichet, Graduate student, M.Sc. Program, Dept. Neurology & Neurosurgery, McGill University
1990	Sarah Sultan, Royal College Program on Psychopharmacology (3 months)
1991	Richard Camicioli, Clinical Research Fellow (4 months)
1992-1994	Michel Panisset, MRC fellow (2 years)
1992-1994	Yamina Lakmache, Graduate Student, Ph.D. Program, Department of Psychology, Université de Montréal
1994	Joanna Vainer, Royal College Program on Psychopharmacol. (3 months)
1994-1995	Evelyn Keller, Clinical Research Fellow, Sandoz Canada (12 months)
1995-1996	François Rousseau, Clinical Research Fellow, Sandoz Canada (12 months)
1996-2002	Andrew Law, Graduate Student, PhD Program, Dept. Neurology & Neurosurgery, McGill University
1996-1997	Yizhuang Zou, Clinical Research Fellow in Psychiatry, Novartis Canada (12 months)
1997-1998	Ling Han, Clinical Research Fellow, Novartis Canada (12 month)
2000	Howard Margolese, Clinical Research Fellow, Royal College (3 months)
2001	Emmanuelle Levy, Clinical Research Fellow, Royal College (3 month)
2002	Seonghwan Kim, Clinical Research Fellow, University of Seoul (2 months)
2002	Ned Bhanji, Clinical Research Fellow, Royal College (2 months)
2005	Catherine Agbokou, Clinical Research Fellow, Royal College (2 months)
2006	Florian Ferreri, Clinical Research Fellow, Royal College (2 months)
2006-2007	Dennis Seow, Clinical Research Fellow (6 months)
2007-2008	Brice Berdugo, Interne en pharmacie, Hôpital Pitié-La Salpêtrière, Paris
2009	Marina Tedeschi Dauar, Clinical Research Fellow, Sao Paulo (4 months)
2009-	Antoine Leuzy, summer student, then MSc student
2010- 2011	Mohammed Eid M Alotaibi, MSc student
2010-2012	Liyong Wu, Clinical Research Fellow (18 months)

2011-	Dorothy Shoemaker, MSc student
2011-2013	Cynthia Forlini (PhD, IPN)
2012-	Laksanum Cheewakriengkrai, Clinical Research Fellow, Bangkok (24 months)
2012-	Seqian Wang, MSc student
2013-	Sara Kazim, Clinical Research Fellow, The Emirates (2 months)

### 3. **RESEARCH STUDENTS SUPERVISED AS EXTERNAL COMMITTEE MEMBER**

1985-1987	Michael Wainberg and Jennifer Stewart, M.Sc. Students, School of PT/OT, McGill University
1986-1988	Warren Zackon, Graduate Student, Ph.D. Program, Department of Psychology, McGill University
1986-1990	Mona Baumgarten, Graduate Student, Ph.D. Program, Department of Epidemiology, McGill University
1987-1993	Lili Liu, Graduate student, M.Sc. Program, Ph.D. Program, School of PT/OT, McGill University
1987-1988	Lizzy Tannenbaum, Graduate student, M.Sc. Program School of PT/OT, McGill University
1988-1990	Hélène Laberge, Graduate Student, M.Sc. Program, School of PT/OT, McGill University
1989-1991	Christian Shreiqui, Graduate Student, M.Sc. Program, Department of Psychiatry, McGill University
1994-1999	Hélène Brassard, Graduate Student, Ph.D. Program, Faculté de droit, Université de Montréal
1997-2002	Christian Duval, Graduate Student, Ph.D. Program Department of Neurology and Neurosurgery, McGill University

### 4. **RECENT THESIS REVIEW (2009-2013)**

Claudie Charbonneau, U de Montréal  
Anna Atti, Karolinska Institutet

## PUBLICATIONS

### A. **Articles and book chapters**

- 1) Sasaki C, Nowacynski W, Kuchel O, Chavez, C, Ledoux F, Gauthier S, Genest J. Plasma progesterone in normal subjects and patients with benign essential hypertension on normal, low, and high sodium intake. The Journal of Clinical Endocrinology and Metabolism, 34, 650-660, 1972.
- 2) Quik M, Sourkes TL, Dubrovsky B, Gauthier S, Role of the raphe nuclei in the regulation of adrenal tyrosine hydroxylase. Brain Research, 122, 183-190, 1977.
- 3) Etienne P, Gauthier S, Johnson C, Collier B, Mendis, I., Dastoor, D., Cole, M., Muller, H.F., Clinical effects of choline in Alzheimer's disease. The Lancet, 311, 508, 1978.
- 4) Etienne, P., Gauthier, S., Dastoor, C., Collier, B., Ratner, J. Lecithin in Alzheimer's disease. The Lancet, 312, 1206, 1978.
- 5) Gauthier, S., Gagner, J.-P., Sourkes, T.L. Central neurogenic regulation of adrenal tyrosine hydroxylase. In "Catecholamines, Basic and Clinical Frontier". I. Kopin, J. Barchas, E. Usdin, (eds.) Pergamon Press, New



York, 73-75, 1979.

- 6) Botez, M.I., Young, S.N., Bachevalier, J., Gauthier, S., Folate deficiency and decreased brain 5-hydroxytryptamine synthesis in man and rat. Nature, 278, 182-183, 1979.
- 7) Gauthier, S. La maladie de Parkinson: Aspects cliniques récents. Physiothérapie Canada, 31, 209-212, 1979.
- 8) Laxer KD, Sourkes TL, Fang TY, Young SN, Gauthier S, Missala, K. Monoamine metabolites in the CSF of epileptic patients. Neurology, 29, 1157-1161, 1979.
- 9) Gauthier S., Gagner J-P, Sourkes TL. Role of descending spinal pathways in the regulation of adrenal tyrosine hydroxylase. Experimental Neurology, 66, 42-54, 1979.
- 10) Young, S.N., Gauthier, S., Anderson, G.M., Purdy, W.C. The significance of and relationships between major and minor tryptophan metabolites in cerebrospinal fluid. In "Biological Psychiatry Today: Developments in Psychiatry, Vol. 2". C. Ballus (ed.). Elsevier/North Holland Biomedical Press, Amsterdam, 504-508, 1979.
- 11) Brown, G.M., Young, S.N., Gauthier, S., Tsui, H., Grota, L.J. Melatonin in human cerebrospinal fluid in day time: Its origin and variation with age. Life Sciences, 25, 929-936, 1979.
- 12) Etienne, P., Gauthier, S., Dastoor, D., Collier, B., Ratner, J. Alzheimer's disease: Clinical effects of lecithin treatment. In "Nutrition and the Brain", Volume 5. A. Barbeau, J.H. Growdon, R.J. Wurtman (eds.). Raven Press, New York, 389-396, 1979.
- 13) Young, S.N., Gibson, C.J., Gauthier, S. Possible mechanisms for the therapeutic window in the antidepressant action of tryptophan. In "Recent Advances in Canadian Neuropsychopharmacology". P. Grof, B. Saxena (eds.). S. Karger New York, 1979.
- 14) Young, S.N., Anderson, G.M., Gauthier, S., Purdy, W.C. The origin of indoleacetic and indolepropionic acid in rat and human cerebrospinal fluid. Journal of Neurochemistry, 34, 1087-1092, 1980.
- 15) Etienne, P. Gauthier, S., Dastoor, C., Collier, B., Ratner, J. Alzheimer's disease: Clinical effects of lecithin treatment. In "Alzheimer's Disease: Early Recognition of Potentially Reversible Deficits". A.I.M. Glenn, L.J. Whally (eds.). Churchill and Livingston, London, 173-178, 1980.
- 16) Young, S.N., Gauthier, S., Lal, S. CNS tryptamine metabolism: Regulation in neurological controls and patients with hepatic coma. D.G. Irwine (ed.). Saskatchewan Health Department, Saskatoon, 57-58, May 1980.
- 17) Young, S.N., Gauthier, S., Anderson, G.M., Purdy, W.C. Tryptophan, 5-hydroxyindoleacetic acid and indoleacetic acid in human cerebrospinal fluid: interrelationships and the influence of age, sex, epilepsy, and anticonvulsant drugs. Journal of Neurology, Neurosurgery, and Psychiatry, 43, 438-445, 1980.
- 18) Sternberg, E.M., Van Woert, M.H., Young, S.N., Magnussen, I., Baker, H., Gauthier, S., Osterland, S.K. Development of a scleroderma-like illness during L-5HTP-carbidopa therapy. New England Journal of Medicine, 303, 782-787, 1980.
- 19) Young, S.N., Gauthier, S. Tryptophan availability and the control of 5-hydroxytryptamine and tryptamine synthesis in human CNS. In "Serotonin: Current Aspects of Neurochemistry and Function". Advances in Experimental Biology and Medicine. B. Harber, S. Gabay, M.R. Issidorides, S.G.A. Alirisates (eds.). Plenum Press, New York, 1981.

- 20) Gauthier, S., Young, S.N., Baxter, D.W. Myoclonies du voile associées à une diminution de l'acide 5-hydroxy-indole-acétique céphalo-rachidien et répondant au clonazepam. Canadian Journal of Neurological Sciences, 8, 51-54, 1981.
- 21) Young, S., Gauthier S. Effects of tryptophan administration on tryptophan, 5-hydroxyindoleacetic acid and indoleacetic acid in human lumbar and cisternal cerebrospinal fluid. Journal of Neurology, Neurosurgery and Psychiatry, 44, 323-328, 1981.
- 22) Etienne, P., Dastoor, D., Gauthier, S., Ludwick, M.A., Collier, B. Lack of effect of a three month treatment with lecithin in Alzheimer's disease. Neurology, 31, 1552-1554, 1981.
- 23) Gagner, J.-P., Gauthier, S., Sourkes, T.L. Transynaptic regulation of adrenal tyrosine hydroxylase in tracing central autonomic pathways. In "Function and Regulation of Monoamine Enzymes: Basic and Clinical Aspects". N.Weiner, M.B.H. Youdim, E. Usdin (eds.). McMillan Publications, 287-296, 1982.
- 24) Young, S.N., Gauthier, S., Chouinard, G., Anderson, G.M., Purdy, W.C. The effects of carbidopa and benserazide on human plasma 5-hydroxytryptophan levels. Journal of Neural Transmission, 52, 83-87, 1982.
- 25) Botez, M.I., Young, S.N., Bachevalier, J., Gauthier, S. Thiamine deficiency and cerebrospinal fluid 5-hydroxyindoleacetic acid: a preliminary study. Journal of Neurology, Neurosurgery, and Psychiatry, 45, 731-733, 1982.
- 26) Perry, T.L., Hansen, S., Wall, R.A., Gauthier, S. Human CSF GABA concentrations: revised downward for controls, but not decreased in Huntington's chorea. Journal of Neurochemistry, 38, 766-773, 1982.
- 27) Young, S.N., Davis, B.A., Gauthier, S. Precursors and metabolites of phenylethylamine, m and p-tyramine and tryptamine in human lumbar and cisternal cerebrospinal fluid. Journal of Neurology, Neurosurgery and Psychiatry, 45, 633-639, 1982.
- 28) Etienne, P., Dastoor, D., Gauthier, S., Ludwick, R., Collier, B. Lecithin in the treatment of Alzheimer's disease. In "Alzheimer's disease - a report of progress in research". S. Corkin, K.L. Davies, J.N. Growdon, E. Usdin, R. Wurtman (eds.). Raven Press, New York, 369-372, 1982.
- 29) Botez, M.I., Young, S.N., Bachevalier, J., Gauthier, S. Effect of folic acid and vitamine B<sub>12</sub> deficiencies on human cerebrospinal fluid 5-hydroxyindoleacetic acid. Annals of Neurology, 12, 479-484, 1982.
- 30) Wood, P.L., Etienne, P., Lal, S., Gauthier, S., Cajal, S., Nair, N.P.V. Reduced lumbar CSF somatostatin levels in Alzheimer's disease. Life Sciences, 31, 2073-2079, 1982.
- 31) Robitaille, Y., Wood, P.L., Etienne P., Lal, S., Finlayson, M.H., Gauthier, S., Nair, N.P.V. Reduced cortical choline acetyltransferase activity in Gerstmann-Straussler Syndrome. Progress in Neuropsychopharmacology and Biological Psychiatry, 6, 529-531, 1982.
- 32) Gauthier, S., Sourkes, T.L. Anatomical and biochemical basis of the extrapyramidal disorders. Progress in Neuropsychopharmacology and Biological Psychiatry, 6, 595-599, 1982.
- 33) Gagner, J.-P., Gauthier, S., Sourkes, T.L. Participation of spinal monoaminergic and cholinergic systems in the regulation of adrenal tyrosine hydroxylase. Neuropharmacology, 22,45-53, 1983.
- 34) Waserman, J., Lal, S., Gauthier, S. Gilles de la Tourette's syndrome in monozygotic twins. Journal of

Neurology, Neurosurgery and Psychiatry, 46, 75-77, 1983.

- 35) Gauthier, L., Gauthier, S. Functional rehabilitation of patients with Parkinson's disease. Physiotherapy Canada, 35, 220-222, 1983.
- 36) Van Houten, M., Nance, D.M., Gauthier, S., Posner, B.I. Origin of insulin-receptive nerve terminals in rat median eminence. Endocrinology, 113, 1393-1399, 1983.
- 37) Gauthier, S., Sniderman, A. Rubral tremor as a manifestation of chylomicron retention disease. Annals of Neurology, 14, 591, 1983.
- 38) Sourkes, T.L., Gauthier, S. Levodopa and other dopamine agonists in the treatment of Parkinson's disease. In "Discoveries in Pharmacology", M.J. Parnham, J. Bruinvels (eds.). Elsevier/North-Holland Biomedical Press, Amsterdam, 249-267, 1983.
- 39) Wood, P.L., Nair, N.P.V., Etienne, P., Lal, S., Gauthier, S., Robitaille, Y., Bird, E.D., Palo, J., Haltia, M., Peatau, A. Lack of cholinergic deficit in the neocortex in Pick's disease. Progress in Neuropsychopharmacology and Biological Psychiatry, 7, 725-727, 1983.
- 40) Young, S.N., Joseph, M.H., Gauthier, S. Studies on kynurenine in human cerebrospinal fluid: lowered levels in epilepsy. Journal of Neural Transmission, 58, 793-204, 1983.
- 41) Wood, P.L., Etienne, P., Lal, S., Nair, N.P.V., Finlayson, M.H., Gauthier, S., Palo, J., Haltia, M., Paetau, A., Bird, E.D. A post-mortem comparison of the cortical cholinergic systems in Alzheimer's disease and Pick's disease. Journal of Neurological Sciences, 62, 211-217, 1983.
- 42) Gauthier, S., Quesney, L.F. Assessment of cortical dopaminergic activity in Parkinson's disease by EEG. Advances in Neurology, 40, 399-402, 1984.
- 43) Sherwin, A., Quesney, F., Gauthier, S., Olivier, A., Robitaille, Y., McQuaid, P., Harvey, C., Van Gelder, N. Enzymic changes in actively spiking area of human epileptic cerebral cortex. Neurology, 34, 929-933, 1984.
- 44) Young, S.N., Gauthier, S., Kiely, M.E., Lal, S., Brown, G.M. Effect of oral melatonin administration on melatonin, 5-hydroxyindoleacetic acid, indoleacetic acid and cyclic nucleotides in human cerebrospinal fluid. Neuroendocrinology, 39, 87-92, 1984.
- 45) Vincken, W., Gauthier, S., Dollfuss, R., Hanson, R., Cosio, M.G. Involvement of upper airway muscles in extrapyramidal disorders - a cause of airflow limitation. New England Journal of Medicine, 311, 438-442, 1984.
- 46) Gagner, J.-P., Gauthier, S., Sourkes, T.L. Descending spinal pathways mediating the responses of adrenal tyrosine hydroxylase and catecholamines to insulin and 2-deoxyglucose. Brain Research, 325, 187-197, 1985.
- 47) Van Houten, M., Khan, M.N., Walsh, R.J., Baquiran, G.B., Renaud, L.P., Bourque, C., Sgro, S., Gauthier, S., Chretien, M., Posner, B.I. N-terminal specificity and axonal localization of adrenocorticotropin binding sites in rat median eminence. Proceedings of the National Academy of Sciences, 82, 1271-1275, 1985.
- 48) Ekker, M., Gauthier, S., Sourkes, T.L. Transneuronal induction of adrenal ornithine decarboxylase through descending spinal pathways. Neurochemistry International, 7, 467-471, 1985.
- 49) Gagner, J.-P., Gauthier, S., Sourkes, T.L. Differential effects of transection of the spinal cord and splanchnic

- nerve on adrenal tyrosine hydroxylase and catecholamines. Neuroscience, 14, 907-920, 1985.
- 50) Lal, S., Wood, P.L., Kiely, M.E., Etienne, P., Gauthier, S., Stratford, J., Ford, R.M., Nair, N.P.V. Cerebrospinal fluid acetylcholinesterase in dementia and in sequential samples of lumbar CSF. Neurobiology of Aging, 5, 269-274, 1984.
- 51) Suranyi-Cadotte, B.F., Nestoros, J.N., Nair, N.P.V., Lal, S., Gauthier, S. Parkinsonism induced by high doses of diazepam. Biological Psychiatry, 20, 451-460, 1985.
- 52) Ghadirian, A.M., Gauthier, S., Bertrand, G. Anxiety attacks in a patient with the right temporal lobe meningioma. Journal of Clinical Psychiatry, 47, 270-271, 1986.
- 53) Yashpal, L. Gauthier, S., Henry, J.L. Substance P given intrathecally at the spinal T<sub>9</sub> level increases adrenal output of free adrenaline and noradrenaline in the rat. Neuroscience, 15, 529-536, 1985.
- 54) Gagner, J.-P., Gauthier, S. Estimation of adrenal catecholamines by elevated-temperature liquid chromatography with amperometric detection. Journal of Chromatography, 342, 363-369, 1985.
- 55) Berger, L. Gauthier, S., Leblanc, R. Akinetic mutism and parkinsonism associated with obstructive hydrocephalus. Canadian Journal of Neurological Sciences, 12, 255-258, 1985.
- 56) Suranyi-Cadotte, B.E., Gauthier, S., Lafaille, F., Deflores, S., Dam, T.V., Nair, N.P.V., Quirion, R. Platelet <sup>3</sup>H-imipramine binding distinguishes depression from Alzheimer dementia. Life Sciences, 37, 2305-2311, 1985.
- 57) Etienne, P., Robitaille, Y., Gauthier, S., Nair, N.P.V. Nucleus basalis neuronal loss and neuritic plaques in advanced Alzheimer's disease. Canadian Journal of Physiology and Pharmacology, 64, 318-324, 1986.
- 58) Gauthier, S. Practical guidelines for the antemortem diagnosis of senile dementia of the Alzheimer type. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 9, 491-495, 1986.
- 59) Gauthier, S. Idiopathic spasmodic torticollis: pathophysiology and treatment. Canadian Journal of Neurological Sciences, 13, 88-90, 1986.
- 60) Gauthier, S., Geoffroy, G., André Barbeau, 1931-1986. Neurology, 36, 802, 1986.
- 61) Gauthier, S., Geoffroy, G. In memoriam of André Barbeau. Movement Disorders, 1, 89-90, 1986.
- 62) Wainberg, M., Barbeau, H., Gauthier, S. Quantitative assessment of the effect of cyproheptadine on spastic parietic gait: a preliminary study. Journal of Neurology, 233, 311-314, 1986.
- 63) Gauthier, S., Robitaille, Y., Quirion, R., Leblanc, R. Antemortem laboratory diagnosis of Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 10, 391-403, 1986.
- 64) Quirion, R., Martel, J.C., Robitaille, Y., Etienne, P., Wood, P.L., Nair, N.P.V., Gauthier, S. Neurotransmitter and receptor deficits in senile dementia of the Alzheimer type. Canadian Journal of Neurological Sciences, 13, 503-510, 1986.
- 65) Gauthier, S., Leblanc, R., Robitaille, Y., Quirion, R., Carlsson, G., Beaulieu, M., Bouchard, R., Dastoor, D., Ervin, F., Gauthier, L., Gauvin, M., Henry, J.L., McLachlan, D., Palmour, R. Transmitter-replacement therapy in Alzheimer's disease using intracerebroventricular infusions of receptor agonists. Canadian Journal of Neurological Sciences, 13, 394-402, 1986.

- 
- 66) Etienne, P., Robitaille, Y., Wood, P., Gauthier, S., Nair, N.P.V., Quirion, R. Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease. Neuroscience, 19, 1279-1291, 1986.
  - 67) Yashpal, L. Gauthier, S., Henry, J.L. Substance P given intrathecally at the spinal T<sub>9</sub> level increases arterial pressure and heart rate in the rat. Journal of the Autonomic Nervous System, 18, 93-103, 1987.
  - 68) Guadirian, A.M., Gauthier, S., Wong, T. Clonazepam in patients abruptly withdrawn from clonazepam while receiving neuroleptic medication. American Journal of Psychiatry, 144, 686, 1987.
  - 69) Gauthier, L., Dalziel, S., Gauthier, S. The benefits of group occupational therapy for patients with Parkinson's disease. The American Journal of Occupational Therapy, 41, 360-365, 1987.
  - 70) Cridland, R.A., Yashpal, K., Romita, V.V., Gauthier, S., Henry, J.L. Distribution of label after intrathecal administration of <sup>125</sup>I-substance P in the rat. Peptides, 8, 213-221, 1987.
  - 71) Arthurs, B., Flanders, M., Coderre, F., Gauthier, S., Dresner, S., Stone, L. Therapy of blepharospasm: medical, surgical or botulinum toxin. Canadian Journal of Ophthalmology, 22, 24-28, 1987.
  - 72) Leblanc, R. Tyler J.L., Mohr, G., Meyer E., Diksic, M., Yamamoto, L., Taylor, L., Gauthier, S., Hakim, A. Hemodynamic and metabolic effects of cerebral revascularization. Journal of Neurosurgery, 66, 529-535, 1987.
  - 73) Gauthier, S., Gauthier, L. Current status of levodopa therapy disease. Canadian Journal of Neurological Sciences, 14, 452-454, 1987.
  - 74) Yashpal, K., Gauthier, S., Henry, J.L. Oxytocin administered intrathecally selectively increases heart rate rather than arterial pressure in the rat. Journal of the Autonomic Nervous System, 20-167-178, 1987.
  - 75) Metuzals, J., Robitaille, Y., Moughton, S., Gauthier, S., Leblanc, R. Transformation of the neurofilamentous network components into PHF-like stands and PHF paracrystals. In "Alteration in the Neuronal Cytoskeleton in Alzheimer's disease", Perry, G (ed) Plenum Publishing Corporation, 1987.
  - 76) Quirion, R., Welner, S., Gauthier, S., Bedard, P. Neurotensin binding sites in primate and human brain: Autoradiographic distribution and effects of MPTP treatment. Synapse, 1, 559-566, 1987.
  - 77) Pilapil, C., Welner, S., Magnan, J., Gauthier, S., Quirion, R. Autoradiographic distribution of multiple classes of opioid receptor binding sites in human forebrain. Brain Research Bulletin, 19, 611-615, 1987.
  - 78) Gauthier, S., Bertrand, G., Parot, P. Jr. Role of surgical anterior rhizotomies in the management of idiopathic spasmodic torticollis. Advances in Neurology, 50, 633-635, 1988.
  - 79) Boisseau, M., Chamberland, G., Gauthier, S. Handwriting analysis in several extrapyramidal disorders. Journal Canadien des Sciences Judiciaires, 20, 139-146, 1988.
  - 80) Redies, C., Diksic, M., Collier, B., Gjedde, A., Thompson, C.J., Gauthier, S., Feindel, W.H. Influx of a choline analog to dog brain measured by PET. Synapse, 2, 406-411, 1988.
  - 81) Metuzals, J., Robitaille, Y., Houghton, S., Gauthier, S., Kang, C.Y., Leblanc, R. Neuronal transformations in Alzheimer's disease. Cell and Tissue Research, 252, 239-248, 1988.

- 
- 82) Araujo, D.M., Lapchak, P.A., Robitaille, Y., Gauthier, S., Quirion, R. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. Journal of Neurochemistry, 50, 1914-1923, 1988.
- 83) Leblanc, R., Gauthier, S., Gauvin, M., Quirion, R., Palmour, R., Masson, H. Neurobehavioral effects of intrathecal somatostatinergic treatment in subhuman primates. Neurology, 38, 1887-1890, 1988.
- 84) Gauthier, S., Masson, H., Gauthier, L., Bouchard, R., Collier, R., Cacher, Y., Bailey, R., Becker, R., Bergman, H., Charbonneau, R., Dastoor, D., Gayton, D., Kennedy, J., Kissel, C., Krieger, M., Kushnir, S., Lamontagne, A., St-Martin, M., Morin, J., Nair, N.P.V., Neirinck, L., Ratner, J., Suissa, S., Tesfaye, Y., Vida, S. Tetrahydroaminoacridine and Lecithin in Alzheimer's Disease. In "Current Research in Alzheimer Therapy", Taylor and Francis, New York, 1988.
- 85) Suranyi-Cadotte, B., Gauthier, S., Lafaille, F., DeFlores, S., Dam, T.V., Nair, N.P.V., Quirion, R. Platelet [<sup>3</sup>H] - Imipramine binding differentiates major depression from Alzheimer's disease in elderly. In "New Concepts in Depression". Briley, M., Fillion, G., (eds) Pierre Fabre Monograph Series, Vol. 2, MacMillan Press, 137-143, 1988.
- 86) Metzals, J., Robitaille, Y., Houghton, S., Gauthier, S., Leblanc, R. Paired helical filaments and the cytoplasmic-nuclear interface in Alzheimer's disease. J. Neurocytology, 17, 827-833, 1988.
- 87) Gauvreau, D., Bouchard, R., Gauthier, S., Mathieu, J., Boily, C., Cholette, A., Robitaille, Y., Bouchard, P., Bouchard, N., Doyon, L.P., Gaudreault, M., Ouellet, A., Dumont, M., Kishka, P., Fournier, C., Nalbantoglu, J., Lacoste-Royal, G., Gautrin, D., Froda, S., de Braekeleer, M., Bouchard, G., Mortimer, J. The Image Project: A Geographical Laboratory for the Integration of Multidisciplinary Data. In "Genetics and Alzheimer's Disease". Sinet, P.M., Lamour, Y., Christen, Y. (eds) Springer-Verlag, 40-50, 1988.
- 88) Wolfe, L.S., Gauthier, S., Haltia, M., Palo, J. Dolichol and dolichylphosphate in the neuronal ceroid-lipofuscinoses and other diseases. American Journal of Medical Genetics, Supplement 5, 233-242, 1988.
- 89) Vida, S., Gauthier, L., Gauthier, S. Canadian Collaborative Study on Tetrahydroaminoacridine and lecithin treatment of Alzheimer's Disease: Effect on mood. Canadian Journal of Psychiatry, 34, 165-170, 1989.
- 90) Lal, S., Nair, N.P.V., Thavundayil, J.X., Tawar, V., Tesfaye, Y., Dastoor, D., Gauthier, S. and Guyda, H. Growth hormone response to Apomorphine, a dopamine receptor agonist in normal aging and in dementia of the Alzheimer type. Neurobiology of Aging, 10, 227-231, 1989.
- 91) Gauvreau, D., Bouchard, R., Gauthier, S., Mathieu, J., Boily, C., Cholette, A., Robitaille, Y., Bouchard, P., Bouchard, N., Doyon, L.-P., Gaudreault, M., Ouellet, A., Dumont, M., Kishka, P., Fournier, C., Nalbantoglu, J., Lacoste-Royal, G., Gautrin, D., Froda, S., de Braekeleer, M., Bouchard, G. The Image Project: A multimatrix model for the study of Alzheimer's disease. In "Familial Alzheimer's Disease: Molecular genetics, clinical aspects and societal prospects. Blass, J.P., Miner, G., Miner, L.A., Richter, R.N., Valentine, J.L. (eds) Dekker, New York, 331-365, 1989.
- 92) Yashpal, K., Gauthier, S., Henry, J.L. Angiotensin II stimulates sympathetic output by a direct spinal action. Neuropeptides, 14, 21-29, 1989.
- 93) Gauthier, S., Bouchard, R., Bacher, Y., Bailey, P., Bergman, H., Carrier, L., Charbonneau, R., Clarfield, M., Collier, B., Dastoor, D., Gauthier, L., Germain, M., Kissel, M., Krieger, M., Kushnir, S., Lamontagne, A., Morin, J., Nair, N.P.V., Neirinck, L., Ratner, J., St-Martin, M., Suissa, S., Tesfaye, Y. Progress report on the

- canadian multicentre trial of Tetrahydroaminoacridine with lecithin in Alzheimer's disease. Canadian Journal of Neurological Sciences, 16, 543-546, 1989.
- 94) Gauthier, D., Gauthier, S. Alzheimer's disease: Current environmental aetiological hypothesis. Canadian Journal of Neurological Sciences, 16, 375-387, 1989.
- 95) Parkinson Study Group. Datatop: A multicentre controlled clinical trial in early Parkinson's Disease. Archives of Neurology, 46, 1052-1060, 1989.
- 96) Parkinson Study Group. Effect of Deprenyl on the progression of disability in early Parkinson's Disease. New England Journal of Medicine, 321, 1364-1371, 1989.
- 97) Gauthier, D., Nalbantoglu, J., Lacoste-Royal, G., Grenon, M., Gauthier, S., Bouchard, R., Mathieu, J., Robitaille, Y., Doyon, L.P., Bergman, H., Cholette, A., De Broakeleer, M., Bouchard, G., Gauvreau, D. Ascertainment of informative Alzheimer's disease families from the IMAGE project registry for genetic linkage analysis studies. Canadian Journal of Neurological Sciences, 16, 468-472, 1989.
- 98) Shoulson, I. and the Parkinson Study Group: Deprenyl and tocopherol antioxydative therapy of Parkinsonism (DATATOP). Acta Neurologica Scandinavia (suppl. 126) 80:171-175, 1989.
- 99) Quirion, R., Aubert, I., Lapchak, P.A., Schaum, R.P., Teolis, S., Gauthier, S., Araujo, D.M. Muscarinic receptor sub-types in human neurodegenerative disorders: focus on Alzheimer's disease. Trends in Pharmacological Sciences, 10 (Supplement), 80-84, December 1989.
- 100) Baumgarten, M., Becker, R., Gauthier, S. Validity and reliability of the dementia behavior disturbance scale. Journal of the American Geriatrics Society, 38, 221-226, 1990.
- 101) Gauthier, L., Gauthier, S. Assessment of functional changes in Alzheimer's disease. Journal of Neuroepidemiology, 9, 103-188, 1990.
- 102) Gauthier, S., Bouchard, R., Lamontagne, A., Bailey, P., Bergman, H., Ratner, J., Tesfaye, Y., St-Martin, M., Bacher, Y., Carrier, L., Charbonneau, R., Clarfield, A.M., Collier, B., Dastoor, D., Gauthier, L., Germain, M., Kissel, C., Krieger, M., Kushnir, S., Masson, H., Morin, J., Nair, N.P.V., Neirinck, L. Tetrahydroaminoacridine - Lecithin combination treatment in intermediate stage Alzheimer's disease: results of a Canadian double-blind cross-over multicentre study. New England Journal of Medicine, 322, 1272-1276, 1990.
- 103) Wainberg, M., Barbeau, H., Gauthier, S. The effects of cyproheptadine on locomotion and on spasticity in spinal cord injured patients. Journal of Neurology, Neurosurgery and Psychiatry, 53, 754-763, 1990.
- 104) Issa, A.M., Gauthier, S., Meaney, M.J. Hypothalamic-pituitary-adrenal function in aged, cognitively impaired and unimpaired rats. Journal of Neuroscience, 10, 3247-3254, 1990.
- 105) Jankovic, J., McDermott, M., Carter, J., Gauthier, S., Goetz, C., Golbe, L., Huber, S., Koller, W., Olanov, C., Shoulson, J., Stern, M., Tanner, C., Weiner, W. and the Parkinson Study Group (PSG). Variable expression of Parkinson's disease: a base line analysis of the DATATOP cohort. Neurology, 40, 1529-1534, 1990.
- 106) Lacoste-Royal, G., Mathieu, M., Nalbantoglu, J., Julien, J.P., Gauthier, S., Gauvreau, D. Lack of association between two restriction fragment length polymorphisms in the genes for the light and heavy neuro-filament proteins and Alzheimer's disease. Canadian Journal of Neurological Sciences, 17, 302-305, 1990.
- 107) Quirion, R., Aubert, I., Robitaille, Y., Gauthier, S., Araujo, D.M., Chabot, J.G. Neurochemical deficits in

- pathological brain ageing: specificity and possible relevance for treatment strategies. Clinical Neuropharmacology, 13, suppl. 3, S73-S80, 1990.
- 108) Beuter, A., Milton, J.G., Labrie, C., Glass, L., Gauthier, S. Delayed visual feedback and motor control in Parkinson's disease. Experimental Neurology, 110, 228-235, 1990.
- 109) Lal, S., Gauthier, S., Wood, P.L., Kiely, M.W., Waserman, J., Nair, N.P.V. Red cell choline in spasmodic torticollis and in a monozygotic twin pair with Tourette's syndrome. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 14, 785-789, 1990.
- 110) Gauthier, S., McDowell, I., Hill, G. Canadian Study of Health and Aging. Psychiatry Journal of the University of Ottawa, 15, 227-229, 1990.
- 111) Liu, L., Gauthier, L., Gauthier, S. Spatial disorientation in individuals with early senile dementia of the Alzheimer type. American Journal of Occupational Therapy, 45, 67-74, 1991.
- 112) Poirier, J., Kogan S., Gauthier, S. Environment, genetics and Idiopathic Parkinson's Disease. Canadian Journal of Neurological Sciences, 18, 70-76, 1991.
- 113) Gauthier, S., Gauthier, L., Bouchard, R., Quirion, R. Treatment of Alzheimer's Disease: hopes and reality. Canadian Journal of Neurological Sciences, 18, 439-441, 1991.
- 114) Stewart, J.E., Barbeau, H., Gauthier, S. Modulation of locomotor patterns and spasticity with clonidine in spinal cord injured patients. Canadian Journal of Neurological Sciences, 18, 321-332, 1991.
- 115) Gauthier, S., Quirion, R., Leblanc, R., Bouchard, R., Gauthier, L. Thérapeutiques interventionnistes de la maladie d'Alzheimer. Dans "Démences et syndromes démentiels: approche neuropsychologique", 271-282. Habib, M., Joannette, Y., Puel, M. (eds) Masson, Paris, 1991.
- 116) Gauthier, S., Gauthier, L. Status of THA as therapy for Alzheimer's disease. Cholinergic basis for Alzheimer therapy. Becker RE and Giacolini E (eds). Birkhäuser, Boston, 224-230, 1991.
- 117) LeWitt, P.A., The Parkinson Study Group. Deprenyl's effect on slowing progression of parkinsonian disability: The DATATOP study. Acta Neurological Scandinavia. 84 (suppl. 136), 79-86, 1991.
- 118) Shoulson, I. and the Parkinson Study Group: Effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease: a preliminary report. In "Neuroprotective Therapy in Early Parkinson's Disease", UK Rinne, E Heinonen (eds.) Orion Corp, Farnos, Turku, Finland, 25-32, 1991.
- 119) Organizing Committee, Canadian Consensus Conference on the Assessment of Dementia. Assessing dementia: The Canadian Consensus. Canadian Medical Association Journal. 144, 851-853, 1991.
- 120) Beuter, A., Carrière, L., McFadyen, B., Gauthier, S. The organization of stepping in patients with Parkinson's disease: bradykinesia or discoordination? Canadian Journal of Neurological Sciences, 19, 8-16, 1992.
- 121) Baumgarten, M., Battista, R.N., Infante-Rivard, C., Hanley, J.A., Becker, R., Gauthier, S. The psychological and physical health of family members caring for an elderly person with dementia. Journal of Clinical Epidemiology, 45, 61-70, 1992.
- 122) Gauthier, S., Amyot, D. Sustained release antiparkinson agents: controlled release levodopa. Canadian Journal of Neurological Sciences, 19 (suppl. 1), 153-155, 1992.



- 
- 123) LeWitt, PA, Galloway, MP, Matson, W., Millbury, P., McDermott, M. Srivastava, DK, Oakes, D. and the Parkinson Study Group. Markers of dopamine metabolism in Parkinson's disease. Neurology, 1992; 42: 2111-2117.
- 124) Aubert, I., Araujo, D.J., Cécyre, D., Gauthier, S., Quirion, R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. Journal of Neurochemistry, 58, 529-541, 1992.
- 125) Petit, D., Montplaisir, J., Lorrain, D., Gauthier, S. Spectral analysis of the REM sleep EEG in right and left temporal regions: a biological marker of Alzheimer's Disease. Annals of Neurology, 32, 172-176, 1992.
- 126) Shoulson, I. and the Parkinson Study Group. An interim report on the effect of selegiline (L-Deprenyl) on the progression of disability in early Parkinson's disease. European Neurology 32 (suppl) 46-53, 1992.
- 127) Aubert, I., Cécyre, D., Gauthier, S., Quirion, R. Characterization of [3M] AF-DX384 putative M<sub>2</sub> binding sites in the rat brain. European Journal of Pharmacology, 217, 173-184, 1992.
- 128) Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's Disease. New England Journal of Medicine, 328, 176-183, 1993.
- 129) Poirier, J., Dea, D., Baccichet, A., Gauthier, S. Modulation of gamma-actin and alpha1-tubulin expression by corticosterone during neuronal plasticity in the hippocampus. Molecular Brain Research, 15:263-268, 1992.
- 130) Dooley NP, Gauthier S, Durham HD. Antibody to beta-amyloid precursor protein recognizes an intermediate filament-associated protein in Alzheimer and control fibroblasts. Journal Neuroscience Research 31:60-67, 1992
- 131) Poirier, J., Baccichet, A., Dea, D., Gauthier, S. Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rat. Neuroscience, 55, 81-90, 1993.
- 132) Gauthier, S., Gauthier, L. What have we learned from the THA trials to facilitate testing of new AChE inhibitors in CNS cholinergic functions and dysfunctions, C. Cuello (ed). Progress in Brain Research, volume 98, Elsevier, 427-429, 1993.
- 133) Poirier, J., Davignon, J., Bouthillier, D., Kogan, S., Bertrand, P., Gauthier, S. Apolipoprotein E polymorphism and Alzheimer's disease. The Lancet, 342, 697-699, 1993.
- 134) Petit, D., Lorrain, D., Gauthier, S., Montplaisir J. Regional spectral analysis of the REM sleep EEG in mild to moderate Alzheimer's disease. Neurobiology of aging, 14, 141-145, 1993.
- 135) Bertrand, P., Guillaume, D., Hellauer, K., Dea, D., Lindsay, J., Kogan, S., Gauthier, S., Poirier, J. Distribution of Herpes virus type 1 in DNA in selected areas of normal and Alzheimer's disease brains: a PCR study. Neurodegeneration, 2, 201-208, 1993.
- 136) Petit, D., Montplaisir, J., Lorrain, D., Gauthier, S. THA does not affect sleep or EEG spectral power in Alzheimer's disease. Biological Psychiatry, 33, 753-754, 1993.
- 137) Shultz, C.W., and the Parkinson Study Group. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Acta Neurologica Scandinavia, supplement, 87: 36-72, 1993.

- 
- 138) The Canadian Study on Health and Aging: study methods and prevalence of dementia. Canadian Medical Association Journal, 150, 899-913, 1994.
- 139) Baumgarten, M., Hanley, J.A., Infante-Rivard, C., Battista, R.N., Becker, R., Gauthier, S. Health of family caregivers of elderly persons with dementia: a longitudinal study. Annals of Internal Medicine, 120, 126-132, 1994.
- 140) Baleschi, M., Amato, M.P., Nencini, P., Praccuci, G., Lippi, A., Amaducci, L., Gauthier, S. et al. Cross-national interrater agreement on the clinical diagnostic criteria for dementia. Neurology, 44, 239-242, 1994.
- 141) Vida, S., Des Rosiers, P., Carrier, L., Gauthier, S. Depression in Alzheimer's disease: receiver operating characteristic analysis of the Cornell scale for depression in dementia and the Hamilton depression scale. Journal of Geriatric Psychiatry and Neurology, 7, 159-162, 1994.
- 142) Reis, M.F, Gold, D.P., Andres, D., Markiewicz, D., Gauthier, S. Personality traits as determinants of burden and health complaints in caregiving. The International Journal of Aging and Human Development, 39, 257-271, 1994.
- 143) Beuter, A., Mergler, D., De Geoffroy, A., Carrière, L., Bélanger, S., Varghese, L., Sreekumar, J., Gauthier, S. Diadochokinesimetry: A study of patients with Parkinson's disease and manganese exposed markers. Neurotoxicology, 15:655-664, 1994.
- 144) Kieburtz, K., McDermott, M., Como, P., Growdon, J., Brady, J., Carter, J., Huber, S., Kanigan, B., Landow, E., Rudolph, A., Saint-Cyr, J. Stern, Y., Tennis, M. Thalen, J., Shoulson, I. and the Parkinson Study Group. The effect of deprenyl and tocopherol on cognitive performance in untreated Parkinson's disease. Neurology, 44:1756-1759, 1994.
- 145) Nalbantoglu, J., Gilfix, B.M., Bertrand, P., Robitaille, Y., Gauthier, S., Rosenblatt, D., Poirier, J. Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series and an analysis of several combined studies. Annals of Neurology, 36:889-895, 1994.
- 146) Poirier, J., Aubert, I., Bertrand, P., Quirion, R., Gauthier, S., Nalbantoglu, J. Apolipoprotein E4 and cholinergic dysfunction in Alzheimer's disease. In: 'Alzheimer's disease: Therapeutic strategies'. Giacobini, E., Becker, R. (eds), Birkhäuser, Boston, 72-76, 1994.
- 147) Gauthier, S., Feldman, H., Mohr, E. Minimal efficacy criterias for medications in Alzheimer's disease. In: Alzheimer's disease - Therapeutic strategies. Giacobini, E., and Becker, R. (Eds), Birkhäuser, Boston, 431-435, 1994.
- 148) Panisset, M., Gauthier, S. Trial designs and outcome variables in anti-dementia drug testing. In: New Trends in the Diagnosis and Therapy of Alzheimer's Disease. Jellinger, KA, Ladurner, G., Windish, M., (Eds), Springer-Verlag, Wien, 91-103, 1994.
- 149) The Canadian Study of Health and Aging: patterns of caring for people with dementia in Canada. Canadian Journal on Aging, 13:470-487, 1994.
- 150) The Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada. Neurology, 44:2073-2080, 1994.

- 
- 151) Aubert, I., Poirier, J., Gauthier, S., Quirion, R. Multiple cholinergic markers are unexpectedly not altered in the rat dentate gyrus following entorhinal cortex lesions. Journal of Neurosciences, 14:2476-2484, 1994.
- 152) Mohr, E., Feldman, H., Gauthier, S. Canadian guidelines for the development of antedementia therapies: a conceptual summary. Canadian Journal of Neurological Sciences, 22: 62-71, 1995.
- 153) Parkinson Study Group. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Archives of Neurology, 52:237-245, 1995.
- 154) Keyserlingk, E.W., Glass, K., Kogan, S., Gauthier, S. Proposed guidelines regarding to participation of persons with dementia as research subjects. Perspectives in Biology and Medicine, 38: 319-362, 1995.
- 155) Montplaisir, J., Petit, D., Lorrain, D., Gauthier, S., Gasselín, A. Sleep in Alzheimer's disease: further considerations on the role of brain stem and forebrain cholinergic populations in sleep-wake mechanisms. Sleep 18, (2), 1995.
- 156) McDermott, M.P., Jankovic, J., Carter, J., Fahn, S., Gauthier, S., Goetz, C.G., Golbe, L.I., Koller, W., Lang, A.E, Olanow, C.W., Shoulson, I., Stern, M., Tanner, C.M., Weiner, W.J., and the Parkinson Group. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. Archives of Neurology 65-70, 1995.
- 157) Aubert, I., Rowe, W., Meaney, M.J., Gauthier, S., Quirion, R. Cholinergic markers in aged memory-impaired and unimpaired Long-Evans rats. Neuroscience, 67: 277-292, 1995.
- 158) Joannette, Y., Ska, B. Poissant, A., Belleville, S., Bellavance, A., Gauthier, S., Gaudreau, D., Lecours, A.R., Peretz, I. AÉvaluation neuropsychologique et profils cognitifs des démences de type Alzheimer: dissociations transversales et longitudinales@. Collection Neuropsychologie, 1995, pp. 91-106.
- 159) Medical and Scientific Advisory Committee, Alzheimer Disease International. Consensus statement on predictive testing for Alzheimer Disease. Alzheimer Disease and Associated Disorders, 9:182-187, 1995.
- 160) Poirier, J., Delisle, M.C., Quirion, R., Aubert, I., Farlow, M., Lahiri, D., Hui, S., Bertrand, P., Nalbantoglu, J., Gilfix, B.G., Gauthier, S. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Progress National Academy of Sciences, 92:12260-12264, 1995.
- 161) Ledoux, S., Bergeron, C., Nalbantoglu, J., Gauthier, S., Cashman, N.R. Polymerase chain reaction quantification of lymphoid amyloid precursor protein mRNAs in Alzheimer Disease and Down syndrome. Neuroscience Letters 193, 137-139, 1995.
- 162) Parkinson Study Group. Impact of Deprenyl and Tocopherol treatment on DATATOP patients requiring levodopa. Annals of Neurology, 39:29-36, 1996.
- 163) Parkinson Study Group. Impact of Deprenyl and Tocopherol treatment on Parkinson disease in DATATOP subjects not requiring levodopa. Annals of Neurology, 39: 37-45, 1996.
- 164) Issa, A., Gauthier, S., Collier, B. Effects of the phosphatase inhibitors calyculin A and okadaic acid on acetylcholine synthesis and content by rat hippocampal formation. Journal of Neurochemistry, 66:1924-1932, 1996.
- 165) Gray, J., Gauthier, S. Stabilization approaches to Alzheimer disease. In: Clinical diagnosis and management of Alzheimer's disease, Gauthier, S. (ed) Martin Dunitz, London, 1996, 261-267.

- 
- 166) Gauthier, S., Thal, L.J., Rossor, M. The future diagnosis and treatment on Alzheimer disease. In: Clinical diagnosis and management of Alzheimer's disease, Gauthier, S. (ed), Martin Dunitz, London, 359-365, 1996.
- 167) Aubert, I., Cécylre, D., Gauthier, S., Quirion, R. Comparative ontogenic profiles of various cholinergic markers including nicotinic and muscarinic receptors in the rat brain. Journal of Comparative Neurology, 369:31-55, 1996.
- 168) Poulin de Courval, L., Saroyan, A., Joseph, L., Gauthier, S. Les aptitudes des médecins de famille à soigner les patients atteints de démence. Canadian Family Physician, 42, 1496-1502, 1996.
- 169) Poirier, J., Delisle, MC., Quirion, R., Aubert, I., Rocheford, J., Rousse, I., Gracon, S., Farlow, M., Gauthier, S. Apolipoprotein E4, cholinergic integrity, synaptic plasticity and Alzheimer disease. In Apolipoprotein E, and Alzheimer's disease, Roses AD, Weisgraber KH, Christen Y (eds) Springer, 20-28, 1996.
- 170) Liu, L., Gauthier, L., Gauthier, S. Personal and extrapersonal orientation in persons with Alzheimer's disease: reliability and validity of three assessments. Canadian Journal of Occupational Therapy, 63, 162-172, 1996.
- 171) Graham, J.E., Rockwood, K., Beattie, B.L., McDowell, I., Eastwood, R., Gauthier, S. Standardization of the diagnosis of dementia in the Canadian Study of Health and Aging. Neuroepidemiology, 15, 246-256, 1996.
- 172) Montplaisir, J., Petit, D., Mc Namara, D., Gauthier, S. Comparisons between SPECT and quantitative EEG measures of cortical impairment in mild to moderate Alzheimer's disease. European Neurology, 36, 197-200, 1996
- 173) Gauthier, S., Montplaisir, J., Petit, D., Joannette, Y., Feldman, H., Mohr, E., Nair, N.P.V., Poirier, J. Outcome variables in pre-symptomatic individuals at higher risk of developing Alzheimer's disease. Alzheimer Disease and Associated Disorders, 10 (suppl 1), 19-21, 1996.
- 174) Liu, L., Gauthier, L., Gauthier, S. The Functional Spatial Abilities Questionnaire for use with persons who are in the early stages of Alzheimer's Disease: preliminary data on reliability and validity. Canadian Journal of Occupational Therapy, 63, 224-233, 1996.
- 175) Gauthier, S., Panisset, M., Poirier, J. Démence de type Alzheimer. Dans: "Précis de Gériatrie", 2ème édition, Arcand M, Hébert R, (eds), Edisem et Maloine, 173-181, 1996.
- 176) Gauthier, S., Poirier, J., Gray, J. Effects on decline or deterioration. In: "Alzheimer's disease: from molecular biology to therapy", Becker, R., Giacobini, E., Robert, P. (eds), Birkhäuser Boston Inc, 381-385, 1996.
- 177) Gauthier, S., Baumgarten, M., Becker, R. Dementia Behavior Disturbance Scale: Theory behind scales and measurements. International Psychogeriatrics 1996, vol. 8 (suppl 3), 325-328.
- 178) Caramelli, P., Poissant A., Gauthier S., Bellavance, A., Gauvreau, D., Lecours, A.R., Joannette, Y. Educational level and neuropsychological heterogeneity in dementia of the Alzheimer type. Alzheimer Disease and Associated Disorders, 11, 9-15, 1997.
- 179) Pallister, C., Jung, S., Shaw, I., Nalbantoglu, J., Gauthier, S., Cashman, N. Lymphocyte content of amyloid precursor protein is increased in Down's syndrome and aging. Neurobiology of Aging, 18, 97-103, 1997.

- 
- 180) Gauthier, S., Poirier, J. Neuroprotection in chronic neurologic disease - Alzheimer's disease. In: "Neuroprotection: fundamental and clinical aspects". Bär, P.R., Beal, M.F. (eds), Marcel Dekker Inc., New York, 447-455, 1997.
- 181) Graham, J.E., Rockwood, K., Beattie, B.L., Eastwood, R., Gauthier, S., Tuokko, M., McDowell, I. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. The Lancet, 349, 1793-1796, 1997.
- 182) Hasssaina, F., Petit, D., Nielsen, T., Gauthier, S., Montplaisir, J. Quantitative EEG and statistical mapping of wakefulness and REM sleep in the evaluation of mild to moderate Alzheimer's disease. European Neurology, 37, 219-224, 1997.
- 183) Gauthier, S., Bodick, N., Erzigkeit, H., Feldman, H., Geldmacher, DS., Huff, J., Mohs, R., Orgogozo, J., M., Rogers, S. Activities of daily living as an outcome measure in clinical trials of dementia drugs. Alzheimer Disease and Associated Disorders, 11 (suppl 3), 6-7, 1997.
- 184) Whitehouse, P., Orgogozo, JM., Becker, RE., Gauthier, S., Portercorvo, M., Erzigkeit, H., Rogers, S., Mohs, RC., Bodick, N., Bruno, G., Dal-Bianco, P. Quality of life assessment in dementia drug development. Alzheimer Disease and Associated Disorders, 11 (suppl 3), 56-60, 1997.
- 185) Bodick, N.C., Offen, W.W., Levey, A.I., Cutler, N.R., Gauthier, S., Satlin, A., Shannon, H.E., Tollefson, G.D., Murley, D.J., Paul, S.M. Effects of xanomeline, a selective muscarinic, receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Archives of Neurology, 54, 465-473, 1997.
- 186) Gauthier, S., Panisset, M., Nalbantoglu, J., Poirier, J. Alzheimer's disease: current knowledge, management and research. Canadian Medical Association Journal, 157, 1047 – 1052, 1997.
- 187) Post, SG., Beerman, B., Brodaty, H., Gaines, A., Gauthier, S., Geldmacher, DS., Hill, S., Hommer, A., Rossor, M., Whitehouse, P., Winblad, B. Ethical issues in dementia drug development. Alzheimer Disease and Associated Disorders, 11 (suppl 3), 26-28, 1997.
- 188) Montplaisir, J., Petit, D., Masson, H., Bédard, M-A., Decary, A., Panisset, M., Gauthier, S., Rémillard, E. Sleep and quantitative EEG in patients with progressive supranuclear palsy. Neurology, 49, 999-1003, 1997.
- 189) Rockwood, K., Beattie, BL., Eastwood, MR., Feldman, H., Mohr, E., Pryse-Phillips, W., Gauthier, S. A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease. Canadian Journal of Neurological Sciences, 24, 140-145, 1997.
- 190) Baumgarten, M., Battista, R.N., Infante-Rivard, C., Hanley, J.A., Becker, R., Gauthier, S. Use of physician services among family caregivers of elderly persons with dementia. Journal of Clinical Epidemiology, 50, 1265-1272, 1997.
- 191) LeWitt, P., Oakes, D., Cui, L. and The Parkinson Study Group. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Movement Disorders, 12, 183-189, 1997.
- 192) Block G., Liss., Reines S., Irr J., Nibbelink D., The CR First Study Group. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. European Neurology, 37, 23-27, 1997.
- 193) Duval, C., Beuter, A., Gauthier, S. Fluctuations tremor at rest and saccadic eye movements in subjects with

- Parkinson's disease. Parkinsonism and related disorders, 3, 195-205, 1997.
- 194) Gauthier, S., Gélinas, I., Gauthier, L. Functional Disability in Alzheimer's Disease. International Psychogeriatrics, 9 (Suppl 1), 163-165, 1997.
- 195) Panisset, M., Gauthier, S. Outcome variables in research and in practice. In: Pharmacotherapy of Alzheimer's disease. Gauthier, S. (Ed), Martin Dunitz, London, 33-41, 1998.
- 196) Gauthier, S., Poirier, J. Achievements and unresolved issues. In: Pharmacotherapy of Alzheimer's disease. Gauthier, S. (Ed), Martin Dunitz, London, 151-159, 1998.
- 197) Gauthier, S. Prevention of Alzheimer's disease. Annales de Médecine Interne, 149, 1-3, 1998.
- 198) Gauthier, S. Treatment strategies for Alzheimer's disease. McGill Journal of Medicine 3, 149-152, 1998
- 199) Gauthier, S. Case report: clinical assessment of Alzheimer's disease and response to donepezil treatment. McGill Journal of Medicine, 3, 153-155, 1998.
- 200) Gauthier S. Costs of diagnostic procedures. In: Health Economics of Dementia, Winblad, B., Wimo, A., Jonsson, B., Karlsson, G. (eds), Joh Wiley and Sons Ltd., 269-273, 1998.
- 201) Beffert, U., Bertrand, P., Champagne, D., Gauthier, S., Poirier, J. HSV-1 in brain and risk of Alzheimer's disease. The Lancet, 352, 238, 1998.
- 202) Gauthier, S., Panisset, M. Current diagnostic methods and outcome variables for clinical investigation of Alzheimer's disease. In: Ageing and Dementia, Jellinger, K., Fazekas, F., Windisch, M. (Eds), Springer Wien. New York, 251-254, 1998.
- 203) Fisk, J.D., Sadovnick, A.D., Cohen, C.A., Gauthier, S., Dossetor, J., Eberhart, A., LeDuc, L. Ethical guidelines of the Alzheimer Society of Canada. Canadian Journal of Neurological Sciences, 125, 242-248, 1998.
- 204) Lakmache, Y., Lassonde, M., Gauthier, S., Frigon, J. Y., Lepore, F. Interhemispheric disconnection syndrome in Alzheimer's disease. Proceedings National Academy of Sciences, 95, 9042-9046, 1998.
- 205) Shoulson, I. And the Parkinson Study Group. DATATOP: a decade of neuroprotective inquiry. Annals of Neurology, 44 (Suppl 1), S160-S166, 1998.
- 206) Beffert U, Bertrand., Champagne D, Gauthier S, Poirier J. Herpes simplex virus type 1 in brain, apolipoprotein E genotype and Alzheimer's disease. McGill Journal of Medicine, 4, 10-14, 1998.
- 207) Beffert U, Bertrand P, Champagne D., Gauthier S, Poirier J. HSV-1 in brain and risk of Alzheimer's disease. Lancet 351, 1330-1331, 1998.
- 208) Hux, M.J., O'Brien, B.J., Iskedjian, M., Goeree, R., Gagnon, M., Gauthier, S. Relationship between severity of Alzheimer's disease and costs of caring. Canadian Medical Association Journal, 159, 457-465, 1998.
- 209) Gauthier, S. Clinical trials and therapy. Current opinion in Neurology, 11, 435-438, 1998.
- 210) Qizibash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M, for the Dementia Trialists'

- Collaboration. Cholinesterase inhibition for Alzheimer's disease: a meta-analysis of the tacrine trials. Journal of the American Medical Association, 280, 1777-1782, 1998.
- 211) Gauthier, S. Update on diagnostic methods, natural history and outcome variables in Alzheimer's disease. Dementia Geriatric Cognitive Disorders, 9 (suppl 3), 2-7, 1998.
- 212) Whitehouse, P., Winblad B., Shostak D., Bhattacharja A., Brod M., Brodaty H., Dor A., Feldman H., Forette, F., Gauthier, S., Hay J., Henke C., Hill S., Mastey V., Neuman P., O 'Brien B., Pugner K., Sano M., Sawada T., Stone R., Wimo A. First International pharmaco-economic Conference on Alzheimer's Disease: report and summary. Alzheimer Disease and Associated Disorders, 12, 266-280, 1998.
- 213) Montplaisir, J., Petit, D., Gauthier, S., Gaudreau, H., Décary, A. Sleep disturbances and EEG slowing in Alzheimer's disease. Sleep research Online, 1, 147-151, 1998.
- 214) Gauthier, S. Managing expectations in the long-term treatment of Alzheimer's disease, Gerontology, 45 (Suppl 1), 33-38, 1999.
- 215) Gauthier, S. Tacrine hydrochloride In: Therapeutic Drugs, 2<sup>nd</sup> edition. C. Dollery (ed), T1-T4, 1999.
- 216) Gauthier, S., Byrne, J., Byrne, L. Research potential. In: "Diagnosis and management of dementia: a manual for memory disorders teams" G.K. Wilcox, R.S. Bucks, K. Rockwood (eds). Oxford Medical Publications 190-208, 1999.
- 217) Rösler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stähelin, H.B., Hartman, R., Gharabawi, M. on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine (Exelon) in patients with Alzheimer's disease: international randomized controlled trial. British Medical Journal, 318, 633-640, 1999.
- 218) Burns A., Rossor, M., Hecker, J., Gauthier, S., Petit, H., Möller, H.J., Rogers, S.L., Friedhoof L.T. and the Donepezil Study Group. Donepezil in the treatment of Alzheimer's disease - results from a multinational clinical trial. Dementia Geriatric Cognitive Disorders, 10, 237-244, 1999.
- 219) Gray J.A., Gauthier S. Stabilization approaches to Alzheimer's disease. In "Clinical Diagnosis and Management of Alzheimer's Disease", Gauthier S (ed), Martin Dunitz, Publisher, London, 269-278, 1999.
- 220) Gauthier S., Thal LJ, Rossor MN. The future diagnosis and management of Alzheimer's disease. In "Clinical Diagnosis and Management of Alzheimer's Disease", Gauthier S (ed), Martin Dunitz, London, 369-378, 1999.
- 221) O'Brien B.J., Goeree R.A., Hux M., Iskedjian M., Blackhouse G., Gauthier S., Gagnon M. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. Journal of the American Geriatrics Society, 47, 570-578, 1999.
- 222) Mendis T., Suchowersky O., Lang A., Gauthier S. Management of Parkinson's disease: a review of current and new therapies. Canadian Journal of Neurological Sciences, 26, 89-103, 1999.
- 223) Patterson, C., Gauthier, S., Bergman, H., Cohen, C., Feightner, J.W., Feldman, H., Grek, A., Hogan, D.B. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. Canadian Medical Association Journal, 160 (12 Suppl), S1-S15, 1999.
- 224) Patterson, C., Gauthier, S., Bergman, H., Cohen, C., Feightner, J.W., Feldman, H., Grek, A., Hogan, D.B. Canadian Consensus Conference on Dementia: a physician's guide to using the recommendations. Canadian

Medical Association Journal, 160, 1738-1742, 1999.

- 225) Cohen, C., Whitehouse, P., Post, S. G., Gauthier, S., Eberhart, A., Leduc, L. Ethical issues in Alzheimer's disease: the experience of a national Alzheimer Society Task Force. Alzheimer Disease and Associated Disorders, 13, 66- 70, 1999.
- 226) Brodaty, H., Dresser, R., Eisner, R., Erkinjuntti, T., Gauthier, S., Graham, N., Jonker, C., Sachs, G., Whitehouse., P. Alzheimer's Disease International and International Working Group for Harmonization of Dementia Drug Guidelines for research involving human subjects with dementia. Alzheimer Disease and Associated Disorders, 13, 71-79, 1999.
- 227) Issa, A.M., Gauthier, S., Collier, B. Enzyme activity and protein of multiple forms of choline acetyl transferase: effects of Calyculin A and Okadaic Acid. Neurochemistry Research, 24, 987-993, 1999.
- 228) Issa, A.M., Gauthier, S., Collier, B. Effects of Calyculin A and Okadaic Acid on Acetylcholine Release and Subcellular Distribution in Rat Hippocampal Formation. J. Neurochemistry, 72, 166-173, 1999.
- 229) Gauthier, S. Do we have a treatment for Alzheimer's disease – yes. Archives of Neurology, 56, 738-739, 1999.
- 230) Gélinas, I., Gauthier, L., McIntyre, M., Gauthier, S. Development of a functional measure for persons with Alzheimer's disease: the Disability Assessment of Dementia. American Journal of Occupational Therapy, 53, 471-481, 1999.
- 231) Gauthier S. Acetylcholinesterase inhibitors in the treatment of Alzheimer's disease. Expert Opinion Investigational Drugs, 8, 1511-1520, 1999.
- 232) Gauthier S. Démences: de l'épidémiologie aux nouvelles approches préventives. Dans "L'année gériatologique, 13, 95-97, 1999.
- 233) Gauthier S., Rockwood K., Gélinas I., Sykes L., Teunisse S., Orgogozo J.M., Erkinjuntti T., Erzigkeit H., Gleeson M., Kittner B., Pontecorvo M., Feldman H., Whitehouse P. Outcome measures for the study of activities of daily living in vascular dementia. Alzheimer Disease and Associated Disorders, 13 (suppl 3), S143-S147, 1999.
- 234) Koller, W.C., Hutton, J.T., Tolosa, E., Capilldeo, R. and the Carbidopa /Levodopa Study Group. Immediate release and controlled-release carbidopa/levodopa in the treatment of Parkinson's disease: a 5-year multicenter study. Neurology, 53, 1012-1019, 1999.
- 235) Gauthier S. Les traitements pharmacologiques d'aujourd'hui. Dans "La maladie d'Alzheimer, prédiction, prévention, prise en charge. Forette F, Christen Y, Boller F (eds) Fondation Nationale de Gérontologie, 85-96, 1999
- 236) Jung SS, Gauthier S, Cashman NR. Cell surface amyloid precursor protein is detectable on human peripheral blood monocytes and is increased in Alzheimer's disease. Neurobiology of Aging, 20, 249-257, 1999.
- 237) Rockwood K, Wentzel C, Hachinski V, Hogan DB, MacKnight C, McDowell I for the Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Prevalence and outcomes of vascular cognitive impairment. Neurology, 54, 447-451, 2000.
- 238) Gauthier, S. Impact of new therapies on the management of Alzheimer's disease. International Medical Journal 2000, 4-6, 2000.



- 
- 239) Gauthier S. From bench to bedside: how to treat dementia. In Evidence & experience in Psychiatry: Dementia. Maj M, Sartorius N (eds), WPA Series, Wiley, 252-254, 2000.
- 240) Rockwood K, MacKnight C, Wentzel C, Black S, Bouchard R, Gauthier S, Feldman H, Hogan D, Kertesz A, and P. Montgomery for the CIVIC investigators. The diagnosis of “mixed” dementia in the Consortium for the Investigation of Vascular Impairment of Cognition (CIVIC). Annals of the New York Academy of Sciences, 903, 522-528, 2000.
- 241) Gauthier S. Cholinesterase inhibitors in the treatment of dementia. In: Annual on Alzheimer’s disease and related disorders, Gauthier S, Cummings J (eds), Martin Dunitz, London, 199-210, 2000.
- 242) The Canadian Study of Health and Aging Working Group. The incidence of dementia in Canada. Neurology, 55, 66-73, 2000.
- 243) Gélinas I, Gauthier S., Cyrus P.A. Metrifonate enhances the ability of Alzheimer’s disease patients to initiate, organize and execute instrumental and basic activities of daily living. Journal of Geriatric Psychiatry and Neurology, 13, 9-16, 2000.
- 244) Rockwood K, Wentzel C, Hachinski V, Hogan D, MacKnight C, McDowell I for the Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Prevalence and outcomes of vascular cognitive impairment. Neurology 54, 447-451, 2000.
- 245) Gauthier S. Alzheimer disease: update on disease-specific pharmacotherapy. Primary Psychiatry, 7, 77-80, 2000.
- 246) Law A, Doré S, Blackshaw S, Gauthier S, Quirion R. Alteration of expression levels of neuronal nitric oxide synthase and haem oxygenase 2 messenger RNA in the hippocampi and cortices of young and aged cognitively unimpaired and impaired Long-Evans rats. Neuroscience, 100, 769-775, 2000.
- 247) Baladi JF, Bailey P, Black S, Bouchard R, Farcnik K, Gauthier S, Kertesz A, Mohr E, Robillard A. Rivastigmine for Alzheimer’s disease: Canadian interpretation of intermediate outcome measures and implications to costs. Clinical Therapeutics, 22, 1549-1561, 2000.
- 248) Young S, Gauthier S. Is placebo control in geriatric psychopharmacology clinical trials ethical? International Journal of Geriatric Psychopharmacology, 2, 113-118, 2000.
- 249) Gauthier S, Gauthier J, Dupin F, Panisset M. Comment déterminer l’aptitude du mandant? In ‘Les mandats en cas d’inaptitude: une panacée?’, Service de la formation permanente du Barreau du Québec, Les Editions Yvon Blais Inc, Cowansville, 71-82, 2001.
- 250) Gauthier S. Alzheimer’s disease: current and future therapeutic perspectives. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 25, 73-89, 2001.
- 251) Patterson C, Gauthier S, Bergman H, Cohen C, Feighhtner JW, Feldman H, Grek A, Hogan D. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. Canadian Journal of Neurological Sciences, 28 (Suppl 1), S3-S16, 2001.
- 252) Chertkow H., Bergman, H., Schipper HM, Gauthier S., Bouchard R., Fontaine S., Clarfield M. Assessment of suspected dementia, Canadian Journal of Neurological Sciences, 28 (Suppl 1), S28-S41, 2001.

- 
- 253) Gauthier S, Ferris S. Outcome measures for probable vascular dementia and Alzheimer's disease with cerebrovascular disease. International Journal of Clinical Medicine, Supp 120, 29-39, 2001.
- 254) Wolfson C., Wolfson DB, Asgharian M, M' Lan CE, Ostbye T, Rockwood K, Hogan DB for the Clinical Progression of Dementia Study Group. A reevaluation of the duration of survival after the onset of dementia. New England Journal of Medicine, 34, 1111-1116, 2001.
- 255) Gauthier S. Muscarinic agonists. In 'Alzheimer's Disease and Related Disorders Annual 2001', S. Gauthier, J. Cummings (eds), Martin Dunitz, London, 85-96, 2001.
- 256) Feldman H., Sauter A., Donald A., Gélinas I., Gauthier S., Torfs K., Parys W., Mehnert A. The Disability Assessment for Dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer's disease. Alzheimer's Disease and Related Disorders, 15, 89-95, 2001.
- 257) Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen W for the Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology, 57, 613-620, 2001.
- 258) Winblad B, Brodaty H, Gauthier S, Morris JC, Orgogozo JM, Rockwood K, Schneider L, Takeda M, Tariot P, Wilkinson D. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? International Journal of Geriatric Psychiatry, 16, 653-666, 2001.
- 259) Law A, Gauthier S, Quirion R. Neuroprotective and neurorescuing effects of isoform-specific nitric oxide synthase inhibitors, nitric oxide scavenger, and antioxidant against beta-amyloid toxicity. British Journal of Pharmacology, 133, 1114-1124, 2001.
- 260) Wentzel C, Rockwood K, MacKnight C, Hachinski V, Hogan D, Feldman H, Ostbye T, Wolfson C, Gauthier S, Verreault R, McDowell I. Progression of impairment in patients with Vascular Cognitive Impairment without dementia. Neurology, 57, 714-716, 2001.
- 261) Law A, Gauthier S, Quirion R. Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer type. Brain Research Reviews, 35, 73-96, 2001.
- 262) Rockwood K, Black S, Gauthier S, Feldman H, Wentzell C. Clinical and neuroimaging findings in mixed dementia. Research and Practice in Alzheimer's Disease, 5, 115-122, 2001.
- 263) Tomosy GF, Weisstub DN, Gauthier S. Regulating ethical research involving cognitively impaired elderly subjects. Canada as a case study. In 'Aging; Decisions at the End of Life', DN Weisstub, DC Thomasma, S. Gauthier, GF Tomosy (Eds), Kluwer Academic Publishers, Dordrecht – Boston – London, 227-254, 2001.
- 264) Gauthier S. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management. Drugs and Aging, 18, 853-862, 2001.
- 265) Gauthier S. Advances in the pharmacotherapy of Alzheimer's disease. Canadian Medical Association Journal, 166; 616-623, 2002.
- 266) Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Han JH. Galantamine is efficacious in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease. The Lancet, 359, 1283-1290, 2002.

- 
- 267) Law A, Zheng WH, Gauthier S, Quirion R. Alterations of nitric oxide synthase expression and activity in Alzheimer`s disease brains. Brain Aging, 2, 34-41, 2002.
- 268) Gauthier S. Diagnostic instruments to assess functional Impairment. In Evidence-based dementia practice. Qizilbask N, Schneider LS, Chui H, Tariot P, Brodaty H, Kaye J, Erkinjuntti T (Eds), Blackwell Science Ltd, Oxford, England, 101-105, 2002.
- 269) Sibley A, MacKnight C, Rockwood K for the Consortium to Investigate Vascular Cognitive Impairment if Cognition (CIVIC). The effect of living situation on the severity of dementia at diagnosis. Dementia and Geriatric Cognitive Disorder, 13, 40-45, 2002.
- 270) Gauthier S, Gélinas I. Evaluation of daily activities in vascular cognitive impairment. In ‘Vascular Cognitive Impairment’, T. Erkinjuntti, S. Gauthier (Eds), Martin Dunitx Ltd, London, 411-416, 2002.
- 271) Ferris S, Gauthier S. Cognitive outcome measures in vascular dementia. In ‘Vascular Cognitive Impairment’, T. Erkinjuntti, S. Gauthier (Eds), Martin Dunitx Ltd, London, 395-400, 2002.
- 272) Rockwood K, Gauthier S, Erkinjuntti T. Prevention and treatment of vascular dementia. In ‘Vascular Cognitive Impairment’, T. Erkinjuntti, S. Gauthier (Eds), Martin Dunitx Ltd, London, 587-595, 2002.
- 273) Erkinjuntti T, Gauthier S. Vascular causes of cognitive impairment – the perspective. In ‘Vascular Cognitive Impairment’, T. Erkinjuntti, S. Gauthier (Eds), Martin Dunitx Ltd, London, 643-651, 2002.
- 274) Panisset M, Gauthier S, Moessler H, Windisch M and the Cerebrolysin Study Group. Cerebrolysin in Alzheimer`s Disease: a randomized, double-blind, placebo-controlled trial with a neurotropic cholinergic agent. Journal of Neural Transmission, 109, 1089-1104, 2002.
- 275) Gauthier S, Grundman M. Alzheimer`s disease: trial designs to establish disease modification. In `Alzheimer`s disease and related disorders Annual 2002`, S. Gauthier, JL Cummings (eds), Martin Dunitz, London, 77-85, 2002.
- 276) Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E, Emir B. The efficacy and safety of donepezil in patients with moderate to severe Alzheimer`s disease. Research and Practice in Alzheimer`s Disease, 6, 302-307, 2002.
- 277) Law A, O`Donnell J, Gauthier S, Quirion R. Neuronal and inducible nitric oxide synthase expressions and activities in the hippocampi and cortices of young adult, aged cognitively unimpaired, and impaired Long-Evans rats. Neuroscience, 112, 267-275, 2002.
- 278) Gauthier S. Assessing the response of patients with Alzheimer`s disease to cholinesterase inhibitors. Geriatrics and Aging, 5, 23-24, 2002.
- 279) Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P on behalf of The Donepezil MSAD Study Investigators` Group. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer`s disease. Current Medical Research and Opinions, 18, 347-354, 2002.
- 280) Gauthier S. Long-term efficacy of cholinesterase inhibitors. Brain Aging, 2, 9-22, 2002.
- 281) Pratt RD, Perdomo CA and the Donepezil VaD 307 and 308 Study Groups. Donepezil-treated patients with

- probable vascular dementia demonstrate cognitive benefits. Annals New York Academy of Sciences, 977, 513-522, 2002.
- 282) Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, Whalen E, Emir B. The Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics, 14, 389-404, 2002.
- 283) Gauthier S. Current and future therapeutic strategies for Alzheimer's disease and related dementias. Expert Review of Neurotherapeutics 2, 277-278, 2002.
- 284) O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST, Sawada T. Vascular Cognitive Impairment. Lancet Neurology, 2, 89-98, 2003.
- 285) Law A, Gauthier S, Quirion R. Alteration of nitric oxide synthase activity in young and aged apolipoprotein E-deficient mice. Neurobiology of Aging, 24, 187-190, 2003.
- 286) Gauthier S. Clinical aspects of Alzheimer's disease. In Clinical management of early Alzheimer's disease. Mulligan R., Van der Linden M., Juillerat A.C. (eds), 21-34, 2003.
- 287) Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, Mastey V, Subbiah P, The Donepezil MSAD Study Investigators Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease, and the impact on caregiver burden. Journal of the American Geriatric Society, 51, 737-744, 2003.
- 288) Gauthier S. Management of later stages of Alzheimer's disease. Research and Practice in Alzheimer's Disease, Vellas B, Winblad B, Grundman M, Fitten LJ, Feldman H, Giacobini E, Kurz A (Eds), vol 7, 146-149, 2003.
- 289) Rockwood K, Davis H, MacKnight C, Vandorpe R, Gauthier S, Guzman A, Montgomery P, Black S, Hogan DB, Kertesz A, Bouchard R, Feldman H. The Consortium to Investigate Vascular Impairment of Cognition: methods and first findings. Canadian Journal of Neurological Sciences, 30, 237-243, 2003.
- 290) Desrosiers RR, Bertrand Y, Nguyen QT, Demeule M, Gabathuler R, Kennard ML, Gauthier S, Béliveau R. Expression of multiple isoforms of melanotransferrin in human body fluids: relevance to Alzheimer's disease. Biochemical Journal, 374, 463-471, 2003.
- 291) Allain H, Bentué-Ferrer D, Tribut O, Gauthier S, Michel BF, Drieu-La Rochelle C. Alzheimer's disease : the pharmacological pathway. Fundamental & Clinical Pharmacology 17, 419-428, 2003.
- 292) Feldman H, Levy AR, Hsiung GY, Peters KR, Donald A, Black SE, Bouchard RW, Gauthier S, Guzman DA, Hogan DB, Kertesz A, Rockwood K for the ACCORD Study Group. A Canadian Cohort study of cognitive impairment and Related Dementias (ACCORD). Study methods and baseline results. Neuroepidemiology, 22, 265-274, 2003.
- 293) Gauthier S, Rockwood K. Does vascular MCI progress at a different rate than Amnesic MCI? International Psychogeriatrics, 15 (suppl 1), 257-259, 2003.
- 294) Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful

- treatment of Alzheimer's Disease: switching cholinesterase inhibitors. Current Medical Research and Opinion, 19, 707-714, 2003.
- 295) Marcusson J, Bullock R, Gauthier S, Kurz A, Schwalen S. Galantamine demonstrates efficacy and safety in elderly patients with Alzheimer's disease. Alzheimer Disease and Related Disorders 17 (Suppl 3), S86-S91, 2003.
- 296) Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ. Mild cognitive impairment can be distinguished from Alzheimer's disease and normal aging for clinical trials. Archives of Neurology 61, 59-66, 2004.
- 297) Gauthier S, Touchon J. Subclassification of mild cognitive impairment in research and in clinical practice. Alzheimer's Disease and Related Disorders Annual 2004, (S. Gauthier, P. Scheltens, JL Cummings, Eds), Martin Dunitz, London, 61-69, 2004.
- 298) McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda J, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez O, Machado J, O'Brien J, Palyfer J, Reid W on behalf of the IPA Special Expert Meeting. Dementia with Lewy bodies. Lancet Neurology, 3, 19-28, 2004.
- 299) Petersen RC, Grundman M, Ferris SH, Thomas RG, Aisen P, Bennett D, Foster N, Jack C, Galasko D, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schulz AN, Schafer K, Mulnard R, van Dyke C, Mintzer J, Zamrini EY, Cahn D, Thal LJ, and the Alzheimer Disease Cooperative Study. The ADCS clinical trial of vitamin E and donepezil HCl (Aricept) to delay clinical progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD): trial design and subjects baseline characteristics. Archives of Neurology, 61, 59-66, 2004.
- 300) Gauthier S. Traitement de la maladie d'Alzheimer: aspects méthodologiques généraux. Revue Neurologique, 160, 261-264, 2004.
- 301) Erkinjuntti T, Román G, Gauthier S, Feldman H, Rockwood K. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke 35, 1010-1017, 2004.
- 302) Erkinjuntti T, Roman G, Gauthier S. Treatment of vascular dementia – evidence from clinical trials with cholinesterase inhibitors. Neurological Research 26, 603-605, 2004.
- 303) Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, Schwam EM, Shah S, Mastey V for the Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer's disease. Neurology 63, 644-650, 2004.
- 304) Blanchet S, Belleville S, Phillips N, Mellah S, Gauthier S, Chertkow H. Electrophysiological study of working memory in mild cognitive impairment patients. Brain and Cognition 54, 144-145, 2004.
- 305) Gauthier S. The benefits of apolipoprotein E epsilon 4 screening to research. Canadian Medical Association Journal 171, 881, 2004.
- 306) Parkinson Study Group. Levodopa and the rate of progression of Parkinson disease, the ELLDOPA study. New England Journal of Medicine, 351, 2498-2508, 2004.

- 
- 307) Gauthier S. Pharmacotherapy of mild cognitive impairment. Dialogues in Clinical Neurosciences, 6, 391-395, 2004.
- 308) Erkinjuntti T, Román G, Gauthier S, Rockwood K. Pharmacological treatment of vascular dementia. In Current Clinical Neurology. Vascular Dementia: Cerebrovascular Mechanisms and Clinical Management. RH Paul, R Cohen, BR Ott, Salloway (Eds), Humana Press Inc., Totowa, NJ, 297-303, 2004.
- 309) Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A, Lang AE and the Parkinson Study Group. Survival in Parkinson disease. Thirteen-year follow-up of the DATATOP cohort. Neurology 64, 87-93, 2005.
- 310) Gauthier S. Drugs for Alzheimer's disease and related dementias. British Medical Journal, 330, 857-858, 2005.
- 311) Gauthier S. The clinical significance of the overlap between dementia and vascular risk factors. Geriatrics & Aging, 8 (Suppl), 4-7, 2005.
- 312) Gauthier S. The use of galantamine in mixed and vascular dementia. Geriatrics & Aging, 8 (Suppl), 11- 15, 2005.
- 313) Gauthier S, Galasko D. How to translate results of randomized clinical trials into clinical practice for the care of persons with Alzheimer's disease? In "Research Advances in Alzheimer Disease and Related Disorders 2004". Khalid Iqbal, Bengt Winblad (Eds). Alzheimer's Association, Chicago, USA, 2005.
- 314) Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on behavioral symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomized, controlled studies. International Journal of Geriatric Psychiatry, 20; 459-464, 2005.
- 315) Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeffer E, Sano M, van Dyck CH, Thal LJ for the Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of Mild Cognitive Impairment. New England Journal of Medicine 352, 2379-2388, 2005.
- 316) Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM, and the Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. International Journal of Geriatric Psychiatry, 20, 559-569, 2005.
- 317) Gauthier S, Touchon J. MCI is not a clinical entity and should not be treated. Archives of Neurology, 62, 1164-1166, 2005.
- 318) Gauthier S. Pharmacotherapy of amnesic mild cognitive impairment: lessons from the Memory Impairment Study. Aging Health, 1, 37-38, 2005.
- 319) Gauthier S. Alzheimer's disease: the benefits of early treatment. European Journal of Neurology 12 (Suppl 3), 11-16, 2005.
- 320) Song X, Mitnitski AB, Rockwood K on behalf of the CIVIC investigators. Index variables for studying outcomes in vascular cognitive impairment. Neuroepidemiology 16, 196-204, 2005.

- 321) Gauthier S, McKeith IG. Classification and diagnostic criteria for dementia with Lewy bodies. In "Dementia with Lewy Bodies", J. O'Brien, I. McKeith, D. Ames, E. Chiu (Eds.), Taylor & Francis, 27-31, 2005.
- 322) McKeith IG, Gauthier S. Pharmacological treatment of dementia with Lewy bodies. In "Dementia with Lewy Bodies", J. O'Brien, I. McKeith, D. Ames, E. Chiu (Eds.), Taylor & Francis, 183-192, 2005.
- 323) Gauthier S, MacKnight C. Clinical trial designs and endpoint selection. In "Trial designs and outcomes in dementia therapeutic research", K. Rockwood, S. Gauthier (Eds.), Taylor & Francis, 37-44, 2005.
- 324) Gauthier S. Functional outcomes. In "Trial designs and outcomes in dementia therapeutic research", K. Rockwood, S. Gauthier (Eds.), Taylor & Francis, 113-118, 2005.
- 325) Camicioli R, Gauthier S. Guidelines for randomized clinical studies in Parkinson's disease in Parkinson's disease with dementia and dementia with Lewy bodies. In "Trial designs and outcomes in dementia therapeutic research", K. Rockwood, S. Gauthier (Eds.), Taylor & Francis, 165-175, 2005.
- 326) Rockwood K, Gauthier S. Conclusions: lessons from clinical trials in dementia. In "Trial designs and outcomes in dementia therapeutic research", K. Rockwood, S. Gauthier (Eds.), Taylor & Francis, 285-295, 2005.
- 327) Gauthier S. Trial designs. In "Dementia", 3<sup>rd</sup> edition, A. Burns, J. O'Brien, D. Ames (Eds), Hodder Arnold, London, 522-525, 2005.
- 328) Vellas B, Gauthier S, Allain H, Andrieu S, Aquino JP, Berrut G, Berthel M, Blanchard F, Camus V, Dartigues JF, Dubois B, Forette F, Franco A, Gonthier R, Grand A, Hervy MP, Jeandel C, Joel ME, Jouanny P, Lebert F, Michot P, Montastruc JL, Nourhashemi N, Ousset PJ, Pariente J, Rigaud AS, Robert P, Ruault G, Strubel D, Touchon J, Verny M, Vetel JM. French Society of Gerontology and Geriatrics. Consensus statement on dementia of Alzheimer type in the severe stage. Journal of Nutrition, Health and Aging, 9, 330-338, 2005.
- 329) Vellas B, Gauthier S, Allain H, Andrieu S, Aquino JP, Berrut G, Berthel M, Blanchard F, Camus V, Dartigues JF, Dubois B, Forette F, Franco A, Gonthier R, Grand A, Hervy MP, Jeandel C, Joel ME, Jouanny P, Lebert F, Michot P, Montastruc JL, Nourhashemi N, Ousset PJ, Pariente J, Rigaud AS, Robert P, Ruault G, Strubel D, Touchon J, Verny M, Vetel JM. Société Française de Gériatrie et de Gérologie. Consensus sur la démence type Alzheimer au stade sévère. Revue Neurologique, 161, 868-877, 2005.
- 330) Vellas B, Gauthier S, Allain H, Andrieu S, Aquino JP, Berrut G, Berthel M, Blanchard F, Camus V, Dartigues JF, Dubois B, Forette F, Franco A, Gonthier R, Grand A, Hervy MP, Jeandel C, Joel ME, Jouanny P, Lebert F, Michot P, Montastruc JL, Nourhashemi N, Ousset PJ, Pariente J, Rigaud AS, Robert P, Ruault G, Strubel D, Touchon J, Verny M, Vetel JM. Société Française de Gériatrie et de Gérologie. Consensus sur la démence type Alzheimer au stade sévère. Presse Médicale, 34, 1545-1555, 2005.
- 331) Perras C, Shukla VK, Lessard C, Skidmore B, Bergman H, Gauthier S. Cholinesterase inhibitors for Alzheimer's disease: a systematic review of randomized controlled trials. [Technology report no 58]. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2005.
- 332) Gauthier S. Profil actuel des consultations mémoire au Canada et besoins futurs. Dementiae, 3, 93-100, 2005.
- 333) Bhanji N, Gauthier S. Emergent complications of donepezil switchover in Dementia with Lewy Bodies.

---

J Neuropsychiatry & Clinical Neurosciences, 17, 552-555, 2005.

- 334) McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien J, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz C, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria R, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee V, Lees A, Litavan I, Londos E, Lopez O, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz J, Trojanowski J, Yamada M, for the Consortium on DLB. Dementia with Lewy Bodies: Diagnosis and Management. Third Report of the DLB Consortium. Neurology, 65, 1863-1872, 2005.
- 335) Feldman H, Gauthier S, Chertkow H, Conn DK, Freedman M, MacKnight C for the 2<sup>nd</sup> Conference on Antidementia Guidelines. Canadian guidelines for the development of antidementia therapies: a conceptual summary. Canadian Journal of Neurological Sciences, 33, 6-26, 2006.
- 336) Gauthier S. Managing discontinuation syndrome in patients with dementia. Journal of Psychiatry & Neuroscience, 31, 72, 2006.
- 337) Gauthier S. Delirium and dementia in the elderly. In "Geriatric Otolaryngology", KH Calhoun, DE Eibling (Eds.). Taylor & Francis, Atlanta, 603-608, 2006.
- 338) Peters KR, Rockwood K, Black SE, Bouchard R, Gauthier S, Hogan D, Kertesz A, Loy-English I, Beattie BL, Sadovnick AD, Feldman HH. Characterizing neuropsychiatric symptoms in subjects referred to dementia clinics. Neurology, 66, 523-528, 2006.
- 339) Poulin de Courval L, Gélinas I, Gauthier S, Gayton D, Liu L, Rossignol M, Sampalis J, Dastoor D. Reliability and validity of the Safety Assessment Scale for people with dementia living at home. Canadian Journal of Occupational Therapy, 73, 67-75, 2006.
- 340) Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B, on behalf of the participants of the IPA Expert Conference on MCI. Mild Cognitive Impairment. The Lancet, 367, 1262-1270, 2006.
- 341) Gauthier S. Clinical features of severe dementia: function. In "Severe Dementia". A Burns, B Winblad (Eds). John Wiley & Sons, Ltd., 117-121, 2006.
- 342) Gauthier S. Use of cholinesterase inhibitors in late stages of Alzheimer's disease. Lancet Neurology, 5, 468-469. 2006.
- 343) Hsiung GYR, Donald A, Grand J, Black SE, Bouchard RW, Gauthier S, Guzman DA, Hogan DB, Kertesz A, Rockwood K, Feldman H. Outcome of cognitively impaired not demented (CIND) at 2-years in the Canadian Cohort Study of Cognitive Impairment and Related Dementias (ACCORD) study. Dementia & Geriatric Cognitive Disorders, 22, 413-420, 2006.
- 344) Hudon C, Belleville S, Souchay C, Gély-Nargeot MC, Chertkow H, Gauthier S. Memory for gist and detail information in Alzheimer's disease and Mild Cognitive Impairment. Neuropsychology, 20, 566-577, 2006.
- 345) Gauthier S, Juby A, Morelli L, Rehel B, Schecter R on Behalf of the EXTEND Investigators. A large,



- naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study. Current Medical Research and Opinions, 22, P1-P15, 2006.
- 346) Gauthier S, Treatment success in Alzheimer's Disease. J Nutrition Health & Aging, 10, 416, 2006.
- 347) Gauthier S. Commentary on Mild Cognitive Impairment. International Psychogeriatrics, 18, 409-410, 2006.
- 348) Gauthier S, Herrmann N, Ferreri F, Agbokou C. Use of memantine to treat Alzheimer's disease. Canadian Medical Association Journal, 175, 501-502, 2006.
- 349) Gagnon JF, Petit D, Fantini ML, Rompré S, Gauthier S, Panisset M, Robillard A, Montplaisir J. REM sleep behavior disorder and REM sleep without atonia in probable Alzheimer's disease. Sleep, 29, 1309-1313, 2006.
- 350) Gauthier S, Vellas B, Farlow M, Burn D. Aggressive course of disease in dementia. Alzheimer's & Dementia, 2, 210-217, 2006.
- 351) Ferreri F, Agbokou C, Gauthier S. Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. Journal of Psychiatry and Neuroscience, 31, 369-376, 2006.
- 352) Allain H, Bentue-Ferrer D, Vellas B, Gauthier S. Pharmacothérapeutique des démences sévères. Année Gériatrique, Serdi, Paris, 84-91, 2006.
- 353) Belleville S, Gilbert B, Fontaine F, Gagnon L, Ménard E, Gauthier S. Improvement of episodic memory in persons with Mild Cognitive Impairment: evidence from a cognitive intervention program. Dementia and Geriatric Cognitive Disorders, 22, 486-499, 2006.
- 354) Touchon J, Portet F, Gauthier S. Prevention trials in AD: one step forward? Neurology, 67 (Suppl 3), S21-S22, 2006.
- 355) Gauthier S. Current and future therapies for Alzheimer's disease and related disorders. Future Neurology, 1, 741-745, 2006.
- 356) Ferreri F, Agbokou C, Gauthier S. Recognition and management of neuropsychiatric complications of Parkinson's disease. Canadian Medical Association Journal, 175, 1545-1552, 2006.
- 357) Gauthier S. Alzheimer's disease – In The Encyclopedia of Aging, R Schulz, L Noelker, K. Rockwood, R Sprott [Eds], 4<sup>th</sup> Edition, vol. 1. Springer Publishing Company, NY, 53-54, 2006.
- 358) Rockwood K, Black SE, Song X, Hogan DB, Gauthier S, MacKnight C, Vandorpe R, Guzman G, Montgomery P, Kertesz A, Bouchard RB, Feldman H. Clinical and radiographic subtypes of vascular cognitive impairment in a clinic-based cohort study. Journal of the Neurological sciences 240, 7-14, 2006.
- 359) Gauthier S, Thal LL, Rossor MN. Future diagnosis and management of Alzheimer's disease. In Clinical Diagnosis and Management of Alzheimer's Disease, S. Gauthier [Ed], Informa Health Care, Abingdon, UK, 379-382, 2007.
- 360) Gauthier S, Erkinjuntti T, Rockwood K. Vascular dementia. In Therapeutic Strategies in Dementia. CW Ritchie, D Ames, CL Masters, J Cummings [Eds], Clinical Publishing, Oxford, 273-286, 2007.

- 
- 361) Gauthier S, Poirier J. Maladie d' Alzheimer. In "Précis de Gériatrie", M. Arcand & R. Hébert, Eds, Edisem Inc., Montréal, 257-266, 2007.
- 362) Gauthier S, Poirier J. Survol des facteurs génétiques et de quelques enjeux éthiques liés à la maladie d' Alzheimer. L'Observatoire de la génétique, [www.ircm.qc.ca/bioéthique/obs/genetique](http://www.ircm.qc.ca/bioéthique/obs/genetique), Fev/Mars 2007.
- 363) Gauthier S. Outcomes for assessment of symptomatic and stabilization /disease modifying treatments. Canadian Journal of Neurological Sciences, 34, Suppl 1, S23-26, 2007.
- 364) Camicioli R, Gauthier S. Clinical trials in Parkinson's disease and Dementia with Lewy Bodies. Canadian Journal of Neurological Sciences, 34, Suppl 1, S109-117, 2007.
- 365) Gauthier S, Juby A, Rehel B, Schechter R. EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease. International Journal of Clinical Practice, 61, 886-895, 2007.
- 366) Katona C, Livingston G, Cooper C, Ames D, Brodaty H, Chiu E on behalf of the Consensus Group. International Psychogeriatric Association consensus statement on defining and measuring treatment benefits in dementia. International Psychogeriatrics, 19, 345-354, 2007.
- 367) Aisen P, Gauthier S, Vellas B, Briand R, Saumier D, Laurin J, Garceau D. Alzhemed: a potential treatment for Alzheimer's disease. Current Alzheimer Research, 4, 473-478, 2007.
- 368) Blair M, Kertesz A, Davis-Farouque N, Hsiung GYR, Black SE, Bouchard RW, Gauthier S, Guzman DA, Hogan DB, Rockwood K, Feldman H. Behavioral measures in frontotemporal lobar degeneration and other dementias: the utility of the Frontal Behavioral Inventory and the NeuroPsychiatric Inventory in a national cohort study. Dementia and Geriatric Cognitive Disorders, 23, 406-415, 2007.
- 369) Belleville S, Chertkow H, Gauthier S. Working memory and control of attention in persons with Alzheimer's disease and mild cognitive impairment. Neuropsychology, 21, 458-469, 2007.
- 370) Burns A, Gauthier S, Perdomo C. Efficacy and safety of donepezil over 3 years: an open-label, multicenter study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry, 22, 806-812, 2007.
- 371) Emre M, Aarsland D, Brown R, Burn DJ, Duykaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders, 22, 1689-1707, 2007.
- 372) Dubois B, Feldman H, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revisiting of the NINCDS-ADRDA criteria. Lancet Neurology, 6, 734-746, 2007.
- 373) Seow D, Gauthier S. Pharmacotherapy of Alzheimer's Disease. Canadian Journal of Psychiatry, 52, 620-629, 2007.
- 374) Vellas B, Andrieu S, Cantet C, Dartigues JF, Gauthier S. Long-term changes in ADAS-cog: what is clinically relevant for disease-modifying trials in Alzheimer? Journal of Nutrition, Health & Aging, 11, 338-341, 2007.

- 
- 375) Herrmann N, Gauthier S, Lysy PG Clinical practice guidelines for severe Alzheimer's disease. Alzheimer's & Dementia, 3, 385-397, 2007.
- 376) Rockwood K, Moorhouse PK, Song X, MacKnight C, Gauthier S, Kertesz A, Montgomery P, Black S, Hogan DB, Guzman A, Bouchard R, Feldman H. Disease progression in vascular cognitive impairment: cognitive, functional and behavioral outcomes in the Consortium to Investigate Vascular impairment of Cognition (CIVIC) cohort study. Journal of Neurological Sciences, 252, 106-112, 2007.
- 377) Peters KR, Rockwood K, Black SE, Hogan DB, Gauthier S, Loy-English I, Hsiung GYR, Jacova C, Kertesz A, Feldman H. Neuropsychiatric symptom clusters and functional disability in cognitively-impaired-not-demented individuals. American Journal of Geriatric Psychiatry, 15. Published on line October 10<sup>th</sup> 2007.
- 378) Ferreri F, Agbokou C, Gauthier S. Effets cardio-vasculaires des inhibiteurs de la cholinesterase dans la maladie d'Alzheimer. Revue Neurologique, 163, 968-974, 2007.
- 379) Dubois B, Burn D, Goetz C, Aarsland D, Brown R, Broe A, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees R, Litvan I, Mizuno Y, McKeith IG, Olanow W, Poewe W, Sampaio C, Tolosa E, Emre M. Diagnostic procedures for Parkinson's Disease Dementia : recommendations from the Movement Disorders Society risk force. Movement Disorders, 22, 2314-2324, 2007.
- 380) Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes MR, Briley JD, Borrie M, Coletta N, Delisle R, Dhalla D, Ehm MG, Feldman H, Fornazzari L, Gauthier S, Goodgame N, Guzman D, Hammond S, Hollingworth P, Hsiung GY, Johnson J, Kelly DD, Keren R, Kertesz A, King KS, Lovestone S, Loy-English I, Matthews PM, Owen MJ, Plumpton M, Pryse-Phillips W, Prinjha RK, Richardson JC, Saunders A, Slater AJ, St George-Hyslop PH, Stinnett SW, Swartz JE, Taylor RL, Wherrett J, Williams J, Yarnall DP, Gibson RA, Irizarry MC, Middleton LT, Roses AD. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer's disease. Archives of Neurology 65, 45-53, 2008.
- 381) Gauthier S. Trial designs and outcomes to monitor novel therapeutics in Alzheimer's disease. In Pharmaceutical and Mechanisms in Alzheimer's Therapeutics, AC Cuello [Ed], Springer, New York, 28-35, 2008.
- 382) Clément F, Belleville S, Gauthier S. Cognitive complaint in mild cognitive impairment and Alzheimer's disease. Journal of the International Neuropsychological Society, 14, 222-232, 2008.
- 383) Reisberg B, Gauthier S. Current evidence for subjective cognitive impairment (SCI) as the pre mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer's disease. International Psychogeriatrics, 20, 1-16, 2008.
- 384) Gauthier S, Loft H, Cummings J. Improvement in behavioral symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. International Journal of Geriatric Psychiatry, 23, 537-545, 2008.
- 385) Poirier J, Gauthier S. Pharmacogenomics and the treatment of sporadic Alzheimer's disease: a decade of progress. Current Pharmacogenomics and Personalized Medicine, 6, 63-76, 2008.
- 386) Gauthier S, Poirier J. Current and future management of Alzheimer's disease. Alzheimer's & Dementia, 4 (suppl 1), S48-S50, 2008.

- 387) Hsiung GYR, Alipour S, Jacova C, Grand J, Gauthier S, Black SE, Bouchard RW, Kertesz A, Loy-English I, Hogan DB, Rockwood K, Feldman H. Transitions from Cognitively Impaired Not Demented to Alzheimer's disease: an analysis of changes in functional abilities in a dementia clinic cohort. Dementia & Geriatric Cognitive Disorders, 25, 483-490, 2008.
- 388) Erkinjuntti T, Gauthier S, Bullock R, Kurz A, Hammond G, Zhu Y, Brashear R, Schwalen S. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analysis from a randomized, controlled trial (GAL-INT-6). Journal of Psychopharmacology, 25 Feb 2008, PMID 18308781.
- 389) Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Wang D, Brashear HR, Nye JS and the GAL-INT-11/18 Study group. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology, 22, 2024-2035, 2008.
- 390) Gauthier S. Symptomatic therapeutic aspects in Alzheimer's disease. In "Dementias". Handbook of Clinical Neurology, vol 89 (3<sup>rd</sup> series), C. Duyckaerts & I. Litvan, Eds, Elsevier, 269-271, 2008.
- 391) Hudon C, Belleville S, Gauthier S. The association between depressive and cognitive symptoms in amnesic mild cognitive impairment. International Psychogeriatrics, 20, 710-723, 2008.
- 392) Gauthier S, Dubois B, Feldman H, Scheltens P. Status report on the revised research diagnostic criteria for Alzheimer's disease. Lancet Neurology, 7, 668-670, 2008.
- 393) Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Filit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, Hyman B, Kuller L, schenk D, Snyder S, Thomas RG, Tuszyynski MH, Velas B, Wurtman RJ, Snyder PJ, Frank RA, Albert M, Doody R, Ferris S, Kaye J, Koo E, Morrison-Bogorad M, Reisberg B, Salmon DP, Gilman S, Mohs R, Aisen PS, Breitner JC, Cummings JL, Kawas C, Phelps C, Poirier J, Sabbah M, Touchon J, Khachaturian AS, Bain LJ. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimer's & Dementia, 4, 156-163, 2008.
- 394) Peters KR, Rockwood K, Black SE, Hogan DB, Gauthier S, Loy-English I, Hsiung GY, Jacova C, Kertesz A, Feldman HH. Neuropsychiatric symptom clusters and functional disability in cognitively-impaired-not-demented individuals. American Journal of Geriatric Psychiatry, 16, 136-144, 2008.
- 395) Poewe W, Gauthier S, Aarsland D, Leverenz JB, Barone P, Weintraub D, Tolosa E, Dubois B. Diagnosis and management of Parkinson's disease dementia. International Journal of Clinical Practice, 62, 1581-1587, 2008.
- 396) Letenneur L, Pérès K, Fleury H, Garrigue I, Barberger-Gateau P, Helmer C, Orgogozo JM, Gauthier S, Dartigues JF. Seropositivity to Herpes Simplex virus antibodies and risk of Alzheimer's disease: a population-based cohort study. PlosOne, 3, e3637, Epub Nov 4<sup>th</sup> 2008.
- 397) Herrmann N, Gauthier S. Management of severe Alzheimer's disease. Canadian Medical Association Journal, 179, 1279-1297, 2008.
- 398) Belleville S, Bherer L, Lepage E, Chertkow H, Gauthier S. Task switching capacities in persons with Alzheimer's disease and mild cognitive impairment. Neuropsychologia, 46, 2225-2233, 2008.
- 399) Berdugo B, Gauthier S. Utilisation d'un timbre cutané dans la maladie d'Alzheimer. Une nouvelle approche galénique. Pharmactuel, 41, 153-157, 2008.
- 400) Gauthier S, Seow D. Pharmacotherapy of Alzheimer's disease. Current and future perspectives. US

Neurological Disease 2007, 2, 46-47, 2008.

- 401) Gauthier S. Pharmacology of Parkinson Disease Dementia and Lewy Body dementia. In “Dementia in Clinical Practice”, Giannakopoulos P, Hof P [Eds], Frontiers in Neurology and Neuroscience, Vol 24. Karger, 135-139, 2009.
- 402) Gauthier S. Dimebon improves cognitive function in people with mild to moderate Alzheimer’s disease. Evidence Based Mental Health, 12, 21, 2009.
- 403) Erkinjuntti T, Gauthier S. The concept of Vascular Cognitive Impairment. In “Dementia in Clinical Practice”, Giannakopoulos P, Hof P [Eds], Frontiers in Neurology and Neuroscience, Vol 24. Karger, 79-85, 2009.
- 404) Robert P, Onyike C, Leentjens A, Dujardin K, Aalten P, Starkstein S, Verhey F, Yessavage J, Clement JP, Drapier D, Bayle F, Benoit M, Boyer P, Lorea PM, Thibault F, Cummings J, Gauthier S, Grossberg G, Vellas B, Byrne J. Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. European Psychiatry, 24, 98-104, 2009.
- 405) Andrieu S, Coley N, Aisen P, Carrillo M, Dekosky S, Durga J, Fillit H, Frisoni G, Froelich L, Gauthier S, Jones R, Jonsson L, Khachaturian Z, Morris J, Orgogozo JM, Ousset PJ, Robert P, Salmon E, Sampaio C, Verhey F, Wilcock G, Vellas B. Methodological issues in primary prevention trials for neurodegenerative dementia. Journal of Alzheimer’s Disease, 16, 235-270, 2009.
- 406) Saumier D, Aisen P, Gauthier S, Vellas B, Ferris SH, Duong A, Suhy J, Oh J, Lau W, Garceau D, Haine D, Sampalis J. Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer’s disease: the Alzhemed (tramiprosate) experience. Journal of Nutrition Health & Aging, 13, 370-372, 2009.
- 407) Khachaturian Z, Snyder PJ, Doody D, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian A, Korczyn AD, Phelps C, Roses A, Simpkins JW, Schneider LS, Albert MS, Egge R, Deves A, Ferris S, Greenberg BD, Johnson C, Kukull WA, Poirier J, Schenk D, Thies W, Gauthier S, Gilman S, Bernick C, Cummings JL, Fillit H, Grundman M, Kaye J, Mucke L, Reisberg B, Sano M, Pickeral O, Petersen RC, Mohs RC, Buckholtz N, Carrillo M, Corey-bloom JP, Foster NL, Jacobsen S, Lee V, Potter WZ, Sabbagh MN, salmon D, Trojanowski JQ, Wexner N, Bain LJ. A roadmap for the prevention of dementia II: Leon Thal symposium 2008. Alzheimer’s & Dementia, 5, 85-92, 2009.
- 408) Khachaturian Z, Cami J, Andrieu S, Avila J, Rovira MB, Breteler M, Froelich L, Gauthier S, Gomez-Isla T, Khachaturian AS, Kuller LH, Larson EB, Lopez OL, Martinez-Lage JM, Petersen RC, Schellenberg GD, Sunyer J, Vellas B, Bain LJ. Creating a transatlantic research enterprise for preventing Alzheimer’s disease. Alzheimer’s & Dementia, 5, 361-366, 2009.
- 409) Gauthier S, Poirier J. Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008”. Who may benefit from disease-modifying studies in Alzheimer’s disease? Alzheimer’s & Dementia, 5, 147-148, 2009.
- 410) Villeneuve S, Belleville S, Massoud F, Bocti C, Gauthier S. The impact of vascular risk factors and diseases on cognition in persons with mild cognitive impairment. Dementia and Geriatric Cognitive Disorders, 27, 375-381, 2009.
- 411) Hudon C, Belleville S, Gauthier S. The assessment of recognition memory using the remember/know procedure in amnesic mild cognitive impairment and probable Alzheimer’s disease. Brain and Cognition, 70, 171-179, 2009.
- 412) Ballard C, Gauthier S, Cummings J, Brodaty H, Grossberg G, Robert P, Lyketsos C. Management of agitation

and aggression associated with Alzheimer's disease. Nature Reviews - Neurology, 5, 1-11, 2009

- 413) Gauthier S, Aisen PS, Ferris SH, Saumier D, Duong A, Haine D, Garceau D, Suhy J, Oh J, Lau W, Sampalis J for the ALPHASE group. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the ALPHASE study. Journal of Nutrition, Health and Aging, 13, 550-557, 2009.
- 414) Gauthier S. Top cited papers in International Psychogeriatrics: efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics, 21, 454, 2009.
- 415) Gauthier S. Will CSF analysis become routine in persons with memory complaints? Lancet Neurology, 8, 595-596, 2009.
- 416) Rolleston F, Corman J, Gauthier S, O'Hara P, Schmaltz R. Ethics issues with private research ethics boards: a breakout session at the 2009 NCEHR National Conference. Journal of Academic Ethics, DOI 10.1007/s10805-009-9084-1., published online 28 July 2009.
- 417) Ferris S, Inl R, Robert P, Winblas B, Gatz G, Tennigkeit F, Gauthier S. Severe Impairment Battery Language scale: a language-assessment tool for Alzheimer's patients. Alzheimer's & Dementia, 5, 375-379, 2009.
- 418) Ferris S, Inl R, Robert P, Winblas B, Gatz G, Tennigkeit F, Gauthier S. Treatment effects of memantine on language in moderate to severe Alzheimer's patients. Alzheimer's & Dementia, 5, 369-374, 2009.
- 419) Wilkinson D, Schindler R, Schwam E, Waldemar G, Jones R, Gauthier S, Lopez O, Cummings J, Xu Y, Feldman H. Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 28, 244-251, 2009.
- 420) Gauthier S, Scheltens P. Can we do better in developing new drugs for Alzheimer's disease? Alzheimer's & Dementia, 5, 489-491, 2009.
- 421) Gauthier S. Should we treat patients with very mild Alzheimer's disease with a cholinesterase inhibitor? Journal of Psychiatry & Neuroscience, 34, 480, 2009.
- 422) Plosker GL, Gauthier S. Cerebrolysin. A review of its use in dementia. Drugs Aging 26, 893-915, 2009.
- 423) Suh Guk-Hee, Wimo A, Gauthier S, O'Connor D, Ikeda M, Homma A, Dominguez J, Yang BM. International price comparisons for the Alzheimer drugs: a way to close the affordability gap. International Psychogeriatrics, 21, 1116-1126, 2009.
- 424) Brambati SM, Belleville S, Kergoat MJ, Chayer C, Gauthier S, Joubert S. Single – and multiple-domain amnesic mild cognitive impairment: two sides of the same coin? Dementia and Geriatric Cognitive Disorders 28, 541-549, 2009
- 425) Gauthier S. Innovations thérapeutiques dans la maladie d'Alzheimer. Revue de Gériatrie, 34 (Suppl B), B15-B16, 2009.
- 426) Davidson JE, Irizarry MC, Bray B, Wetten S, Galwey N, Gibsin R, Borrie M, Delisle R, Feldman H, Hsiung GY, Fornazzari L, Gauthier S, Guzman D, Loy-English I, Keren R, Kertesz A, St. George-Hyslop P, Wherret

- J, Monsch AU. An exploration of cognitive subgroups in Alzheimer's disease. Journal of the International Neurological Society, 16, 233-243, 2009.
- 427) Bélanger S, Belleville S, Gauthier S. Inhibition impairments in Alzheimer's disease, mild cognitive impairment and healthy aging: effect of congruency proportion in a Stroop task. Neuropsychologia 48, 581-590, 2009.
- 428) Gauthier S, Leuzy A. Diagnosis of prodromal Alzheimer's disease: do you really want to know? Canadian Journal of Neurological Sciences, 37, 2, 2010.
- 429) Moorhouse P, Song X, Rockwood K, Black S, Kertesz A, Gauthier S, Feldman H, Consortium to investigate vascular impairment of cognition. Executive dysfunction in vascular cognitive impairment in the consortium to investigate vascular impairment of cognition study. Journal of Neurological Sciences 288, 142-146, 2010.
- 430) Black S, Gauthier S, Dalziel W, Keren R, Correira J, Hew H, Binder C. Canadian Alzheimer's disease caregiver survey: baby-boomer caregivers and burden of care. International Journal of Geriatric Psychiatry, 25, 807-813, 2010.
- 431) Bélanger S, Belleville S, Gauthier S. Inhibition impairments in Alzheimer's disease, mild cognitive impairment and healthy aging: effect of congruency proportion in a Stroop task. Neuropsychologia, 48, 581-590, 2010
- 432) Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, Lyketsos C. Management of behavioral problems in Alzheimer's disease. International Psychogeriatrics, 22, 346-372, 2010.
- 433) Massoud F, Gauthier S. Update on the pharmacological treatment of Alzheimer's disease. Current Neuropharmacology 8, 69-80, 2010.
- 434) Gauthier S, Juby A, Dalziel W, Réhel B, Schechter R. Effects of rivastigmine on common symptomatology of Alzheimer's disease: a large, naturalistic, community-based study (EXPLORE). Current Medical Research Opinion, 26, 1149-1160, 2010.
- 435) Gauthier S, Leuzy A. Update on criteria for an earlier (pre-dementia) diagnosis of Alzheimer's Disease. The Canadian Review of Alzheimer's Disease and other Dementias, 13, 15-17, 2010.
- 436) Gauthier S. Trial designs. In "Dementia", 4<sup>th</sup> Edition, D. Ames, A. Burns, J. O'Brien [Eds], 523-526, 2010.
- 437) Erkinjuntti T. Gauthier S. What is vascular cognitive impairment? In "Dementia", 4<sup>th</sup> Edition, D. Ames, A. Burns, J. O'Brien [Eds], 541-552, 2010.
- 438) Gauthier S, Lopez O, Waldemar G, Jones R, Cummings J, Zhang R, Schindler R, Schwam E. Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease. International Psychogeriatrics, 22, 973-983, 2010.
- 439) De Medeiros K, Robert P. Gauthier S, Stella F, Politis A, Leoutsakos J, Taragano F, Kremer J, Brugnolo A, Porsteinsson A, Geda Y, Brodaty H, Gazdag G, Cummings J, Lyketsos C, NPI-C Research Group. The Neuropsychiatric Inventory – Clinician rating approach (NPI-C); reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. International Psychogeriatrics, 22, 984-994, 2010.

- 
- 440) Aarsland D, Ehrt U, Gauthier S. Rivastigmine for the treatment of Parkinson's disease dementia. Aging Health, 6, 277-284, 2010.
- 441) Gauthier S, Garcia A, Sano M, Robert P, Senanaroung V, Woodward M, Bodaty H. Priorities for research consortia on Alzheimer's disease. Alzheimer's & Dementia, 6, 359-362, 2010.
- 442) Lopez O, Schwam E, Cummings J, Gauthier S, Jones R, Wilkinson D, Waldemar G, Zhang R, Schindler R. Predicting cognitive decline in Alzheimer's disease. An integrated analysis. Alzheimer's & Dementia, 6, 431-439, 2010.
- 443) Desmarais JE, Gauthier S. Clinical use of cholinergic drugs in Alzheimer's disease. Nature Reviews/Neurology, 6, 418-420, 2010.
- 444) Robert P, Ferris S, Gauthier S, Ihl R, Winblad B, Tennigkeit F. Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Alzheimer's Research & Therapy, 2, 24, 2010.
- 445) Dubois B, Feldman H, Jacova C, Cummings J, DeKosky S, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurology 9, 1118-1127, 2010.
- 446) Reisberg B, Jamil IA, Khan S, Monteiro I, Torossian C, Ferris S, Sabbagh M, Gauthier S, Auer S, Shulman MB, Kluger A, Frannsen E, Weigel J. Staging dementia. In "Principles and practice of geriatric psychiatry", 3<sup>rd</sup> Ed. Abou-Saleh M, Katona C, Kumar A Eds. Wiley-Blackwell Publications, Chichester, England, 162-169, 2010.
- 447) Farlow MR, Grossberg G, Gauthier S, Meng X, Olin JT. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease. Current Medical Research & Opinion, 26, 2441-2447, 2010.
- 448) Winblad B, Gauthier S, Astrom D, Stender K. Memantine benefits functional abilities in moderate to severe Alzheimer's disease. Journal of Nutrition Health and Aging, 14, 770-774, 2010.
- 449) Plosker GL, Gauthier S. Spotlight on cerebrolysin in dementia. CNS Drugs 24, 263-266, 2010.
- 450) Massoud F, Desmarais JE, Gauthier S. Switching cholinesterase inhibitors in older adults with dementia. International Journal of Geriatric Psychiatry, 23, 372-378, 2011.
- 451) Aisen P, Gauthier S, Ferris SH, Saumier D, Haine D, Garceau D, Duong A, Suhy J, Oh J, Lau WC, Sampalis J, for the Alphase group. Tramiprosate in mild-to-moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Archives of Medical Sciences, 7, 102-111, 2011.
- 452) Waldemar G, Gauthier S, Jones R, Wilkinson D, Cummings J, Lopez O, Zhang R, Xu Y, Sun Y, Knox S, Richardson S, Mackell J. Effects of donepezil on emergence of apathy in mild to moderate Alzheimer's disease. International Journal of Geriatric Psychiatry, 26, 150-157, 2011.
- 453) Belleville S, Clément F, Mellah S, Gilbert B, Fontaine F, Gauthier S. Training-related brain plasticity in subjects at risk of developing Alzheimer's disease. Brain, 134, 1623-1634, 2011.
- 454) Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's Disease. The Lancet, 377, 1019-1031, 2011.



- 
- 455) Cummings J, Jones R, Wilkinson D, Lopez O, Gauthier S, Waldemar G, Zhang R, Xu Y, Sun Y, Richardson S, Mackell J. Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis. The Journal of Alzheimer's Disease, 21, 843-851, 2011.
- 456) Gillette-Guyonnet S, Andrieu S, Nourhashemi F, Gardette V, Coley N, Canter C, Gauthier S, Ousset JP, Vellas B for the REAL.FR Study Group. Long-term progression of Alzheimer's disease in patients under antidementia drugs. Alzheimer's & Dementia, 7, 579-592, 2011.
- 457) Gauthier S, Patterson C, Gordon M, Soucy JP, Schubert F, Leuzy A. Commentary on the NINCDS-AA revised criteria for Alzheimer Disease: a Canadian perspective. Alzheimer's & Dementia, 7, 330-332, 2011.
- 458) Ihl R, Frölich L, Winblad B, Schneider L, Burns A, Möller HJ & WFSBP Task Force on Treatment Guidelines for Alzheimer's disease and other dementias. Guidelines on dementia. The World Journal of Biological Psychiatry, 12, 2-32, 2011.
- 459) Gauthier S. Treatment of Alzheimer's disease. The past, the present, and the future. Canadian Journal of Psychiatry, 56, 577-578, 2011.
- 460) Villeneuve S, Massoud F, Bocti C, Gauthier S, Belleville S. The nature of episodic memory deficits in MCI with and without vascular burden. Neuropsychologia, 49, 3027-3035, 2011.
- 461) Holthoff VA, Ferris S, Ihl R, Robert P, Winblad B, Gauthier S, Sternberg K, Tennigkeit F. Validation of the relevant outcome scales for Alzheimer's disease (ROSA): a novel multi-domain assessment for daily medical practice. Alzheimer's Research & Therapy, 3, 27, 2011.
- 462) Vellas B, Aisen P, Sampaio C, Carrillo M, Scheltens P, Scherrer B, Frisoni G, Weiner M, Schneider L, Gauthier S, Snyder P, Gispen-de-Wied C, Hendrix S, Feldman H, Cedarbaum J, Petersen R, Siemens E, Andrieu S, Prulovic D, Touchon J, Hampel H. Prevention trials in Alzheimer's disease: an EU-US task force report. Progress in Neurobiology, 95, 594-600, 2011.
- 463) Jones R, Wilkinson D, Lopez O, Cummings J, Waldemar G, Zhang R, Xu Y, Mackell, Gauthier S. Collaborative research between academia and industry using a large clinical trial database: a case study. Trials, 12, 233, 2011.
- 464) Wu L, Rsa-Neto P, Gauthier S. Use of biomarkers in clinical trials for Alzheimer's disease: from concept to application. Molecular Diagnosis & Therapy, 15, 313-325, 2011.
- 465) Peters F, Ergis AM, a, Dieudonné B, Verny M, Jolicoeur P, Belleville S. Abnormal temporal dynamics of visual attention in Alzheimer's disease and in dementia with Lewy bodies. Neurobiology of Aging 33, 1-10, 2011.
- 466) Ihl R, Ferris S, Robert P, Winblad B, Gauthier S, Tennigkeit F. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild to moderate Alzheimer's disease. International Journal of Geriatric Psychiatry, 27, 15-21, 2012.
- 467) Holthoff VA, Ferris S, Gauthier S, Ihl R, Robert P, Winblad B, Sternberg K, Tennigkeit F and The ROSA Study Group. Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open-label, single-arm, multicenter clinical study. International Journal of Geriatric Psychiatry on line 11 April 2012, DOI: 10.1002/gps.3805, 2012.

- 
- 468) Rainville C, Lepage E, Gauthier S, Kergoat MJ, Belleville S. Executive function deficits with MCI: a study with a Tower of London task. Journal of Clinical and Experimental Neuropsychology, 34, 306-324, 2012.
- 469) Wu L, Rosa-Neto P, Hsiung GYR, Sadovnick AD, Masellis M, Black SE, Jia J, Gauthier S. Early-onset Familial Alzheimer's Disease (EOFAD). Canadian Journal of Neurological Sciences, 39, 436-445, 2012.
- 470) Leuzy A, Gauthier S. Ethical issues in the management of Alzheimer's disease. Expert Review in Neurotherapeutics, 12, 557-567, 2012.
- 471) Gauthier S, Wu L, Rosa-Neto P, Jia J. Prevention strategies for Alzheimer's disease. Translational Neurodegeneration, DOI:10.1186/2047-9158-1-13, 2012.
- 472) Lee WJ, Tsai CF, Gauthier S, Wang SJ, Fuh JL. The association between cognitive impairment and neuropsychiatric symptoms in patients with Parkinson's disease dementia. International Psychogeriatrics, 24, 1980-1987, 2012.
- 473) Liu WJ, Wang LN, Tan JP, Ji P, Gauthier S, Zhang YL, Ma TX, Liu SN. Burden, anxiety and depression in caregivers of veterans with dementia in Beijing. Archives of Gerontology and Geriatrics, 55, 560-563, 2012.
- 474) Gauthier S. Management of Alzheimer's disease using disease-modifying drugs. Neurodegenerative Disease Management, 2, 1-4, 2012.
- 475) Clément F, Gauthier S, Belleville S. Executive functions in mild cognitive impairment : emergence and breakdown of neural plasticity. Cortex <http://dx.doi.org/10.1016/j.cortex.2012.06.004>, 2012.
- 476) Gauthier S, Patterson C, Chertkow H, Gordon M, Herrmann N, Rockwood K, Rosa-Neto P, Soucy JP on behalf of the CCCDTD4 participants. Recommendations of the 4<sup>th</sup> Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Canadian Journal of Geriatrics, 15, 120-126, 2012.
- 477) Gauthier S, Patterson C, Chertkow H, Gordon M, Herrmann N, Rockwood K, Rosa-Neto P, Soucy JP on behalf of the CCCDTD4 participants. Recommendations of the 4<sup>th</sup> Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Canadian Journal of Neurological Sciences, 39 (supplement 5), S1-S8, 2012.
- 478) Wu L, Rowley J, Mohades S, Leuzy A, Dauar MT, Shin M, Fonov V, Jia J, Gauthier S, Rosa-Neto P and the Alzheimer's Disease Neuroimaging Initiative. Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PloS ONE 7(10): e47905, doi:10.1371/journal.pone.0047905, 2012.
- 479) Cheewakriengkrai L, Gauthier S. Book review of "Neurodegeneration: the molecular pathology of dementia and movement disorders". Canadian Journal of Neurological Sciences, 39, 856, 2012.
- 480) Gauthier S. Les traitements pharmacologiques actuels de la maladie d'Alzheimer et perspectives futures. Le défi de la maladie d'Alzheimer : Synergies franco-québécoises, Tillement JP, Hauw JJ, Papadopoulos V (eds), Médecine Sciences Publications, Lavoisier, Paris, 89-92, 2013.
- 481) Gauthier S, Molinuevo J. Benefits of combination treatment in Alzheimer's disease. Alzheimer's & Dementia, 9, 326-331, 2013.
- 482) Dubois B, Gauthier S, Cummings J. The utility of the new research criteria for Alzheimer's disease. International Psychogeriatrics, 25, 174-184, 2013.
- 483) Forlini C, Gauthier S, Racine E. Should physicians prescribe cognitive enhancers to healthy individuals?

Canadian Medical Association Journal, DOI:10.1503/cmaj.121508.

- 484) Masellis M, Sherborn K, Rosa-Neto P, Sadovnick DA, Hsiung GYR, Black SE, Prasad S, Williams M, Gauthier S. Early-onset dementias: diagnostic and etiological considerations. Alzheimer Research & Therapy, in press.
- 485) Gauthier S, Leuzy A, Racine E, Rosa-Neto P. Diagnosis and management of Alzheimer's disease: past, present and future ethical issues. Progress in Neurobiology, doi.org/10.1016/j.pneurobio.2013.01.003.
- 486) Cheewakriengkrai L, Gauthier S. A 10-year perspective on donepezil. Expert Opinion On Pharmacotherapy, 14, 331-338, 2013.
- 487) Arrighi HM, Gélinas I, McLaughlin TP, Buchanan J, Gauthier S. Longitudinal changes in functional disability in Alzheimer's disease patients. International Psychogeriatrics, 25, 929-937, 2013.
- 488) Herrmann N, Gauthier S, Boneva N, Lemming OM, on behalf of the 10158 investigators. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally-enriched sample of patients with moderate-to-severe Alzheimer's disease. International Psychogeriatrics, 25, 919-927, 2013.
- 489) Gauthier S, Leuzy A, Rosa-Neto P. How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease? Neurodegenerative Diseases, DOI:10.1159/000353748.
- 490) Gauthier S, Robillard A, Cohen S, Black S, Sampalis J, Colizza D, de Takacs F, Schecter R on behalf of the EMBRACE investigators. Real-life effectiveness and tolerability of rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease. Current Medical Research and Opinion, 29, 1-12, 2013.
- 491) Patterson C, Gauthier S. Diagnosis and treatment of dementia: the Fourth Canadian Consensus Conference. Alzheimer's Research & Therapy 2013, 5(Suppl 1): SX.
- 492) Rive B, Gauthier S, Costello S, Marre C, François C. Synthesis and comparison of the meta-analysis evaluating the efficacy of memantine in moderate to severe stages of Alzheimer's disease. CNS Drugs, DOI:10.1007/s40263-013-0074-x.
- 493) Palmour N, Vanderbyl BL, Zimmerman E, Gauthier S, Racine E. Alzheimer's disease dietary supplements in websites. HEC Forum, DOI:10.1007/s10730-013-9217-1.
- 494) Parent M, Bedard MA, Aliaga A, Minuzzi L, Mechawar N, Soucy JP, Schirmacher E, Kostikov A, Gauthier S, Rosa-Neto P. Cholinergic depletion in Alzheimer's disease shown by [18F]FEOBV autoradiography. International Journal of Molecular Imaging, submitted.
- 495) Rowley J, Fonov V, Wu O, eskildsen S, Scoemaker D, Wu L, Mohades S, Shin M, Sziklas V, Shmuel A, Dagher A, Gauthier S, Rosa-Neto P and the Alzheimer's Disease Neuroimaging Initiative. White matter abnormalities and structural hippocampal disconnections in AD, naMCI and aMCI. Brain, submitted.
- 496) Leuzy A, Rosa-Neto P, Gauthier S. Revising the diagnostic criteria for Alzheimer's disease: the use of biomarkers and attendant ethical implications. International Journal of Science and Society, in press.

## **B. Published abstracts**

1. Gauthier, S., Gagner, J.-P., Sourkes, T.L., Neural regulation of adrenal tyrosine hydroxylase. Canadian Journal

- of Neurological Sciences, 5, 347-348, 1978.
2. Young, S.N., Gauthier, S., Anderson, G.M., Purdy, W.C. The influence of anti-Parkinsonian drugs on tryptophan metabolism. Canadian Journal of Neurological Sciences, 6, 93, 1979.
  3. Sourkes, T.L., Gagner, J.-P., Gauthier, S. Neural components of the responses to stressors: Central pathways mediating the induction of adrenal tyrosine hydroxylase. Canadian Journal of Neurobiological Sciences, 7, 229, 1980.
  4. Gauthier, S., Young, S.N. Serotonin metabolism in epileptic patients. Canadian Journal of Neurological Sciences, 7, 326, 1980.
  5. Gagner, J.-P., Gauthier, S., Sourkes, T.L. Central pathways regulating adrenal tyrosine hydroxylase. Neuroscience Abstracts, 6, 1980.
  6. Gauthier, S., Etienne, P., Dastoor, D., Collier, B., Ludwick, R. Lack of effect of a 3-month treatment with lecithin in Alzheimer's disease. Neurology, 31(2), 89, 1981.
  7. Sherwin, A.L., Quesney, L.F., McQuaid, P., Olivier, A., Harvey, C., Robitaille, Y., Gauthier, S., Van Gelder, N.M. Enzymic changes in actively spiking areas of human epileptic cortex. Neurology, 32(2), A128, 1982.
  8. Gauthier, S., Saint-Louis, J. Adrenal tyrosine hydroxylase activity and catecholamine content after unilateral hypothalamic de-efferentation. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 7 (Supplement), 144, 1983.
  9. Yashpal, K., Gauthier, S., Henry, J.L. Substance P intrathecally at spinal T9 level increases adrenal medullary output of adrenaline and noradrenaline in the rat. Neuroscience Abstracts, 9, 18, 1983.
  10. Gauthier, S., Vinken, W., Dollfuss, R., Hanson, R., Cosio, M.G. Obstruction des voies aériennes supérieures dans les maladies extra-pyramidales. Canadian Journal of Neurological Sciences, 11, 410, 1984.
  11. Gauthier, L., Gauthier, S., Joannette, Y. Visual neglect in left-, right-, and bilateral Parkinsonians. Journal of Clinical and Experimental Neuropsychology, in press.
  12. Berger, L., Gauthier, S., Leblanc, R. Akinetic mutism and parkinsonism: a case with two distinct dopaminergic deficient states. Canadian Journal of Neurological Sciences, 12, 215, 1985.
  13. Gauthier, L., Gauthier, S. Group rehabilitation as an adjunct to medical therapy in idiopathic Parkinson's disease. Canadian Journal of Neurological Sciences, 12, 181, 1985.
  14. Yashpal, K., Romita, V.V., Gauthier, S., Henry, J.L. TRH intrathecally increases arterial pressure and heart rate in the rat. Canadian Journal of Neurological Sciences, 12, 216, 1985.
  15. Gauthier, S., Diksic, M., Yamamoto, L., Tyler, J., Feindel, W. Positron Emission Tomography with <sup>11</sup>C-choline in human subjects. Canadian Journal of Neurological Sciences, 12, 214, 1985.
  16. Quirion, R., Dalpé, M., Lemoine, P., Gauthier, S., Etienne, P., Nair, N.P.V. Localization of neurotransmitter and neuropeptide receptors in human brain. Canadian Journal of Neurological Sciences, 12, 174, 1985.
  17. Villemure, J.G., Théron, J., Yamamoto, L., Diksic, M., Hand, R., Worthington, C., Tyler, J., Trop, D., Abou-Madi, M., Archer, D., Morin, L., Ravussin, P., Leblanc, R., Luneau, C., Prescott, L., Gauthier, S., Feindel, W.

- Superseleative arterial administration of BCNU in high grade gliomas: clinical trial and positron emission tomography correlations. Canadian Journal of Neurological Sciences, 12, 172, 1985.
18. Rubin, M., Berkovic, S., Andermann, F., Gauthier, S. Secondary paroxysmal choreoathetosis. Canadian Journal of Neurological Sciences, 2, 218, 1985.
  19. Barbeau, H., Wainberg, M., Gauthier, S. Case study of Cyproheptadine/Periactin as an antispastic agent. Canadian Journal of Neurological Sciences, 2, 218, 1985.
  20. Evans, A.C., Redies, C., Gauthier, S., Tyler, J.L., Diksic, M., Meyer, E., Yamamoto, Y.L., Hakim, A. Study of metabolic and haemodynamic aspects of Huntington's disease by PET. Canadian Journal of Neurological Sciences, 13, 179, 1986.
  21. Gauthier, S., Boisseau, M., Chamberland, G. Handwriting analysis in several extrapyramidal disorders. Canadian Journal of Neurological Sciences, 13, 185, 1986.
  22. Leblanc, R., Tyler, J.L., Mohr, G., Meyer, E., Diksic, M., Yamamoto, Y.L., Hakim, A., Taylor, L., Gauthier, S. Cerebral blood flow and metabolism following extracranial to intracranial bypass. Canadian Journal of Neurological Sciences, 13, 196, 1986.
  23. Gauthier, S., Lafaille, F., Robitaille, Y., Leblanc, R., Olivier, A., Lal, S., Nair, N.P.V., Quirion, R. Choline acetyltransferase activity and muscarinic receptor density in fresh cortex from Alzheimer and epileptic patients. Neuroscience Abstracts, 12, 99, 1986.
  24. Yashpal, K., Gauthier, S., Henry, J.L. Oxytocin: intrathecal administration to the rat increases heart rate but not arterial pressure. Neuroscience Abstracts, 12, 529, 1986.
  25. Chan, C.W.Y., Rogers, M.W., Lafontaine, S., Gauthier, S. Is motor planning impaired in Parkinson's disease? Proc. Int. Union of Physiol. Sciences, 16, 256, 1986.
  26. Robitaille, Y., Quirion, R., Leblanc, R., Gauthier, S. Morphological and biochemical correlates of pre-frontal biopsies in a betanechol perfusion program for SD/SDAT. Canadian Journal of Neurological Sciences, 14, 98, 1987.
  27. Gauvreau, D. et al. The IMAGE (Investigations de la Maladie d'Alzheimer: Génétique et Epidémiologie) project: a multidimensional approach to Alzheimer's disease. Clinical Neurology and Neurosurgery, 89-2, Suppl.II, 28, 1987.
  28. Stewart, J., Barbeau, M., Gauthier, S. The effects of clonidine on clinical spasticity and in modulation of the locomotor pattern in chronic spastic spinal cord patients. Neuroscience Abstracts, 13, 353, 1987.
  29. Redies, C., Diksie, M., Collier, B., Gjedde, A., Gauthier, S., Thompson, C.J., Feindel, W.H. Influx of choline analog into dog brain measured by PET. Neuroscience Abstract, 13, 1113, 1987.
  30. Redies, C., Diksic, M., Collier, B., Gjedde, A., Thompson, C.J., Gauthier, S., Feindel, W.H. Endothelial transport of choline analog measured by PET. Canadian Journal of Neurological Sciences, 14, 343, 1987.
  31. Leblanc, R., Gauthier, S., Gauvin, M., Quirion, R., Palmour, R., Masson, H. Neurobehavioral effects of intrathecal somatostatinergic therapy in subhuman primates. Canadian Journal of Neurological Sciences, 15, 214, 1988.
  32. Bouchard, R., Gauthier, L., Gauthier, S., Leblanc, R. Intracerebroventricular bethanechol chloride in

- Alzheimer's Disease: dose-related response in a patient. Canadian Journal of Neurological Sciences, 15, 229, 1988.
33. Gauthier, S., Masson, H., Gauthier, L., Bacher, Y., Becker, R., Bergman, H., Charbonneau, R., Collier, B., Dastoor, D., Gayton, D., Kissel, C., Krieger, M., Kushnir, S., Nair, N.P.V., Neirinck, L., Ratner, J., St-Martin, M., Suissa, S., Tesfaye, Y., Vida, S., Bouchard, R., Morin, J., Lamontagne, A., Bailey, P., Kennedy, J. Tetrahydroaminoacridine (THA) avec lécithine dans la maladie d'Alzheimer. Canadian Journal of Neurological Sciences, 15, 230, 1988.
  34. Gauthier, L., Gauthier, S., Joannette, Y. Visual neglect and Idiopathic Parkinson's Disease. Canadian Journal of Neurological Sciences, 15, 232, 1988.
  35. Dannenbaum, E.S., Weis, P.L., Kearney, R.E., Gauthier, S. The effect of activation tasks on parkinsonian rigidity. Neuroscience abstracts, 14, 388, 1988.
  36. Lacoste-Royal, G., Mathieu, M., Nalbantoglu, J., Freire, M., Julien, J.P., Gauthier, S., Gauvreau, D. Neurofilament genes and Alzheimer's Disease, is there an association? Neuroscience abstracts, 14, 1087, 1988.
  37. Issa, A.M., Gauthier, S., Rowe, W., Meaney, M.J. Hypothalamic-pituitary-adrenal dysfunction is associated with cognitive impairments in aged rats. Neuroscience abstracts, 15, 1080, 1989.
  38. Aubert, I., Araujo, D.M., Gauthier, S., Quirion, R. Brain cholinergic receptors in human neurodegenerative diseases. Neuroscience abstracts, 15, 859, 1989.
  39. Shoulson, I. and the Parkinson Study Group: Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Acta Neurol. Scandinavica (Supplement 12) 80: 171-175, 1989
  40. Jankovic, J., McDermott, M., Carter, J., Gauthier, S., Goetz, C., Golbe, L., Huber, S., Koller, W., Olanow, C., Shoulson, I., Stern, M., Tanner, C., Weiner, W and the PSG. Variable clinical expression of Parkinson's disease: analysis of the DATATOP database. Neurology, 40 (Suppl. 1), 168, 1990.
  41. Ledoux, S., Nalbantoglu, J., Gauthier, S., Cashman, N.R. Lymphoid cell amyloid beta protein precursor gene expression in Alzheimer's disease. Neurology, 40 (Suppl. 1), 209, 1990.
  42. Shoulson, I., Parkinson Study Group. Deprenyl in Early Parkinson's Disease; symptomatic versus protective efficacy. Neurology, 40 (Suppl), 153, 1990.
  43. Gauthier, L., Liu, L., Gauthier, S. Spatial disorientation in Alzheimer's disease: results of a one- year follow-up. Neurobiology of Aging, 11, 257, 1990.
  44. Gauthier, S., Gauthier, L., Bouchard, R. Canadian therapeutic trials for Alzheimer's disease in the 80's: lessons for the 90's. Neurobiology of Aging, 11, 341-342, 1990.
  45. Aubert, I, Cécycy, D., Araujo, D.M., Gauthier, S., Quirion, R. Alterations of the cholinergic system in Alzheimer's and Parkinson's disease. Neurobiology of Aging, 11, 340, 1990.
  46. Aubert, I., Cécycy, D., Araujo, D.M., Gauthier, S., Quirion, R. Comparative expression of cholinergic markers during brain development. Neuroscience abstracts, 16, 536, 1990.

47. Gauthier, S., Cécylre, D., Aubert, I., Quirion, R. Characterization and autoradiographic distribution of [3H] AF-DX384 muscarinic binding sites in the rat brain. Neuroscience Abstracts, 16, 1060, 1990.
48. Shoulson, I. and the Parkinson Study Group: Deprenyl in early Parkinson's disease: symptomatic versus protective efficacy (abstract). Neurology (suppl. 1) 40: 153, 1990.
49. Environmental Influences Working Group of the Parkinson Study Group and the Parkinson Study Group (CM Tanner, Presenter, Chicago, IL): Smoking and Age at Onset of Parkinson's Disease: Analysis of the DATATOP Cohort (abstract). Annals of Neurology 28: 295, 1990.
50. The Parkinson Study Group (PG Como, Presenter, Rochester, NY): Effect of Deprenyl on Neuropsychological Function in Early Parkinson's Disease (abstract). Annals of Neurology 28: 297, 1990.
51. Kieburtz, K. Como, P., McDermott, M. and the Parkinson Study Group: Neuropsychological evaluation in early untreated Parkinson's disease (abstract). Annals of Neurology 28: 236, 1990.
52. Hall, WJ, Oakes, D. and the Parkinson Study Group: Statistical issues in monitoring a 2 X 2 factorial clinical trial (abstract). Controlled Clinical Trials 11: 264, 1990.
53. Oakes, D., McDermott, M., Ebert, S., Plumb, S., Watts, A., Shoulson, I. and the Parkinson Study Group: Investigator effects in a multicenter trial for Parkinson's disease (abstract). Controlled Clinical Trials 11: 284, 1990.
54. Peulsio, R.M., Rudolph, A., Orme C., Evans, P., Plumb, S., Oakes, D., Shoulson, I. and the Parkinson Study Group: DATATOP: Managing an accelerated trial (abstract). Controlled Clinical Trials 11: 304, 1990.
55. Dooley, N.P., Durham, H.D., Nalbantoglu, J., Gauthier, S., Cashman, N. Alu repeat family (ARF)- and amyloid precursor protein (APP)- RNA expression in Alzheimer and control fibroblasts. Neuroscience Abstracts, 16, 786, 1990.
56. Petit, D., Lorrain, D., Montplaisir, J., Gauthier, S. EEG spectral analysis in Alzheimer's disease: EEG slowing more prominent during REM sleep than during wakefulness. Sleep Research, 20, 392, 1991.
57. LeWitt, P.A., Galloway, M., Oakes, D., Watts, A., Matson, W. Parkinson Study Group. Homovanillic acid, other monoamine neurotransmitter metabolites, and Xanthine in Parkinsonian CSF. Neurology, 41 (suppl 1), 379, 1991.
58. Pelusio, R.M., Miller, C., Orme, C., Andrews, M., Casaceli, C., Lieou, J., Kieburtz, K. Wiscon, J., Shoulson, I. and the Parkinson Study Group: Use of Computer Applications to Facilitate Retroactive Updates to a Database (abstract). Controlled Clinical Trials 12: 707, 1991.
59. Clark, C, Edland, S.E, Galasko, D., Morris, J., Koss, E., Fillenbaum, G., and the CERAD Investigators. Variations in annual scores of the Mini-Mental State (MMS) examination in patients with Alzheimer's disease (AD): a CERAD study. Neurology, 42 (Suppl 3) 276, 1992.
60. McDermott, M.P., Jankovic, J. and the Parkinson Study Group. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. Neurology 42(Suppl 3), 441, 1992.
61. Shoulson, I. and the Parkinson Study Group. Neuroprotective Therapy for Parkinson's disease. Movement disorders 7(Suppl 1), 14, 1992.
62. Liu, L., Gauthier, L., Gauthier, S. The reliability and validity of a battery for assessment of spatial orientation

- skills (SOS): comparison between Alzheimer and normal elderly groups. The Gerontologist 32 (suppl 2), 40, 1992.
63. Petit, D., Montplaisir, J., Lorrain, D., Gauthier, S. Temporal asymmetry in the awake and REM sleep in mild to moderate Alzheimer's disease. Sleep Research, 21:305, 1992.
  64. Montplaisir, J., Petit, D., Lorrain, D., Gauthier, S. Decreased K Complexes and sleep spindles in Alzheimer's disease: the role of cholinergic mechanisms. Journal of Sleep Research, suppl. 1,153: 306, 1992.
  65. Petit, D., Lorrain, D., Montplaisir, J., Gauthier, S. Daytime vigilance in mild to moderate Alzheimer patients. Journal of Sleep Research, suppl. 1, 178: 356, 1992.
  66. Petit, D., Montplaisir, J., Lorrain, D., Gauthier, S. Sleep and computerized EEG in Alzheimer's disease: Effects of THA. Neurosciences Abstracts 18 (part 1) 567: 239, 1992.
  67. Lewitt, P., Galloway, M., Matson, W., Millbury, P., McDermott, M., Oakes, D., Shoulson, I. and the Parkinson Study Group (DATATOP Study): Neurosciences Abstracts 18: 1248, 1992.
  68. LeWitt, P., Galloway, M., Matson, W., McDermott, M., Oakes, D. and the Parkinson Study Group: Markers of endogenous dopamine synthesis in Parkinson's disease. Neurology, 42 (suppl 3) 42: 421, 1992.
  69. Pelusio, RM, Wixsom, J., Rudolph, A., Orme, C., Shoulson, I. and the Parkinson Study Group. Subject file checklists to facilitate clinical trial closeout activities. Controlled Clinical Trials, 13: 438, 1992.
  70. Aubert, I., Poirier, J., Baccichet, A., Gauthier, S., Quirion, R. Nicotinic acetylcholine receptors are decreased in the rat dentate gyrus following entorhinal cortex lesions. Neurosciences Abstracts, 18: 788, 1992.
  71. Gauthier, S., Parent, A.R., Dea, D., Quirion, R., Poirier, J. Inositol phosphate binding sites and neuronal plasticity following entorhinal cortex lesioning. Neurosciences Abstracts, 19, 607, 1992.
  72. Baldereschi, M., Amato, M.P., Neucini, P. Pracucci, B., Lippi, AI, Amaducci, L., Gauthier, S. et al. Interater agreement on the diagnosis of dementia: the WHO age-associated dementia project. Neurology, 43: A233, 1993.
  73. Lewitt, P. and the Parkinson Study Group. Monoaminergic metabolism, substance P, Met-enkephalin and biopterin in Parkinson's disease. Neurology, 43, A408, 1993.
  74. Aubert, I., Gauthier, S., Quirion, R. Comparative study of cholinergic receptors in Alzheimer's and Parkinson's diseases using quantitative in vitro receptor autoradiography. Neurosciences Abstracts, 19: 222, 1993.
  75. Issa, A.M., Gauthier, S., Collier, B. The phosphate inhibitors calcyculin A and okadaic acid alter presynaptic cholinergic function in rat brain. Neurosciences Abstracts, 19: 915, 1993.
  76. Guillaume, D., Bertrand, P., Hellauer, K., Dea, D., Lindsay, J., Kogan, S., Gauthier, S., Poirier, J. Distribution of HSV-1 DNA in selected areas of normal and Alzheimer's disease brains: A PCR study. Neurosciences Abstracts, 19: 1256, 1993.
  77. Pallister, C., Shaw, I., Ledoux, S., Gauthier, S., Cashman, N. Lymphocyte abundance of amyloid precursor protein (APP) is increased in Down's Syndrome and aging. Neurology, 44 (supp2),A206, 1994.
  78. Nalbantoglu, JI, Gilfix B.M., Bertrand, P., Robitaille, Y., Gauthier, S., Rosenblatt, D. S., Poirier, J. Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series. Neurobiology of



Aging, 15 (suppl) S134, 1994.

79. Aubert I, Cécyre D, Gauthier S, Quirion R. Autoradiographic distribution of nicotinic receptor sites labeled with [3H] cytosine in the human brain: comparison with muscarinic receptors. Neurosciences Abstracts, 20: 1168, 1994.
80. Lackmache, Y., Leporé, F., Gauthier, S., Lassonde, M. Corpus callosum pathology in Alzheimer's subjects: disruption in interhemispheric transfer. Neurosciences Abstracts, 20: 1777, 1994.
81. Montplaisir, J., Petit, D., Gauthier, S., Hassaina, F. Topography of REM sleep EEG slowing in mild Alzheimer's disease. Journal of Sleep Research, 3(suppl 1): 172, 1994.
82. Issa, A.M., Gauthier, S., Collier, B. Subcellular distribution of acetylcholine in rat brain following exposure to calyculin A or okadaic acid. Society for Neuroscience, vol. 21, page 69, 1995.
83. Lakmache, Y., Gauthier, S., Leporé, F., Lassonde, M. Sparing of primary sensory and motor abilities in intermediate stages of Alzheimer's disease. Society for Neuroscience, vol. 21, page 1488, 1995.
84. Delisle, M.C., Poirier, J., Quirion, R., Aubert, I., Farlow, M., Bertrand P., Dean, D., Gauthier, S., Nalbantoglu, J., Gilfix, B.G. Apolipoprotein E4 and cholinergic dysfunction in Alzheimer disease: effect on treatment outcome. Society for Neuroscience, vol. 21, page 1976, 1995.
85. Panisset, M., Sadikot, A., Gauthier, S. Posterior ventral pallidotomy in Parkinson's disease with disabling dyskinesias. Neurology 46: A200, 1996.
86. Whitehouse, P.J., Amaducci, L., Feldman, H., Ferris, S., Gauthier, S., Homma, A., Khachaturian, Z., Levy, R., Orgogozo, J.M., Post, S., Reisberg, B., Rossor, M., Thal, L., Winblad, B. International Working Group on Harmonization of Dementia Drug Guidelines. Neurobiology of Aging, 17 (suppl 48) S3, 1996.
87. Gauthier, S. Update on diagnostic methods, natural history, and outcome variables in Alzheimer's disease. Neurobiology of Aging, 17 (suppl 4S), S45, 1996.
88. Krzywkowski, P., Momoli, F., Rocheford, J., Gauthier S., Poirier, J. Cholinergic systems in apolipoprotein E knock-out mice. Society for Neurosciences 22, 206, 1996.
89. Rajput, A.H., Jankovic J., McDermott, M., The Parkinson Study Group. Diagnostic accuracy in early Parkinson's disease. Neurology 48, A369, 1997.
90. Gauthier, S., Panisset, M., Poirier, J. Advances in the diagnosis of Alzheimer's disease. Biological Psychiatry 42, 1465, 1997.
91. Arguin, C., Théroux, L., Danik, M., Dea, D., Charbonneau, B., Gauthier, S., Poirier, J. Screening for mutations in the low density lipoprotein receptor gene in AD patients. Society for Neurosciences 23, 828, 1997.
92. Champagne, D., Bertrand, P., Gauthier, S., Poirier, J. Incidence of herpes simplex virus type 1 DNA from brain ApoE4 allele carriers: a risk factor for AD? Society for Neurosciences 23, 24-30, 1997.
93. Gélinas, I., Gauthier, S., Cyrus, P.A., Ruzicka, B.B., Gulanski B. The efficacy of metrifonate in enhancing the ability of Alzheimer's disease patients to perform basic and instrumental activities of daily living. Neurology 50: A90-91, 1998.
94. Gélinas, I., Liu, L., Gauthier, S., Tsuyoshi, S. Validity of a Japanese translation of the Disability Assessment

- for Dementia (DAD). Abstract book of the 12th International Congress of the World Federation of Occupational Therapists B1.09, 1998.
95. Jung, S.S., Gauthier, S., Cashman, N. Peripheral monocytes support BAPP as a transmembrane holoprotein. Neurobiology of Aging, 19, S39, 1998.
  96. Gauthier S. Changes in activities of daily living. Neurobiology of Aging, 19, S149, 1998.
  97. Gauthier S., Patterson C., Bergman H., Cohen C., Freightner J., Feldman H., Grek A., Hogan D. Recommendations from the Canadian Consensus Conference on Dementia. Annals of Neurology 44, 515, 1998.
  98. Feldman H., Donald A. and the ACCORD Study Group. A comparative diagnostic study of the Canadian Study of Health and Aging (CSHA) with a Canadian Cohort of Related Dementias and the (ACCORD) study. Neurology 52 (suppl 2), A431-A432, 1999.
  99. Panisset M., Gauthier S. and the Cerebrolysin Study Group. Cerebrolysin (CL): a neurotropic agent for the treatment of Alzheimer's disease (AD). Canadian Journal of Neurological Sciences 26 (suppl 1), S16-S17, 1999.
  100. Gauthier S and the Canadian Cerebrolysin Study Group. Results of a 6-months randomized placebo-controlled study with Cerebrolysin in Alzheimer's disease. European Journal of Neurology, 6 (Suppl 3), 28, 1999.
  101. Gauthier S, Lussier I., TriAD Study Group. Donepezil treatment is associated with alleviation of caregiver burden in Alzheimer's disease: interim results from an open-label multicentre clinical trial. European Journal of Neurology, 16 (Suppl 3), 116, 1999.
  102. Gauthier S. The clinical relevance of therapies to delay progression of symptoms in Alzheimer's disease. International Psychogeriatrics, 11 (Suppl 1), 26, 1999.
  103. Gauthier S. Ethique de la recherche et démence. International Psychogeriatrics, 11 (Suppl 1), 27-28, 1999.
  104. Gauthier S, Lussier I and the TriAD Study Group. An open-label trial to assess the effectiveness of donepezil treatment on caregiver burden in Alzheimer's disease- an interim report. International Psychogeriatrics, 11 (Suppl 1), 115-116, 1999.
  105. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease. Neurology 54 (suppl 2), A469, 2000.
  106. Gauthier S, Feldman H, Hecker J, Vellas B, Subbiah P, Whalen E. Efficacy of donepezil on functional, behavioral and cognitive symptoms in patients with moderate to severe Alzheimer's disease. Journal of the American Geriatrics Society, 48, S2, 2000.
  107. Panisset M, Gauthier S, Moessler H, Windisch M. Treatment of Alzheimer's disease: a randomized double-blind, placebo-controlled trial with a neurotropic agent. Neurobiology of Aging 21 (1S), S28, 2000.
  108. Gauthier S. Functional assessment tools and their use in long term management of Alzheimer's disease. Neurobiology of Aging 21 (1S), S75, 2000.
  109. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. Donepezil provides benefits in global function in moderate to severe Alzheimer's disease. Neurobiology of Aging 21 (1S), S93, 2000.

110. Vellas B, Feldman H, Gauthier S, Hecker J, Subbiah P, Whalen E. Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress. Neurobiology of Aging 21 (1S), S93, 2000.
111. Panisset M, Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. Use of the Severe Impairment Battery in a clinical trial of donepezil in moderate to severe Alzheimer's disease. Neurobiology of Aging 21 (1S), S94, 2000.
112. Pratt RD, Gauthier S, Burns A, Perdomo CA. Donepezil provides long-term clinical benefits for patients with Alzheimer's disease. Neurobiology of Aging 21 (1S), S95, 2000.
113. Gauthier S, Feldman H, Hecker J, Vellas B, Subbiah P, Whalen E. Benefits of donepezil on performance of basic and instrumental activities of daily living in moderate to severe Alzheimer's disease. Neurobiology of Aging 21 (1S), S161, 2000.
114. Hecker J, Foti D, Gauthier S, Vellas B, Subbiah P, Whalen E. Benefits of donepezil in the treatment of behavioral problems in moderate to severe Alzheimer's disease. Neurobiology of Aging 21 (1S), S162, 2000.
115. Panisset M, Gauthier S, Moessler H, Windisch M. A randomized, double-blind, placebo-controlled trial with cerebrolysin in Alzheimer's disease. European Neuropsychopharmacology, 10 (Suppl 3) S355, 2000.
116. Gauthier S, Feldman H, Hecker J, Vellas B, Subbiah P, Whalen E. Effects of donepezil on behavior and other domains in moderate to severe Alzheimer's disease. European Neuropsychopharmacology, 10 (Suppl 3) S359, 2000.
117. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. Donepezil provides benefits in global function in moderate to severe Alzheimer's disease. European Journal of Neurology 27 (Suppl 3), 133-134, 2000.
118. Gauthier S, Burns A, Perdomo C, Pratt R. Donepezil provides long-term clinical benefits for patients with Alzheimer's disease. European Journal of Neurology (Suppl 3), 134-135, 2000.
119. Gauthier S, Lussier I, the TriAD Study Group. Caregiver burden in Alzheimer's disease: results from an open-label, randomized, multicentre clinical trial evaluating the effectiveness of donepezil hydrochloride vs donepezil with TriAD. Canadian Journal of Neurological Sciences, 28 (Suppl 2), S35, 2001.
120. Gauthier S. Controversies in therapy. Journal of the Neurological Sciences, 87 (Suppl 1), S118, 2001.
121. Gauthier S, Lilienfeld S. Reminyl (galantamine) improves function and behavior in AD with cerebrovascular components and in VaD. International Psychogeriatrics, 13 (Suppl 2); 232-S, 2001.
122. Gauthier S. Traitement de la maladie d'Alzheimer: les autres voies. Revue Neurologique, 157 (Suppl 1), S31-S32, 2001.
123. Gauthier S. Long term treatment with cholinesterase inhibitors in Alzheimer's Disease. The International Journal of Neuropsychopharmacology, 5 (suppl 1), S38, 2002.
124. Hsiung GY, Johnston D, Donald A, Feldman H and the ACCORD Study Group. An analysis of vascular risk factors and apoE genotypes in subtypes of dementia in the ACCORD study. Neurology 58(Suppl 3); A107, 2002.

125. Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P. Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients. Neurobiology of Aging, 23, S72, 2002.
126. Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Emir B, Subbiah P, Mastey V. Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits. Neurobiology of Aging, 23, S74-S75, 2002.
127. Rockwood K, MacKnight C, Black S, Feldman H, Gauthier S, Hogan D, Vandorpe R, Kertesz A. The Consortium to Investigate Vascular Impairment of Cognition: methods and impact of diagnostic criteria on the study of vascular cognitive impairment. Neurobiology of Aging, 23, S157, 2002.
128. Poulin de Courval L, Dastoor D, Gauthier S, G elinas I, Rossignol M, Sampalis J, Liu L, Gayton D. Evaluation de la s ecurit e des personnes souffrant de d emence et vivant   domicile. Revue M edicale de Bruxelles, 23 (Suppl 1), A72, 2002.
129. Gauthier S. Signes avant-coureurs et d etection pr ecocce de la d emence. Revue M edicale de Bruxelles, 23 (Suppl 1), A86, 2002.
130. Belleville S, Gilbert B, Gagnon L, M enard E, Fontaine F, Gauthier S. Intervention cognitive chez les personnes  g ees souffrant d'un trouble l ger de la cognition (Mild Cognitive Impairment). Revue M edicale de Bruxelles, 23 (Suppl 1), A170, 2002.
131. Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, Mastey V, Subbiah P. Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease. European Journal of Neurology 9 (suppl 2), 34-35, 2002.
132. Gauthier S, Lageix P. Perspectives de la recherche clinique. Actes du colloque du 7 juin 2002 sur le consentement   la recherche chez les personnes inaptes. Centre de recherche sur le vieillissement, Institut Universitaire de g riatrie de Sherbrooke, 47-55, 2003.
133. Gauthier S, Feldman H, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM. Donepezil shows significant benefits in global function, cognition, ADL, and behavior in patients with severe Alzheimer's disease. Neurology 60 (Suppl 1), A413, 2003.
134. Gauthier S, Feldman H, Hecker J, Vellas B, Xu Y, Ieni J, Schwam E. Donepezil shows significant benefit in global function, cognition, ADL and behavior in patients with severe Alzheimer's disease. International Psychogeriatrics 15 (Suppl 2), 68.
135. Gauthier S, Brashear HR, Lilienfeld S. Galantamine demonstrates sustained safety and efficacy over 24 months in patients with probable vascular dementia. International Psychogeriatrics 15 (Suppl 2), 69, 2003.
136. Bhanji NH, Gauthier S. Dementia with Lewy Bodies: preliminary observations on cholinesterase inhibitor switching. International Psychogeriatrics 15 (Suppl 2), 179, 2003.
137. Gauthier S. The evidence for long-term benefits in the treatment of dementia. International Psychogeriatrics 15 (Suppl 2), 374, 2003.
138. Gauthier S. Treating behavioral symptoms in Alzheimer's disease: value of cholinesterase inhibitors. International Psychogeriatrics 15 (Suppl 2), 381-382, 2003.

139. Gauthier S. Traitements médicamenteux de la démence modérée à sévère. Revue Neurologique 10, 5S13, 2003.
140. Gauthier S. Clinical trials in Alzheimer's disease. Journal Canadian Geriatrics Society 6, 125-126, 2003.
141. Gauthier S, Gold DA, Lussier I, TriAD Study Group. Response to donepezil therapy as measured by a patient-centered caregiver interview. Journal Canadian Geriatrics Society 6, 132, 2003.
142. Gauthier S. EXTEND program: interim data analysis suggests that rivastigmine benefits patients with AD who have failed on a cholinesterase inhibitor. Journal Canadian Geriatrics Society 6, 132-133, 2003.
143. Gauthier S. What can we expect from add-on and survival designs in order to establish disease progression? Neurobiology of Aging, 25 (Suppl 1), S11, 2004.
144. Gauthier S. Behavioral benefit by memantine treatment in moderate to severe Alzheimer. International Journal of Neuropsychopharmacology, 7 (Suppl 1), S380, 2004.
145. Möbius H, Stöffler A, Wirth Y, Gauthier S. Memantine positively influences behavior in moderate to severe Alzheimer's disease. Neurobiology of Aging 25 (Suppl 2), S18, 2004.
146. Gauthier S. How to translate results of randomized clinical trials into clinical practice? Neurobiology of Aging 25 (Suppl 2), S92, 2004.
147. Gauthier S et al. A Canadian study on the genetics of late-onset Alzheimer's disease associations: "GenADA". Neurobiology of Aging 25 (Suppl 2), S138, 2004.
148. Shah SN, Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, Schwam E, Leaderer M. Pharmacoeconomic benefits of donepezil treatments in severe Alzheimer's disease. Neurobiology of Aging 25 (Suppl 2), S208, 2004.
149. Fornazzari L, Nadkarni S, Surh L, Newton R, Salvarrey A, Apanasiewicz N, Miranda D, St George Hyslop P, Borrie M, Feldman H, Gauthier S et al. Inter-rater reliability of neuropsychological assessments used in the Canadian study on genetics of Alzheimer's disease associations (GenADA). Neurobiology of Aging 25 (Suppl 2), S323, 2004.
150. Gauthier S, Wirth Y, Stöffler A, Möbius HJ. Memantine has positive effects on behavior in moderate to severe Alzheimer's disease. European Journal of Neurology 11 (Suppl 2), 188, 2004.
151. Möbius HJ, Wirth Y, Gauthier S. Memantine: behavioral benefits for moderate to severe Alzheimer's patients. Neurology 64 (Suppl 1), A104, 2005.
152. Feldman H, Gauthier S, Hecker J, Vellas B, Ieni J, Xu Y, Schwam E. Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers. Neurology 64 (Suppl 1), A105, 2005.
153. Galasko DR, Gauthier S, Bennett D, Sano M, Kaye J, Marson D, Peterson R. Impairment of activities of daily living in patients with amnesic Mild Cognitive Impairment in an ADCS randomized clinical trial. Neurology 64 (Suppl 1), A144, 2005.
154. Gauthier S. Designs and outcomes for studies to establish the efficacy of cognitive training. Int Psychogeriatrics 17 (Suppl 2), 69-70, 2005.

155. Belleville S, Gilbert B, Melah S, Fontaine S, Blanchet S, Gauthier S. Cognitive improvement and neural substrate of memory intervention in persons with mild cognitive impairment. Int Psychogeriatrics 17 (Suppl 2), 70, 2005.
156. Gauthier S, Wirth Y, Moebius HJ. Positive effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Int Psychogeriatrics 17 (Suppl 2), 206, 2005.
157. Gilbert B, Belleville S, Mellah S, Gauthier S. Effect of a multifactorial memory intervention on the subjective complaint of persons with mild cognitive impairment. Int Psychogeriatrics 17 (Suppl 2), 241, 2005.
158. Hudon C, Belleville S, Lepage E, Gauthier S, Chertkow H. Characterization of the episodic memory impairment in Alzheimer's disease and mild cognitive impairment. Int Psychogeriatrics 17 (Suppl 2), 241, 2005.
159. Gauthier S. Memantine effects on behavior and activities of daily living: benefits for patients and caregivers. Int Psychogeriatrics 17 (Suppl 2), 241, 2005.
160. Gauthier S. Does rapid decline dementia have a genetic basis? Int Psychogeriatrics 17 (Suppl 2), 241, 2005.
161. Gauthier S. New data on the clinical relevance of BuChE in the progression of MCI and established dementia. Neurobiology of Aging, 27 (Suppl 1), S8, 2006.
162. Gauthier S. Translating results from clinical research into healthcare policies. Neurobiology of Aging, 27 (Suppl 1), S8, 2006.
163. Gauthier S. Long term treatment of Alzheimer's disease. Alzheimer's & Dementia, 2 (Suppl 1), S1-S2, 2006.
164. Gauthier S, Cooper J, Loft H. Specific benefits of memantine on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Alzheimer's & Dementia, 2 (Suppl 1), S370, 2006.
165. Gauthier S. Treatment options for Alzheimer's disease. Neurodegenerative Diseases, 4 (suppl 1), 102, 2007.
166. Aisen P, Gauthier S, Briand R, Saumier D, Soulban G, Garceau D. A Phase III study of the efficacy, safety and disease modification effect of tramiprosate in mild to moderate Alzheimer's disease. Alzheimer's & Dementia, 3 (Suppl 2), S197, 2007.
167. Gauthier S, Aisen P, Vellas B, Briand R, Saumier R, Soulban G, Laurin J, Garceau D. The efficacy of tramiprosate in the treatment of mild to moderate Alzheimer's disease: results of an 18-month Phase III trial. Journal of Neurology, 254 (Suppl 3), 11, 2007.
168. Gauthier S, Cummings JL, Loft H. Specific benefits of memantine on behavioural symptoms in patients with moderate to severe Alzheimer's disease. European Journal of Neurology, 14 (Suppl 1), 49, 2007.
169. Gauthier S. The clinical relevance of symptomatic benefits of memantine. European Journal of Neurology, 14 (Suppl 1), 323, 2007.
170. Gauthier S. New treatments for dementia. International Psychogeriatrics, 19, (Suppl 1), 10-11, 2007
171. Gauthier S. Trial designs in Subjective Cognitive Impairment studies. International Psychogeriatrics, 19, (Suppl 1), 56, 2007.

- 
172. Belleville S, Gilbert B, Fontaine F, Mellah S, Clement F, Blanchet S, Caza N, Gauthier S. Episodic memory training in persons with Mild Cognitive impairment. International Psychogeriatrics, 19, (Suppl 1), 68.
  173. Gauthier S, Cummings J, Loft H. Specific benefits of memantine on behavioural symptoms in patients with moderate to severe Alzheimer's disease. Canadian Journal of Geriatrics, 10, 105, 2007.
  174. Bélanger S, Belleville S, Gauthier S. Inhibition deficits in persons with Mild Cognitive impairment"study with an adapted version of the Stroop paradigm. Canadian Journal of Geriatrics, 10, 109, 2007.
  175. Gauthier S, Dalziel W, Keren R, Juby A, Rehel B, Schechter R. EXPLORE: improvements in symptoms of early AD following 12 months of treatment with rivastigmine. Canadian Journal of Geriatrics, 10, 113, 2007.
  176. Gauthier S. Management of behavioural problems in Alzheimer's disease. Neurobiology of Aging, 29, S9-S10, 2008.
  177. Bocti C, Belleville S, Labelle MA, Massoud F, Gauthier S. The value of the HIV dementia scale in vascular mild cognitive impairment. Alzheimer's & Dementia, 4 (Suppl 2), T252, 2008.
  178. Fokkens J, Ferris S, Robert P, Winblad B, Gauthier S. development of a language assessment tool for patients with Alzheimer's disease. Alzheimer's & Dementia, 4 (Suppl 2), T519, 2008.
  179. Gauthier S, Guuilhaume-Goulan C, Rive B. Memantine decreases and prevent the emergence of key behavioral symptoms of Alzheimer's disease. Alzheimer's & Dementia, 4 (Suppl 2), T764-765, 2008.
  180. Kokkens J, Ferris S, Robert P, Winblad B, Gauthier S. Assessment of memantine treatment effects on language. Alzheimer's & Dementia, 4 (Suppl 2), T780-781, 2008.
  181. Gauthier S, Lopez O, Schwam E, Feldman H, Waldemar G, Jones RW, Wilkinson D, Zhang R, Schindler R. Impact of donepezil therapy on function in relation to MMSE in patients with Alzheimer's disease. Alzheimer's & Dementia, 4 (Suppl 2), T781, 2008.
  182. Gauthier S, Douillet P, Doody R, Fox NC, Orgogozo JM for the Xaliprodem AD Study Team. Effect of xaliprodem, a compound with neurotrophic properties, on the progression of Alzheimer's disease. Results of two large 18-month studies assessing clinical efficacy and cerebral atrophy. Journal of Nutrition, Health & Aging, 12, 538, 2008.
  183. Gauthier S. Diagnosis of Alzheimer's disease in its pre-dementia stage. Journal of Nutrition, Health & Aging, 13, 63, 2009.
  184. Gauthier S. How a consensus was reached between family doctors and specialists towards diagnosis and treatment. Journal of Nutrition, Health & Aging, 13, 72, 2009.
  185. Gauthier S, Aisen P, Ferris S, Garceau D, Saumier D, Duong A, Sampalis J. A Phase III, placebo-controlled, double-blind randomized trial assessing the effect of tramiprosate on hippocampus volume changes in patients with mild-to-moderate Alzheimer's disease (the Alphase Study). Neurology 72 (Suppl 3), A246-247, 2009.
  186. Aisen P, Gauthier S, Ferris S, Garceau D, Saumier D, Duong A, Sampalis J. A Phase III, placebo-controlled, double-blind randomized trial of tramiprosate in the clinical management of patients with mild-to-moderate Alzheimer's disease (the Alphase Study). Neurology 72 (Suppl 3), A271, 2009.

187. Gauthier S, Lopez O, Schwam E, Waldemar G, Jones R, Wilkinson D, Zhang R, Schindler R. Impact of donepezil therapy on function in relation to MMSE in patients with Alzheimer's disease. Neurology 72 (Suppl 3) A301-302, 2009.
188. Gauthier S. Ethical considerations. Journal of Nutrition, Health & Aging, 13, S20, 2009.
189. Gauthier S. Treatment of apathy and neuropsychiatric symptoms in Alzheimer disease. Journal of Nutrition, Health & Aging, 13, S32, 2009.
190. Gauthier S, Lopez O, Schwam E, Waldemar G, Jones R, Wilkinson D, Zhang R, Schindler R. Impact of donepezil therapy on function in relation to MMSE in patients with Alzheimer's disease. Journal of Nutrition, Health & Aging, 13, S397, 2009.
191. Winblad B, Gauthier S. Memantine shows beneficial effects on functional abilities in moderate-to-severe Alzheimer's disease. Journal of Nutrition, Health & Aging, 13, S401, 2009.
192. Minuzzi L, Quirion R, Gauthier S, Rosa-Neto P. Declines of hippocampal metabotropic glutamate receptors in Alzheimer's disease. Alzheimer's & Dementia, 5 (Suppl 1), P56, 2009.
193. Robert P, Ferris S, Gauthier S, Gatz G, Winblad B, Tennigkeit F. The need for a new practical Alzheimer Disease practical scale. Alzheimer's & Dementia, 5 (Suppl 1), P186, 2009.
194. Gauthier S. Methodological issues for preventive trials. Alzheimer's & Dementia, 5 (Suppl 1), P142, 2009.
195. Reisberg B, Gauthier S, Shulman M, Torossian C, Zhu W, Boksay I, Monteiro I, Prichep L, Mosconi L, Vedvyas A, Jamil I, De Leon M. Subjective Cognitive Impairment: the pre-MCI stage of AD: antecedents and consequences. International Psychogeriatrics, 21 (Suppl 2), S15, 2009.
196. De Medeiros K, Robert P, Gauthier S, Stella F, Politis A, Taragano F, Kremer J, Brugnolo A, Porsteinsson A, Geda Y, Brodaty H, Lyketsos C. The NPI-C: a clinician-rated assessment of neuropsychiatric symptoms in dementia. International Psychogeriatrics, 21 (Suppl 2), S92-93, 2009.
197. Gauthier S. New criteria for Alzheimer's disease including "predementia". Journal of the Neurological Sciences, 285 (Suppl 1), S40, 2009.
198. Rosa-Neto P, Rowley J, Shoemaker D, Van Noort B, Kandratavicius L, Minuzzi L, Gauthier S. Declines of metabotropic glutamate receptors in patients with early AD: in vivo evidence of a novel biomarker for hippocampal dysfunction. Neurology 74 (Suppl 2), A487, 2010.
199. Gauthier S. Why so few drugs for AD? Neurobiology of Aging, 31 (Suppl 1), S11, 2010.
200. Gauthier S. Cognition initiative to address the need for expanded domains and increased measurement sensitivity at mild levels of impairment. Alzheimer's & Dementia, 6, S169, 2010.
201. Ferris S, Gauthier S, Ihl R, Robert P, Winblad B, Holtoff V, Stenberg K, Tennigkeit F. The relevant outcome scale for Alzheimer's disease (ROSA): a new instrument for daily medical practice. Alzheimer's & Dementia, 6, S348, 2010.
202. Arrighi HM, Gélinas I, Gauthier S. Longitudinal changes in functional disability in Alzheimer's disease patients. Alzheimer's & Dementia, 6, S368, 2010.



- 
203. Gauthier S. Nouvelles thérapeutiques en Alzheimer: avancées et perspectives. Cahiers de l'année gériatrique, 2, 17.1, 2010.
204. Gauthier S. Alternatives pharmacologiques: les traitements spécifiques de la maladie d'Alzheimer. Cahiers de l'année gériatrique, 2, 34.4, 2010.
205. Gauthier S, Sol O, Lemarie JC, Pando M. How biomarkers can help investigators and the pharmaceutical industry in AD clinical trials, from concept to application. Journal of Nutrition, Health and Aging, 14 (Suppl 2), S9, 2010.
206. Rowley J, Schoemaker D, Mohades S, Fonov V, Wu O, Dagher A, Shmuel A, Gauthier S, Rosa-Neto P. Declines in entorhinal cortex structural connectivity in amnesic MCI. Alzheimer's & Dementia 7 (suppl), S35-36, 2011.
207. Schoemaker D, Soder R, Sziklan V, Rowley J, Carbonell F, Mohades S, Shmuel A, Gauthier S, Rosa-Neto P. Hippocampal resting-state connectivity lateralize memory function in aMCI brain networks. Alzheimer's & Dementia 7 (suppl), S77-78, 2011
208. Rosa-Neto P, Gauthier S, Soucy JP, Rowley J, Mohades S, Schoemaker D, Minuzzi L. PET and tissue autoradiography evidence of decline of metabotropic glutamate receptor type 5 (MGLUR5) in the prefrontal cortex of AD. Alzheimer's & Dementia 7 (suppl), S110, 2011.
209. Gauthier S, Dubois B. New diagnostic criteria for Alzheimer's disease. International Psychogeriatrics, 23 (Suppl), S41-42, 2011.
210. Gauthier S, Interactions between clinical neurology practice and clinical trials. Chinese Journal of Neurology 44, (Suppl) 1-2, 2011.
211. Gauthier S, Rosa-Neto P. EOFAD: opportunities for proof-of-concept studies to modify disease progression. Neurobiology of Aging 33, S12, 2012.
212. Gauthier S. The challenge of treating prodromal Alzheimer's disease patients. Neurobiology of Aging 33, S12-13, 2012.
213. Gauthier S. Comment les cliniques mémoire doivent se préparer à de nouvelles clientèles et de nouvelles molécules. Maladie d'Alzheimer et déclin cognitif. Recherche et pratique clinique. Vol 17, 48, 2012. Serdi Edition.
214. Gauthier S. Pharmacological treatment of Alzheimer's disease. Alzheimer's & Dementia, P2, 2012.
215. Rowley J, Wu L, Mohades S, Dauar M, Leuzy A, Shin M, Zaccaria C, Fonov V, Gauthier S, Rosa-Neto P. Brain amyloid deposition and metabolism in early and late MCI. Alzheimer's & Dementia, P12, 2012.
216. Soucy JP, Soder R, Rosa-Neto P, Gauthier S. Defining an optimal approach for evaluating regional metabolism with 18F-FDG-PET imaging: anatomical versus probabilistic volumes of interest. Alzheimer's & Dementia P20, 2012.
217. Rowley J, Wu L, Mohades S, Dauar MT, Shin M, Leuzy A, Zaccaria C, Fonov V, Gauthier S, Rosa-Neto P. Regional patterns of amyloidosis and synaptic dysfunction associated with auditory verbal learning: a PET

- study utilizing FDG and AV45 from ADNI. *Alzheimer's & Dementia*, P46, 2012.
218. Dauar M, Rowley J, Wu L, Shin M, Mohades S, Fonov V, Leuzy A, Gauthier S, Rosa-Neto P. Association between brain amyloidosis, synaptic dysfunction and cognitive performance measured with ADAS-cog and MMSE scores in early and late MCI and Alzheimer's disease. *Alzheimer's & Dementia*, P48, 2012.
219. Wu L, Rowley J, Mohades S, Dauar M, Leuzy A, Shin M, Zaccaria C, Fonov V, Gauthier S, Rosa-Neto P. Brain beta-amyloid deposition and metabolism in early and late MCI. *Alzheimer's & Dementia*, P485, 2012.
220. Belleville S, Lepage E, Kergoat MJ, Gauthier S. Measuring multiple cognitive domains optimizes prediction of future decline in persons with MCI. *Alzheimer's & Dementia*, P486-7, 2012.
221. Leuzy A, Rowley J, Mohades S, Dauar M, Wu L, Gauthier S, Rosa-Neto P. Confrontation naming deficits are associated with amyloidosis in early MCI and with synaptic dysfunction in late MCI and Alzheimer's disease: an [18F] AV45/[18F]FDG-PET study. *Alzheimer's & Dementia*, P507, 2012.
222. Rowley J, Wu L, Mohades S, Dauar MT, Shin M, Leuzy A, Zaccaria C, Fonov V, Gauthier S, Rosa-Neto P. Regional patterns of amyloidosis and synaptic dysfunction associated with auditory verbal learning: a PET study utilizing FDG and AV45 from ADNI. *Alzheimer's & Dementia*, P519, 2012.
223. Dauar M, Wu L, Rowley J, Shin M, Mohades S, Fonov V, Leuzy A, Gauthier S, Rosa-Neto P. Association between brain amyloidosis, synaptic dysfunction and cognitive performance measured with ADAS-cog and MMSE scores in EMCI, LMCI and Alzheimer's disease. *Alzheimer's & Dementia*, P524, 2012.
224. Gauthier S, Black S, Cohen S, Robillard A, Hubert M, Schecter R, de Tackacsy F, Rehel B. Eighteen-month follow-up data from the Canadian EMBRACE registry with the rivastigmine patch in patients with Alzheimer's disease. *Alzheimer's & Dementia*, P600, 2012.

### **C. Books and educational material**

1. Clinical diagnosis and management of Alzheimer's disease. Gauthier S (Ed). Martin Dunitz, London, 1996.
2. Slide kit and companion document to Clinical diagnosis and management of Alzheimer's disease. Gauthier S. Martin Dunitz, London, 1996.
3. Alzheimer's disease in primary care. Gauthier, S., Burns, A., Petit, W. Martin Dunitz, London, 1997.
4. La enfermedad de Alzheimer en atención primaria. Gauthier, S., Burns, A., Petit, W., Bernejo, F., Martin Dunitz, London, 1997.
5. La malattia di Alzheimer: una guida per il medico di base. Gauthier S, Amaducci L, Burns A, Pettit W. Martin Dunitz, London, 1997.
6. Alzheimer - demenz in der primärversorgung. Gauthier S, Burns A, Pettit W, Kurz A. Martin Dunitz, London, 1997.
7. La maladie d'Alzheimer en médecine générale. Gauthier S, Burns A, Pettit W. Martin Dunitz, London, 1997.
8. Birinci basamak sađik hizmetlerinde Alzheimer hastalığı. Gauthier S, Burns A., Pettit W. Martin Dunitz, London, 1997.

9. Pharmacotherapy of Alzheimer's disease. Gauthier S (Ed). Martin Dunitz, London, 1998.
10. Alzheimer's disease in primary care. Gauthier S. Martin Dunitz, London, 1999 (2<sup>nd</sup> edition)
11. Clinical diagnosis and management of Alzheimer's disease. Gauthier S (Ed), Martin Dunitz, London, 1999 (2<sup>nd</sup> edition).
12. Alzheimer Hastaliginin farmakoterapisi. Gauthier S (Ed). Martin Dunitz, London, Yelkovan Yaymcilik, Istanbul, 2000.
13. Alzheimer's Disease and Related Disorders Annual. Gauthier S, Cummings J (Eds) Martin Dunitz, London, 2000.
14. Clinical diagnosis and management of Alzheimer's disease. Gauthier S (Ed), Martin Dunitz, London, 2001 (2<sup>nd</sup> edition, revised).
15. Management of dementia. Lovestone S, Gauthier S, Martin Dunitz, London, 2001.
16. Alzheimer's Disease and Related Disorders Annual 2001. Gauthier S, Cummings J (Eds). Martin Dunitz, London, 2001.
17. Aging: culture, health, and social change. Weisstub DN, Thomasma DC, Gauthier S, Tomossy GF (Eds.). International Library of Ethics, Law, and the New Medicine, Vol 10, Kluver Academic Publishers, Boston, 2002.
18. Aging: caring for our elders. Weisstub DN, Thomasma DC, Gauthier S, Tomossy GF (Eds.). International Library of Ethics, Law, and the New Medicine, Vol 11, Kluver Academic Publishers, Boston, 2002.
19. Aging: decisions at the end of life. Weisstub DN, Thomasma DC, Gauthier S, Tomossy GF (Eds.). International Library of Ethics, Law, and the New Medicine, Vol 12, Kluver Academic Publishers, Boston, 2002.
20. Vascular Cognitive Impairment. Erkinjuntti T, Gauthier S (Eds). Martin Dunitz, London, 2002.
21. Alzheimer's Disease and Related Disorders Annual 2002. Gauthier S, Cummings J (Eds). Martin Dunitz, London, 2002.
22. Alzheimer's Disease and Related Disorders Annual 2004. Gauthier S, Scheltens, P, Cummings J (Eds). Martin Dunitz, London, 2004.
23. Alzheimer Disease. Neuropsychology and Pharmacology. Emilien G, Durlach C, Minaker KL, Winblad B, Gauthier S, Maloteaux JM. Birkäuser Publishers Ltd, Basel, 2004.
24. Alzheimer's Disease and Related Disorders vol 5. Gauthier S, Scheltens, P, Cummings J (Eds). Martin Dunitz/Taylor & Francis, London, 2005.
25. Designs and outcomes in dementia therapeutic research. K. Rockwood, S. Gauthier. Taylor & Francis, 2005.
26. Clinical Diagnosis and Management of Alzheimer's Disease. Gauthier S (Ed), Informa Healthcare,

London, 2007 (3<sup>rd</sup> edition).

27. Vascular Cognitive Impairment in Clinical Practice. Wahlund LO, Erkinjuntti T, Gauthier S (Eds), Cambridge University Press, Cambridge, 2009.
28. Management of Dementia. Gauthier S, Ballard C. Informa Healthcare, London, 2009 (2<sup>nd</sup> Edition).
29. Case studies in Dementia. Gauthier S, Rosa-Neto P. Cambridge Press, 2011.
30. La maladie d'Alzheimer. Poirier J, Gauthier S. Quebecor, 2011.
31. Advances in Alzheimer's Disease management. Gauthier S, Rosa-Neto P. Future Medicine, London, 2012.
32. Ich habe mich selbst verloren. Poirier J, Gauthier S. Kösel-Verlag, München, 2013.

## PRESENTATIONS AT NATIONAL AND INTERNATIONAL MEETINGS

1. Gauthier, S., Gagner, J.-p., Sourkes, T.L. Central Neurogenic regulation of adrenal tyrosine hydroxylase activity. Presented at the Founding Meeting of the Canadian College of Neuropsychopharmacology, Montreal, Canada, April 20-21, 1978.
2. Gauthier, S., Gagner, J.-P., Sourkes, T.L. Neural regulation of adrenal tyrosine hydroxylase. Presented as the McNaughton Prize Essay in Neurology at the 13th Canadian Congress of Neurological Sciences, Vancouver, Canada, June 21-24, 1978.
3. Gauthier, S., Gagner, J.-P., Sourkes, T.L. Central neurogenic regulation of adrenal hydroxylase activity. Presented at the IVth International Catecholamine Symposium, Pacific Grove, California, September 17-22, 1978.
4. Gauthier, S., Young, S.N. Serotonin metabolism in epileptic patients. Presented at the XIIth Canadian Neurological Society Meeting, Ottawa, Canada, June, 1980.
5. Gauthier, S., Etienne, P., Dastoor, D., Collier, B., Ludwick, R. Lack of effect of a 3-month treatment with lecithin in Alzheimer's disease. Presented at the 33rd American Academy of Neurology Meeting, Toronto, Canada, April, 1981.
6. Gauthier, S., Gagner, J.-P., Sourkes, T.L., Saint-Louis, J. Stress reactions: Functional neuroanatomy of adrenomedullary stimulation. Presented at the 20th American College of Neuropsychopharmacology, San Diego, California, December 16-18, 1981.
7. Gauthier, S., Sourkes, T.L. Anatomical and biochemical basis of the extrapyramidal disorders. Presented at the 5th Meeting of the Canadian College of Neuropsychopharmacology, Quebec, Canada, May 12-14, 1982.
8. Gauthier, S., Quesney, L.F. Assessment of cortical dopaminergic activity in Parkinson's disease by EEG. Presented at the VIIth International Symposium on Parkinson's disease, Frankfurt a.M., FRG, June 28-30, 1982.
9. Gauthier, S., Saint-Louis, J. Adrenal tyrosine hydroxylase activity and catecholamine content after unilateral hypothalamic de-efferentation. Presented at the 5th International Catecholamine Symposium, Goteborg, Sweden, June 12-16, 1983.

10. Gauthier, S., Vincken, W., Dollfuss, R., Hansen, R., Cosio, M.G. Obstruction des voies aériennes supérieures dans les maladies extra-pyramidales. Congrès québécois de la recherche clinique en sciences neurologiques, Montréal, 4-5 mai, 1984.
11. Gauthier, S., Diksic, M., Yamamoto, L., Tyler, J., Feindel, W. Positron Emission Tomography with <sup>11</sup>C-choline in human subjects. Presented at the XXth Congress of Neurological Sciences, Montreal, June 1985.
12. Gauthier, S., Bertrand, G., Parot, P.Jr. Role of surgical anterior rhizotomies in the management of idiopathic spasmodic torticollis. Presented at the 2nd International Dystonia Symposium, New York, May 1986.
13. Gauthier, S., Leblanc, R., Quirion, R., Carlsson, G., Beaulieu, M., Bouchard, R., Dastoor, D., Ervin, F., Gauthier, L., Gauvin, M., Henry, J.L., Palmour, R., Robitaille, Y. Progress report on transmitter-replacement therapy in Alzheimer's disease using intracerebroventricular infusions of receptor agonists. Presented at the 1st Canadian Symposium on Organix Dementias, London, Canada, June 1986.
14. Gauthier, S., Boisseau, M., Chamberland, G. Handwriting analysis of several extrapyramidal disorders. Presented at the 21st Canadian Congress of Neurological Sciences, London, Canada, June 1986.
15. Gauthier, S., Gauthier, L. Role of Levodopa in idiopathic Parkinson's disease. Presented at the 2nd Canadian Symposium on Disorders of Muscle Tone, Lake Louis, Alberta, Canada, February 1987.
16. Gauthier, S., Masson, H., Gauthier, L., Bouchard, R., Bailey, R., Becker, R., Collier, B., Gayton, D., Kennedy, J., Kissel, C., Lamontagne, A., Nair, N.P.V., Ratner, J., St-Martin, M., Morin, J., Suissa, S., Tesfaye, Y., Vida, S. Tetrahydroaminoacridine and lecithin in Alzheimer's disease. Presented at the International Symposium and Cholinesterase inhibitors, Springfield, USA, March 1988.
17. Gauthier, S. History of L-Dopa. Presented at the 11th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montreal, Canada, May 1988.
18. Gauthier, S. Brain Imaging in dementia. Presented at the 11th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montreal, Canada, May 1988.
19. Gauthier, S., Masson, H., Gauthier, L., Bacher, Y., Becker, R., Bergman, H., Charbonneau, R., Collier, B., Dastoor, D., Gayton, D., Kissel, C., Krieger, M., Kushnir, S., Nair, N.P.V., neirinck, L., Ratner, J., St-Martin, M., Suissa, S., Tesfaye, Y., Vida, S., Bouchard, R., Morin, J., Lamontagne, A., Bailey, P., Kennedy, J. Tetrahydroaminoacridine (THA) avec lécithine dans la maladie d'Alzheimer. Presented at the XXIIIrd Canadian Congress of Neurological Sciences, Quebec City, Canada, June 1988.
20. Gauthier, S., McDowell, I., Hill, G. Canadian Study of Health and Aging. Vth Congress of the International Federation of Psychiatric Epidemiology, Montreal, June 1990.
21. Gauthier, S., Gauthier, L., Bouchard, R. Canadian therapeutic trials for Alzheimer's disease in the 80's: lessons for the 90's. Presented at the Second International Conference on Alzheimer's Disease and Related Disorders, Toronto, Ontario, July 1990.
22. Gauthier, S., Gauthier, L., Bouchard, R., Quirion, R., Sultan, S. Treatment of Alzheimer's Disease: Hopes and Reality. Presented at the Second International Conference on Alzheimer's Disease and Related Disorders, Toronto, Ontario, July 1990.
23. Gauthier, S. Ethical issues in research involving subjects with dementia. Symposium at the 59th Annual Meeting

of the Royal College of Physicians and Surgeons of Canada, Toronto, September 14th, 1990.

24. Gauthier, S. Nouvelles avenues thérapeutiques pour la maladie d'Alzheimer. Symposium at the 2nd Congrès International Francophone de Gérontologie, Montréal, Québec, October 3rd, 1990.
25. Gauthier, S., Gauthier, L., Bouchard, R., Quirion R. Treatment of Alzheimer's disease: Hopes and Reality. Symposium of the Network of Centres of Excellence on Adult Neurodegenerative Disorders, London, Ontario, October 4th, 1990.
26. Gauthier, S. Diagnostic, epidemiological and therapeutic aspects of Alzheimer's disease. Alzheimer' Symposium - Canadian Association of Gerontology 19th Annual Scientific and Educational Meeting, Victoria, B.C., October 1990.
27. Gauthier, S., Amyot, D. Sustained release on antiparkinson agents: Controlled release levodopa. Presented at the 3rd Canadian Conference on Neurodegenerative Disorders - Parkinsonism, L'Estere, Québec, April 1991.
28. Gauthier, S., Gauthier, L. Status of THA as therapy for Alzheimer's disease. Presented at the 2nd International Symposium on Advances in Alzheimer Therapy, Springfield, Illinois, May 1991.
29. Gauthier, S. L-Dopa induced dyskinesias. Presented in a Symposium on dyskinesias at the 14th Annual Scientific meeting of the Canadian College of Neuropsychopharmacology, Hamilton, Ontario, June 1991.
30. Gauthier, S. Maladie d'Alzheimer. Présenté au 8 ème Congrès Scientifique Annuel de la Société Québécoise de Gériatrie, Sherbrooke, Ontario, Octobre 1991.
31. Gauthier, S., Gauthier, L. . What have we learned from the THA Trials of new AChE inhibitors. Presented at the 8th International cholinergic Symposium, Montreal, July 1992.
32. Gauthier, S., New research on causes and treatments of Parkinson's and Alzheimer's diseases. Presented at the annual meeting of the Canadian Association of Gerontology, Edmonton, October 1992.
33. Gauthier, S. Cognitive enhancers. Presented at the Regional meeting of the International Psychiatry Association, Toronto, April 1993.
34. Gauthier, S. and the CSHA clinical examination working group. Usefulness of clinical and laboratory assessment in the diagnosis of age-associated dementias LCDC workshop, Aylmer, May 1993.
35. Gauthier S. Outcome variables in dementia. 16th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montreal, June 1993.
36. Gauthier, S., Gauthier, L. Overview of functional and behavioral changes in dementias and their relevance to clinical efficacy of antidementia drugs. Presented at the 6th International Congress of the International Psychiatric Association, Berlin, Germany, September 5-10, 1993.
37. Keyserlingk, E.W., Glass, K.C., Gauthier, S., Kogan, S. Developing legally and ethically sound guidelines for the protection of research subjects with Alzheimer's disease and other dementias. International Bioethics Meeting, Montreal, November 1993.
38. Gauthier, S., Feldman, H., Mohr, E. Minimal efficacy criteria for medications in Alzheimer disease. Presented at the Third International Springfield Symposium on Advances in Alzheimer Therapy, Springfield, Illinois, USA, May 11-15, 1994.

39. Gauthier, S. The Canadian Multi Center study of converting patients with Idiopathic Parkinson's Disease to Sinemet CR. Presented at the 29th meeting of the Canadian Congress of Neurological Sciences, June 26, 1994.
40. Gauthier, S. Clinician's view on outcome methodologies for pharmacologic trials in mild moderate and severe Alzheimer's disease. Presented at a special meeting of the International Psychogeriatric Association. July 26, 1994.
41. Gauthier, S. Xanomeline clinical update: efficacy and genetic subgroup responses and global clinical assessment. Presented at the 4th International Conference on Alzheimer's Disease and related disorders, Minneapolis, July 29-August 3rd, 1994.
42. Gauthier, S., Poirier, J. The use of apolipoprotein E in Alzheimer diagnosis. Presented at the 10th annual meeting of Alzheimer Disease International, Edinburgh, Scotland, September 19-23, 1994.
43. Gauthier, S., Panisset, M., Rockwood, K. Concepts actuels de la démence vasculaire. Présenté au 5ième Congrès International de Gérontologie, Strasbourg, France, 10-12 octobre 1994.
44. Gauthier, S., Montplaisir, J., Petit, D., Joannette, Y., Feldman, H., Mohr, E., Nair, N.P.V., Poirier, J. Position paper on outcome variables in presymptomatic individuals at higher risk of developing Alzheimer's Disease. Presented at 3rd meeting of the National Institute of Aging/ Fisher Foundation, Washington, December 1-2, 1994.
45. Gauthier, S. Impact of Article 21 on Research involving demented subjects. Presented at the Quebec Society of Law and Medicine, Sheraton Centre, Montreal, January 30, 1995.
46. Gauthier, S., Gauthier, L., Gélinas, I. Validation of the Disability Assessment in Dementia scale. Presented at the annual meeting of the Alzheimer Society of Canada, Edmonton, April 29, 1995.
47. Gauthier, S. Safety and efficacy of muscarinic agonists in Alzheimer ' s disease. Presented at the Alzheimer Disease International Annual Meeting, Buenos-Aires, September 15, 1995.
48. Gauthier, S. Use of activities of daily living scales in dementia research. Presented at the first meeting on Harmonization of Guidelines for approval of antidementia drugs, London, September 29, 1995.
49. Gauthier, S. Consent to research for vulnerable people. Presented at the 75th Anniversary Conference at the Office of the Public Guardian and Trustee of Ontario. Serving Vulnerable People Balancing Protection and Autonomy. Toronto, November 3rd, 1995.
50. Gauthier, S. La recherche impliquant des groupes vulnérables: problèmes particuliers reliés à la population vieillissante. Presented at the meeting on AResearch Ethics, Theory and Practice@, Montreal, March 9-10th 1996.
51. Gauthier, S., Baumgarten, M., Becker, R. The Dementia Behaviour Disturbance Scale: theory behind scale and measurement. Presented at the International Psychogeriatric Association Conference on behaviour disturbance of dementia, Washington, DC, April 1-2, 1996.
52. Gauthier, S., Poirier, J., Gray, J. Effects on decline or deterioration. Presented at the 4th International Nice/Springfield Alzheimer Symposium, Nice, April 10-14, 1996.
53. Gauthier, S. Les populations humaines: facteurs de risque pour la maladie d ' Alzheimer. Présenté au 64ième Congrès de l'Association Canadienne Française pour l'Avancement des Sciences, Montréal, 13-14 mai, 1996.
54. Gauthier, S. Genes and ethical issues and impacts on the design of clinical trials. Presented at the 19th Annual

Meeting of the Canadian College of Neuropsychopharmacology, Toronto, June 2-5, 1996.

55. Gauthier, S. Canadian Guidelines for the development of antidementia therapies. Presented at the 5th International Conference on Alzheimer's Disease and Related Disorders, Osaka, Japan, July 23-27, 1996.
56. Gauthier, S., G elinas, I., Gauthier, L. Functional disability in Alzheimer's disease. Presented at Alzheimer's disease: Applied Diagnosis and Assessment Conference, a special meeting of the IPA, Geneva, Switzerland, November 10-12, 1996.
57. Gauthier, S. Epidemiology and pathophysiology of Alzheimer's disease. Presented at the 2nd Aloys-Alzheimer Symposium, W urzburg, Germany, June 14th 1997.
58. Gauthier, S. Preserving dignity in late stages of progressive dementias using advance directives and legal guardianship. Presented at the XXII International Congress on Law and Mental Health, Montr eal, June 19-21, 1997.
59. Gauthier, S., Panisset, M., Poirier, J. Advances in the diagnosis of Alzheimer's disease. Presented at the 6th World Congress of Biological Psychiatry, Nice, France, June 22-27, 1997.
60. Gauthier, S. Natural history of Alzheimer's disease. Symptomatic domains and patterns of progression. Presented at the 66th Annual Meeting of the Royal College of Physicians and Surgeons of Canada, Vancouver, BC, September 26th 1997.
61. Gauthier, S. Managing expectations in the long-term treatment of Alzheimer's disease. Presented at the 13th Meeting of Alzheimer's Disease International, Helsinki, Finland, September 29th 1997.
62. Gauthier, S., Rossor, M., Hecker, J., Burns, A., Petite, H., M oller, H.J., Rogers, S.L., Friedhoff, L.T. Results from a multinational phase III clinical trial of donepezil in Alzheimer's disease. Presented at the Fifth International Geneva/Springfield Alzheimer Symposium, Geneva, April 15-18, 1998.
63. Gauthier, S., Prevel Katsanis, L., Cochrane, L., Murray, S., Nicole, Y. Redefining phase IV studies in the treatment of Alzheimer's disease. Presented at the Fifth International Geneva/Springfield Alzheimer Symposium, Geneva, April 15-18, 1998.
64. Gauthier, S. D emences: de l' pid miologie aux nouvelles approches pr ventives et th rapeutiques. Presented at the VI A Congr s Francophone de G rontologie, Geneva, April 19-22, 1998.
65. Gauthier, S. Importance et mesure des sympt mes neuropsychiatriques associ s   la maladie d'Alzheimer. Pr sent  au 66i me congr s de l'ACFAS, Qu bec, 15-18 mai 1998.
66. Duval, C., Beuter, A., Gauthier, S. L' tude des relations possibles entre les fluctuations pr sentes dans le tremblement et dans les saccades oculaires chez les patients atteints de la maladie de Parkinson. Pr sent  au 66i me congr s de l'ACFAS, Qu bec, 15-18 mai 1998.
67. Gauthier, S., Rossor, M., Hecker, J., Petit, M., M oller H.J., Mohr, E., Burns, A., Friedhoff, L.T., Rogers, S.L. Donepezil produces clinical, global and cognitive test improvements in patients with Alzheimer's disease: result of the 30-week multinational donepezil study. Presented at the 151<sup>st</sup> Annual Meeting of the American Psychiatric Association, Toronto, May 30 - June 4, 1998
68. Gauthier, S. Treatment of Alzheimer's disease: present and future. Presented at the 33<sup>rd</sup> Meeting of the



- Canadian Congress of Neurological Sciences, Montréal, June 16-20, 1998.
69. Gauthier, S., Weisstub, D.N. The right and means of participation of persons with dementia in medical research. Presented at the XXIII International Congress on Law and Mental Health, Paris, July 1-3, 1998.
  70. Gauthier, S. Changes in activities of daily living. Presented at the 6th International Conference on Alzheimer's Disease, Amsterdam, July 18-23, 1998.
  71. Gauthier, S. Functional changes in Alzheimer's disease. Presented at Aging 2000, Regional Meeting of the International Psychogeriatric Association, Munich, September 13-18, 1998.
  72. Gauthier, S., Rockwood, K., Gelinas, I., Sykes, L., Teunisse, S., Orgogozo, JM., Erkinjuntti, H., Gleeson, M., Kittner, B., Pontocorvo, M., Feldman, H., Whitehouse, P. Outcome measures for the study of activities of daily living in vascular dementia. Presented at the 3<sup>rd</sup> International Conference on Harmonization of Dementia Drugs Guidelines. Osaka, October 7-9, 1998.
  73. Gauthier, S., Patterson, C., Bergman, H., Cohen, C., Feightner, J., Feldman, H., Grek, A., Hogan, D. Recommendations from the Canadian Consensus Conference on Dementia. Presented at the Neurology Outcomes Research: Current Science and Future Directions, American Neurology Association, Montreal, October 17, 1998.
  74. Gauthier S. Efficacy and improvement of daily functioning in the treatment of Alzheimer's disease. Presented at the 11<sup>th</sup> Congress of the European College of Neuropsychopharmacology, Paris, October 31<sup>st</sup> 1998.
  75. Gauthier S. Les traitements pharmacologiques d'aujourd'hui. Presented at the 10<sup>th</sup> Congress of the Fondation Nationale de Gérontologie, Paris, January 18<sup>th</sup> 1999.
  76. Gauthier S. New Canadian Clinical Guidelines. Presented at the 12<sup>th</sup> Annual Alzheimer Symposium, Toronto Rehabilitation Institute, Toronto, January 22<sup>nd</sup> 1999.
  77. Gauthier S. Clinical trial designs. Presented at the Pharmacotherapy of Dementia and Associated Disorders Conference, Toronto, January 28-29, 1999.
  78. Gauthier S. Strategies to delay appearance and progression of Alzheimer's disease. Presentation at the Convention '99 of the Ontario Nursing Home Association, Toronto, March 9<sup>th</sup> 1999.
  79. Gauthier S. Research on Alzheimer Disease. Kral Memorial Lecture, London, Ont., April 8<sup>th</sup> 1999.
  80. Gauthier S. Alzheimer's disease research: what's new. Plenary presentation at the 21<sup>st</sup> National Conference of the Alzheimer Society of Canada, Ottawa, April 22-24, 1999.
  81. Gauthier S. *To treat or not to treat*: new dilemmas in the management of dementia. Presented at the XXIV<sup>th</sup> International Congress on Law and Mental Health, Toronto, June 13-18, 1999.
  82. Gauthier S. Strategies to delay progression of symptoms in Alzheimer's disease: the clinical relevance of therapies to delay progression of symptoms in Alzheimer's disease. Presented at the 9<sup>th</sup> Congress of the International Psychogeriatric Association, Vancouver, August 15-20, 1999.
  83. Gauthier S. Ethique de la recherche et démence. Presented at the 9<sup>th</sup> Congress of the International Psychogeriatric Association, Vancouver, August 15-20, 1999.

84. Gauthier S. Efficacy and safety of cholinesterase inhibitors. Luigi Amaducci Course, 4<sup>th</sup> Congress of the European Federation of Neurological Societies, Lisbon, September 7-11, 1999.
85. Gauthier S. Alzheimer's disease: Quality of life as an integrating concept. Presented at the 1<sup>st</sup> Hellenic Conference on Alzheimer's disease and Related Disorders, Thessaloniki, January 13-16, 2000.
86. Gauthier S. Measuring Activities of Daily Living. Presented at the 2<sup>nd</sup> Pharmaco-economic Conference on Dementia, Stockholm, April 4<sup>th</sup> 2000.
87. Gauthier S. Assessment of ADL in clinical trials for prevention of Alzheimer's disease: a requirement for conversion into dementia. Presented at the 6<sup>th</sup> International Stockholm-Springfield Symposium on Advances in Alzheimer Therapy, Stockholm, April 5-8, 2000.
88. Gauthier S, Feldman H, Hecker J, Vellas B, Subbiah P, Whalen E. Donepezil improves neuropsychiatric symptoms in moderate to severe Alzheimer's disease. Presented at the American Psychiatric Association 2000 Annual Meeting, Chicago, May 13-18, 2000.
89. Gauthier S, Feldman H, Hecker J, Vellas B, Subbiah P, Whalen E. Efficacy of donepezil on functional, behavioral and cognitive symptoms in patients with moderate to severe Alzheimer's disease. Presented at the American Geriatrics Society 2000 Annual Scientific Meeting, Nashville, May 17-21, 2000.
90. Gauthier S. Research and its implications. Presented at plenary session of the World Alzheimer Congress, Creative Care , Washington, July 9-18, 2000.
91. Gauthier S. Use of acetylcholinesterase inhibitors. Presented at the Luigi Amaducci Course on Dementia, 5<sup>th</sup> Congress of the European Federation of Neurological Societies, Copenhagen, October 10-14, 2000
92. Gauthier S, Gauthier J, Dupin F, Panisset M. Comment déterminer l'aptitude du mandant? Formation permanente du Barreau du Québec sur les mandats, Longueuil, 26 Janvier 2001.
93. Gauthier S. Future needs for treatment of Alzheimer's disease. Presented to the Alberta Task Force on the treatment of dementia, Edmonton April 26<sup>th</sup> 2001.
94. Gauthier S. Controversies in therapy. Presented at the XVII World Congress of Neurology, London, 17-22 June 2001.
95. Gauthier S. Treatment of Alzheimer's disease and vascular dementia: is there a difference? Presented at the Tenth Congress of the International Psychogeriatric Association, Nice, September 9-14<sup>th</sup> 2001.
96. Gauthier S. Traitement de la maladie d'Alzheimer: les autres voies. Presented at the 6<sup>ème</sup> Réunion francophone sur la maladie d'Alzheimer et les syndromes apparentés, Bordeaux, October 9-13, 2001.
97. Gauthier S. The continuum of care in Alzheimer's disease. Presented at the Annual Neuropsychiatry Congress, Seoul, October 25-26, 2001.
98. Gauthier S, Rockwood K. Does vascular MCI progress at a different rate than amnesic MCI? Presented at the International Psychogeriatric Association special meeting on Vascular Burden of the Brain, Madrid, November 28-30, 2001.
99. Gauthier S. Functional milestones as target for therapy. Presented at the 7<sup>th</sup> International Geneva-Springfield Symposium on Advances in Alzheimer's Disease, Geneva, April 3-7, 2002

100. Gauthier S. Long term treatment with cholinesterase inhibitors. Presented at the XXIII CINP Congress, Montreal June 23-27, 2002.
101. Gauthier S. Troubles cognitifs légers: approches concernant l'investigation et le traitement. Presented at the Congrès Annuel de l'ANLLF et de l'ANQ, Cannes, September 13-15, 2002.
102. Gauthier S. Troubles cognitifs légers. Presented at the Congrès International Francophone de Gériologie, Bruxelles, September 22-26, 2002.
103. Gauthier S. Aetiological hypothesis towards Alzheimer's disease modification. Presented at the Alzheimer Disease International Annual Meeting, Barcelona, October 23-26, 2002.
104. Gauthier S. Functional outcomes in Alzheimer research. Presented at the 2<sup>nd</sup> Asia-Pacific Meeting on the Harmonization of Dementia Drugs Guidelines, Beijing, November 18-20, 2002.
105. Gauthier S. Neuropsychiatric manifestations of Dementia with Lewy Bodies. International Psychogeriatrics Association special meeting on DLB, Budapest, November 20-22, 2002.
106. Rockwood K, Black S, Gauthier S, Feldman H. The subclassification of patients with vascular cognitive impairment by their clinical presentation and radiographic profile. First Congress of the International Society for Vascular Behavioral and Cognitive Disorders (VasCog), Göteborg, August 28-31, 2003.
107. Gauthier S. Psychotropic drugs in DLB and PDD. Third International Workshop on Dementia with Lewy Bodies and Parkinson's Disease Dementia (DLB/PDD), Newcastle, September 17-10, 2003.
108. Gauthier S. Management of Alzheimer's disease. Hong Kong Geriatric Society, College of Physicians & Neurological Society Joint Meeting, Hong Kong, April 27<sup>th</sup> 2004.
109. Gauthier S. Etudes cliniques de la maladie d'Alzheimer. 72<sup>ème</sup> Congrès de l'ACFAS, Montréal, 10-14 mai 2004.
110. Gauthier S. Clinical trial designs. 39<sup>th</sup> Canadian Congress of Neurological Sciences, Calgary June 8-12, 2004.
111. Gauthier S. How to translate results of randomized clinical trials into clinical practice? Ninth International Conference on Alzheimer Disease and Related Disorders, Philadelphia, July 17-22, 2004.
112. Gauthier S. The treatment of severe phases of Alzheimer's disease. XXXV Congress of the Italian Society of Neurology, Genoa 25-29 2004.
113. Gauthier S. Vascular dementia: risk factors and preventive measures. 20<sup>th</sup> International Conference of Alzheimer Disease International, Kyoto, Oct 15-17, 2004.
114. Gauthier S. Disease-modification randomized clinical trials in AD. Drug Discovery in Neurodegenerative Diseases, Cold Spring Harbor, New York, Dec 2-5, 2004.
115. Gauthier S. Consultations mémoires au Canada et besoins futurs. Journées CM2R, Montpellier, 10-11 mars 2005.
116. Gauthier S. The importance of early treatment in Alzheimer's disease. 4<sup>th</sup> National Conference on Alzheimer's Disease & Related Disorders, Thessaloniki, March 1-3, 2005.

117. Gauthier S. Can pharmacologic treatment of MCI reduce or postpone the incidence of dementia? 18<sup>th</sup> Congress of the International Association of Gerontology, Rio de Janeiro, June 26-30, 2005.
118. Gauthier S. Treatment options of VaD and AD with CVD. 18<sup>th</sup> Congress of the International Association of Gerontology, Rio de Janeiro, June 26-30, 2005.
119. Gauthier S. The importance of non-cognitive symptoms in dementia. Second Professor Prasop Ratanakorn Honorary Lecture, Bangkok, September 30<sup>th</sup> 2005.
120. Gauthier S. Nouvelles perspectives en thérapeutique. Les Unités de Soins Alzheimer, 4<sup>ème</sup> Congrès National, Nice, 1-2 décembre 2005.
121. Gauthier S. Maladie d'Alzheimer et déclin cognitif rapide : bases génétiques et pharmacologiques. Journées de Neurologie de Langue Française, Toulouse, 12-15 avril 2006.
122. Gauthier S. Genetic basis for rapidly progressive Alzheimer's disease. 9<sup>th</sup> International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. Geneva April 19-22, 2006.
123. Gauthier S. Long-term treatment of Alzheimer's disease. 10<sup>th</sup> International Conference on Alzheimer's disease and related disorders, Madrid, July 15-20, 2006.
124. Gauthier S. Management of behavioral complications of Alzheimer's disease. IX Jornadas de la Enfermedad de Alzheimer, 4<sup>th</sup> Congreso Latinoamericano de Neuropsiquiatria, Buenos Aires, September 6-8<sup>th</sup> 2006.
125. Questions relatives à l'aptitude. Mental Health, Ethics and Social Policy, International Symposium, Montreal, October 13<sup>th</sup> 2006.
126. Gauthier S. Future strategies in the prevention and treatment of Alzheimer's disease. 5<sup>th</sup> Asia-Pacific Regional Meeting of the IWGHDDG, Manila, October 21<sup>st</sup>, 2006.
127. Gauthier S. Is MCI a useful concept: Yes. 1<sup>st</sup> Congress on Controversies in Neurology, Berlin, Sept 7<sup>th</sup>-9<sup>th</sup> 2007.
128. Gauthier S. Alzheimer's disease: treatments on the horizon. 4<sup>th</sup> Canadian Colloquium on Dementia. Vancouver, 18-20<sup>th</sup> 2007.
129. Gauthier S. Treatment of dementia in Canada: a success story based on multidisciplinary. Expert Psychiatri Series, Canadian Psychiatric Association, Montreal, November 15-18<sup>th</sup> 2007.
130. Gauthier S. Management of Alzheimer's disease using disease-modifying drugs. 4<sup>th</sup> International Winter-Conference on Alzheimer's Disease, Züers, Austria, December 7<sup>th</sup>-10<sup>th</sup>, 2007.
131. Gauthier S. What is new in dementia. 120<sup>th</sup> Anniversary of the Siriraj Hospital, Bangkok, Thailand, March 17-21<sup>st</sup>, 2008.
132. Gauthier S. Review of pharmaco-economic data from previous clinical trials. 5<sup>th</sup> International Pharmaco-economic Conference on Alzheimer's Disease. Newark, NJ, USA. March 27-29<sup>th</sup> 2008.
133. Gauthier S. Alzheimer's disease: epidemiology, diagnosis and treatment options. European Latin American Neurology symposium, Santiago de Chile, May 29-31<sup>th</sup> 2008.

134. Gauthier S. Selection of efficacy outcomes in disease-modifying trials that are meaningful to clinicians, patients and payers. 1<sup>st</sup> Conference on Clinical Trials on Alzheimer's Disease, Montpellier, France, September 17-19<sup>th</sup> 2008.
135. Gauthier S. Le travail en réseau au Québec. Symposium international, Maladie d'Alzheimer : forçons l'avenir, Liège, Belgique, 19 septembre 2008.
136. Gauthier S. Cognitive decline in aging. Aging Research Center, Karolinska Institutet, Stockholm, June 3<sup>rd</sup> 2009.
137. Gauthier S. How to evaluate memory complaints. 5<sup>th</sup> Congresso Brasileiro de Cérebro Comportamento e Emoções, Gramado, Brazil, June 12<sup>th</sup> 2009.
138. Gauthier S. Selection of efficacy outcomes in disease-modifying trials that are meaningful to clinicians, patients and payers. 9<sup>th</sup> World Congress of Biological Psychiatry, Paris June 28<sup>th</sup> –July 2<sup>nd</sup> 2009.
139. Gauthier S. Non cognitive outcomes in dementia. WFSBP treatment guidelines on dementia. 9<sup>th</sup> World Congress of Biological Psychiatry, Paris June 28<sup>th</sup> –July 2<sup>nd</sup> 2009.
140. Gauthier S. (1) Current and emerging treatments of Alzheimer's disease. (2) Imaging and biological markers as outcomes for AD interventions. 3<sup>rd</sup> International Congress of Asian Society Against Dementia (ASAD), Seoul October 11-13<sup>th</sup> 2009.
141. Gauthier S. Behavioral Neurology. 19<sup>th</sup> World Congress of Neurology, Bangkok October 24-30, 2009.
142. Gauthier S. Nouveaux traitements pour la maladie d'Alzheimer. Atelier mémoire, UNESCO, Paris 28 novembre 2009.
143. Gauthier S. Why so few drugs for AD? The question. 11<sup>th</sup> International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. Geneva March 24<sup>th</sup>-27<sup>th</sup> 2010.
144. Gauthier S. Cognition initiative to address the need for expanded domains and increased measurement sensitivity at mild levels of impairment. ICAD, Honolulu, July 10<sup>th</sup>-15<sup>th</sup> 2010.
145. Gauthier S. Update on diagnosis and treatment of Alzheimer's disease. Helsinki University Department of Neurology, Helsinki, September 21<sup>st</sup>, 2010.
146. Gauthier S. Role of amyloid brain imaging in the revised criteria for the diagnosis of Alzheimer's disease. 26<sup>th</sup> International Conference of Alzheimer's Disease International, Toronto, March 26<sup>th</sup>-29<sup>th</sup> 2011.
147. Gauthier S. Treatment of Alzheimer's disease. 31<sup>st</sup> Annual Scientific Meeting of the Canadian Geriatrics Society, Vancouver April 14<sup>th</sup>-16<sup>th</sup> 2011.
148. Gauthier S. Impact of new diagnostic criteria and new treatment of galantamine for Alzheimer's disease. 52<sup>nd</sup> Annual Meeting of Japanese Society of Neurology, Nagoya, May 18<sup>th</sup>-20<sup>th</sup> 2011.
149. Gauthier S. WFSBP treatment guidelines on dementia. 10<sup>th</sup> World Congress of Biological Psychiatry, Prague, May 20<sup>th</sup>-June 2<sup>nd</sup> 2011.
150. Gauthier S. Traitements actuels et leurs perspectives. Rencontres scientifiques et médicales France-Québec, Académie Nationale de Médecine, Paris, 24 octobre 2011.

151. Gauthier S. Alzheimer's Disease Neuroimaging Initiative. 5th International congress of the Asian Society Against Dementia, Hong Kong, November 5<sup>th</sup>-6<sup>th</sup> 2011.
152. Gauthier S. Prise en charge et contrôle de l'hypertension artérielle. 20<sup>ème</sup> Congrès annuel de la Société Québécoise d'hypertension artérielle, Québec, 18-20 janvier 2012.
153. Gauthier S. New perspectives: how will we treat our AD patients in the future. Advanced Postgraduate Course in Geriatrics, Session 3. Neuro- and Psychogeriatrics. Martigny, Switzerland, January 23<sup>rd</sup> -27<sup>th</sup> 2012.
154. Gauthier S. Prevention of late-life dementias through control of vascular risk factors. Chinese Congress of Cerebrovascular Diseases (CCCD), Chengdu, March 1-3<sup>rd</sup> 2012.
155. Gauthier S. How can we prove that lifestyle changes and other interventions are effective to delay the onset of Alzheimer's disease, what do you tell persons at risk and how safe should the treatments be? Lifestyle Approaches for the Prevention of Alzheimer's Disease, Perth, March 30<sup>th</sup>-31<sup>st</sup> 2012.
156. Gauthier S. La recherche sur la maladie d'Alzheimer : défis et solutions pour travailler avec une population vulnérable. 15<sup>ème</sup> Congrès annuel de l'AQIIRC, Québec, 19-20 avril 2012.
157. Gauthier S. Combination therapies for Alzheimer's disease. 32<sup>nd</sup> Annual Scientific Meeting of the Canadian Geriatrics Society, Québec, April 19<sup>th</sup>-21<sup>st</sup>, 2012.
158. Gauthier S. Problems in treating very early Alzheimer's disease; Early onset familial AD. 12<sup>th</sup> International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, Stockholm, May 9<sup>th</sup>-12<sup>th</sup> 2012.
159. Gauthier S. Comment les cliniques mémoire doivent se préparer à l'arrivée de nouvelles clientèles et de nouvelles molécules. 11<sup>ème</sup> Réunion francophone sur la maladie d'Alzheimer et les syndromes apparentés. Toulouse, 22-24 mai 2012.
160. Gauthier S. Early onset familial Alzheimer Disease (EOFAD): opportunity to test disease modifying drugs for AD. Presented at the 6<sup>th</sup> Asian Society Against Dementia International congress, Kuala Lumpur, June 14<sup>th</sup>-16<sup>th</sup> 2012.
161. Gauthier S. Diagnosing very early Alzheimer's disease: from research criteria to clinical practice. Asian Workshop on Geriatric Psychiatry, Japanese Psychogeriatric Society, Tokyo, September 15<sup>th</sup> 2012.
162. Gauthier S. Knowledge transfer in the field of Alzheimer's disease. National Dementia Research Forum, Canberra, September 27<sup>th</sup>-28<sup>th</sup> 2012.
163. Gauthier S. (1) AD diagnosis and disease progression markers. (2) Pharmacological therapy for cognition and behavior. (3) Future of pharmacotherapy for Alzheimer's disease. Presented at the VIth IberoAmerican Conference on Alzheimer's, Santiago (Chile), October 18<sup>th</sup>-20<sup>th</sup> 2012.
164. Gauthier S. (1) Perspectives sur les réunions consensuelles canadiennes. (2) Démences à début précoce et à progression rapide. 1<sup>er</sup> Congrès québécois sur la maladie d'Alzheimer, Montréal, 15-17 novembre 2012.
165. Gauthier S. Adaptation des cliniques mémoire dans le diagnostic précoce et les nouveaux traitements de la maladie d'Alzheimer. Entretiens Jacques Cartier, Lyon, 20 novembre 2012.
166. Gauthier S. Discussant, Symposium on Alzheimer's disease diagnosis – implications for prevention and treatment, Stockholm, December 6<sup>th</sup>-7<sup>th</sup> 2012.

167. Gauthier S. How can we improve transfer of outcomes from RCTs to clinical practice with disease-modifying drugs? The 11<sup>th</sup> International Conference on Alzheimer's & Parkinson's disease, Florence, March 6<sup>th</sup>-10<sup>th</sup> 2013.
  
168. Gauthier S. (1) Role of biomarkers for the early diagnosis of Alzheimer's disease. (2) MCI is a valid target for treatment. Singapore International Neurocognitive Symposium, April 5<sup>th</sup>-6<sup>th</sup> 2013.

Updated July 5th, 2013